US20170231909A1 - Foam prepared from nanoemulsions and uses - Google Patents
Foam prepared from nanoemulsions and uses Download PDFInfo
- Publication number
- US20170231909A1 US20170231909A1 US15/368,236 US201615368236A US2017231909A1 US 20170231909 A1 US20170231909 A1 US 20170231909A1 US 201615368236 A US201615368236 A US 201615368236A US 2017231909 A1 US2017231909 A1 US 2017231909A1
- Authority
- US
- United States
- Prior art keywords
- oil
- composition
- agent
- foam
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/16—Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/87—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
Definitions
- Foams and, in particular, foam emulsions are complex dispersion systems which do not form under all circumstances. Slight shifts in foam emulsion composition, such as by the addition of active ingredients, may destabilize the foam.
- Micro emulsions and nano emulsion can be monophasic, transparent (or slightly translucent) dispersions of oil and water. Unlike conventional emulsions, micro emulsions and nano emulsion can be thermodynamically stable, making them a favorable vehicle for pharmaceutical compositions, which have to maintain stability for long periods of time. Micro emulsions are sometimes said to be misleadingly called micro emulsions since they can form clear solutions devoid of the opaque color of regular emulsions. Micro emulsions can be oil external, water external and middle phase. Nano emulsions in contrast can be very fine oil in water dispersions. Droplet diameters can be as low as smaller than 100 nm.
- Foams are very complex and sensitive systems and are not formed at will. Mere addition of basic ingredients like oil, water, surfactant and propellant is far from sufficient to produce foams of quality that are homogenous, stable, breakable upon mechanical force and can be used to provide a shelf stable pharmaceutical or cosmetic composition. Small deviations may lead to foam collapse. Much consideration needs to be given to facilitate the introduction of an active agent, such as examining compatibility and non reactivity with the various excipients and container and determining shelf life chemical stability.
- nano droplets can be sterilized by filtration.
- TAG Storage triacylglycerols
- PL phospholipids
- oleosins alkaline proteins
- Oleosins are highly lipophilic proteins, are expressed at high levels in many seeds and are specifically targeted to oil-bodies.
- Oil-bodies are abundant in plant seeds and are among the simplest organelles present in eukaryotes. They are remarkably stable both inside the cells and in isolated preparations.
- Oil bodies are also termed in the literature as “oleosomes”, “lipid bodies” and “spherosomes”.
- the present invention relates to foamable compositions comprising oil in water nano emulsions which produce foam having an improved bubble size compared to the foam produced form a regular oil in water emulsion; to methods of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface using the foamable compositions; and to methods of producing a foam having an improved bubble size.
- the present invention provides a foamable oil in water nano emulsion composition
- a foamable oil in water nano emulsion composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging; wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant
- the present invention provides a foamable oil in water nano emulsion composition
- a foamable oil in water nano emulsion composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging and wherein the viscosity of the nano emulsion is substantially reduced than the viscosity of the a macro emulsion having substaintially the same composition; wherein the composition is contained in a pressurized container is substantially flowable and provides
- the present invention provides a foamable oil in water nano emulsion composition
- a foamable oil in water nano emulsion composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging; wherein the composition prior to addition of propellant is translucent with a blue tint; wherein if the composition is contained in a pressurized container and further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 35% by weight
- a foamable oil in water nano emulsion, composition containing small oil globules including an oil globule system, selected from the group consisting of oil bodies and sub-micron oil globules, about 0.1% to about 5% by weight of at least one stabilizing agent selected from the group consisting of a non-ionic surfactant having an HLB value between 9 and 16, an ionic surfactant, and a polymeric agent water, as well as a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- an oil globule system selected from the group consisting of oil bodies and sub-micron oil globules
- at least one stabilizing agent selected from the group consisting of a non-ionic surfactant having an HLB value between 9 and 16, an ionic surfactant, and a polymeric agent water, as well as a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- the oil globule system consists of oil bodies and the stabilizing agent consists of a polymeric agent.
- the oil globule system consists of oil bodies and the stabilizing agent consists of an ionic surfactant.
- the surface-active agent is a phospholipid.
- the oil bodies are discrete oleaginous particles ranging from about 1 to about 3 ⁇ m in dimension.
- Oil bodies contain triacylclycerols (TAG), surrounded by phospholipids (PL) and oleosins.
- TAG triacylclycerols
- PL phospholipids
- the phospholipids are selected from the group consisting of phosphatidylethanolamine, phosphatidylcholine, lecithin, phosphatidylserine, phosphatidylglycerol and phosphatidylinositol.
- the oleosins are highly lipophilic small proteins of about 25 to 26 kD.
- the oil bodies are derived from the seeds of a plant, selected from the group consisting of almond (Prunus dulcis), anise (Pimpinella anisum), avocado (Persea spp.), beach nut (Fagus sylvatica), borage (also known as evening primrose) (Boragio officinalis), Brazil nut (Bertholetia excelsa), candle nut (Aleuritis tiglium), carapa (Carapa guineensis), cashew nut (Ancardium occidentale), castor (Ricinus communis), coconut (Cocus nucifera), coriander (Coriandrum sativum), cottonseed (Gossypium spp.), crambe (Crambe abyssinica), Crepis alpina, croton (Croton tiglium), Cuphea spp., dill (Anethum gravealis), Euphorbia lag
- Sinapis alba oil palm (Elaeis guineeis), oiticia (Licania rigida), paw paw (Assimina triloba), pecan (Juglandaceae ssp.), perilla (Perilla futescens), physic nut (Gairopha curcas), pilinut (Canariuim ovatum), pine nut (pine spp.), pistachio (Pistachia vera), pongam (Bongamin glabra), poppy seed (Papaver soniferum), rapeseed (Brassica spp.), safflower (Carthamus tinctorius), sesame seed (Sesamum indicum), soybean (Glycine max), squash (Cucurbita maxima), sal tree (Shorea rubusha), Stokes aster (Stokesia laevis), sunflower (Helianthus annuus), tukuma (Astocary
- the foamable composition further includes about 0.1% to about 5% by weight of a foam adjuvant selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain, a fatty acid having 16 or more carbons in their carbon chain, fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, a fatty alcohol having at least one double bond, a fatty acid having at least one double bond, a branched fatty alcohol, a branched fatty acid, and a fatty acid substituted with a hydroxyl group and mixtures thereof.
- a foam adjuvant selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain, a fatty acid having 16 or more carbons in their carbon chain, fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, a fatty
- the foamable composition is substantially alcohol-free.
- the concentration range of oil globules is selected from the group of (i) about 0.05% and about 2% and about 5%, (ii) about 2% (iii) about 5% and about 12%, and (iv) about 12% and about 24%.
- the polymeric agent is selected from the group consisting of a water-soluble cellulose ether and naturally-occurring polymeric material.
- the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, xanthan gum, guar gum, carrageenin gum, locust bean gum and tragacanth gum.
- the foamable composition further includes at least one therapeutic agent.
- the therapeutic agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal anti-inflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agen, an antioxidant, a dicarboxylic acid, azelaic acid
- the therapeutic agent is selected from the components of the oil bodies or sub-micron oil globules.
- the therapeutic agent is suitable to treat a disorder selected from the group consisting of dermatological disorder, a cosmetic disorder, a gynecological disorder, a disorder of a body cavity, wound and burn.
- the present invention provides methods of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface using the foamable compositions described herein.
- the present invention provides a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface, wherein said disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors, comprising: administering topically to a subject having said disorder, a foamed composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging and wherein the viscosity
- the method includes administering topically to a subject having the disorder, a foamed composition containing (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- a foamed composition containing (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent
- the composition further includes an active agent effective to treat a disorder, and wherein the disorder is selected from the group consisting of a vaginal disorder, a vulvar disorder, an anal disorder, a disorder of a body cavity, an ear disorder, a disorder of the nose, a disorder of the respiratory system, a bacterial infection, fungal infection, viral infection, dermatosis, dermatitis, parasitic infections, disorders of hair follicles and sebaceous glands, scaling papular diseases, benign tumors, malignant tumors, reactions to sunlight, bullous diseases, pigmentation disorders, disorders of cornification, pressure sores, disorders of sweating, inflammatory reactions, xerosis, ichthyosis, allergy, burn, wound, cut, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis
- the disorder is selected from the group
- a method to promote the penetration of an active agent into the surface layers of the skin and mucosal membranes includes applying a foamable composition to the surface layers of a skin or mucosal membrane the foamable composition, comprising (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- a foamable composition comprising (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-
- a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface wherein said disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors.
- the method includes applying a foamable composition to the surface layers of a skin, body cavity or mucosal membrane the foamable composition, comprising (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- the composition prior to addition of propellant is translucent with a blue tint.
- the present invention provides a method of producing a foam having improved foam bubble size comprising: (i) preparing a pre foam oil in water emulsion formulation, wherein the pre foam oil comprises (a) oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent selected from the group consisting of a non-ionic surfactant, an ionic surfactant, and a polymeric agent; and (c) water; (ii) subjecting the pre foam formulation to high pressure mechanical stress to produce a nano emulsion; (iii) storing the nano emulsion in a sealed pressurized container that further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 25% by weight of the total composition and having an outlet capable of releasing the pressurized product as a foam; and (iv) releasing the foam, wherein the bubble size of the resultant foam is significantly greater than the bubble size of a resultant foam from the pre foam oil in water emulsion
- FIG. 1A shows pictures of a sample section of the foam produced from composition 13 of Example 9 before nano processing.
- FIG. 1B shows pictures of a sample section of the foam produced from composition 13 of Example 9 after 6 cycles of nano processing.
- FIG. 2A shows pictures of a sample section of the foam produced from composition 11 of Example 8 before nano processing.
- FIG. 2B shows pictures of a sample section of the foam produced from composition 11 of Example 8 after 6 cycles of nano processing.
- FIG. 3A shows pictures of a sample section of the foam produced from composition 7 of Example 7 before nano processing.
- FIG. 3B shows pictures of a sample section of the foam produced from composition 10 of Example 7 after 6 cycles of nano processing.
- FIG. 4A shows pictures of a sample section of the foam produced from composition 14 of Example 9 before nano processing.
- FIG. 4B shows pictures of a sample section of the foam produced from composition 14 of Example 9 after 6 cycles of nano processing.
- FIG. 5A shows pictures of a sample section of the foam produced from composition 15 of Example 9 before nano processing, which foam comprises propellant having 50% more pressure than that of the foam as shown in FIG. 5B .
- FIG. 5B shows pictures of a sample section of the foam produced from composition 15 of Example 9 before nano processing.
- FIG. 5C shows pictures of a sample section of the foam produced from composition 15 of Example 9 after 6 cycles of nano processing.
- the present invention provides a foamable oil in water nano emulsion, composition including small oil globules.
- the terms droplets, globules and particles, when referencing an emulsion, are used interchangeably. All % values are provided on a weight (w/w) basis.
- the foamable oil in water nano emulsion composition is intended for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein “target site”).
- the oil globule system consists of oil globules with an average diameter size in the range of about 1000 nanometers to about 10 nanometers; and the stabilizing agent consists of a polymeric agent.
- a foamable oil in water nano emulsion composition comprising a non-ionic surfactant having an HLB value between 9 and 16; and/or an ionic surfactant.
- oil globules are discrete particles with the majority having a size ranging from about 300 to about 20 nanometers in at least one dimension.
- oil globule system consists of sub-micron oil globules; and the stabilizing agent consists of a surfactant, having an HLB value or a mean HLB value between 9 and 16.
- the ratio of surfactant to oil is high being in the range of the order of about 1:1 to about 1:10
- the sub-micron oil globules contain at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof.
- said submicron oil globules are about 50% to about 100% of the composition.
- the sub-micron oil globules have a number-average size range, selected from (i) 40 nm to 1,000 nm. (ii) 40 nm to 500 nm; (iii) 40 nm to 200 nm; (iv) 40 nm to 100 nm (v) less than 500 nm; (vi) less than 200 nm; and (vii) less than 100 nm.
- sub-micron oil globules are produced by high sheer homogenization.
- a foamable oil in water nano emulsion composition further comprising about 0.1% to about 5% by weight of a foam adjuvant selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain; fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain; a fatty alcohol having at least one double bond; a fatty acid having at least one double bond; a branched fatty alcohol; a branched fatty acid; and a fatty acid substituted with a hydroxyl group and mixtures thereof.
- a foam adjuvant selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain; fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atom
- said foamable composition is substantially alcohol-free.
- a foamable oil in water nano emulsion composition further containing at least one therapeutic agent.
- the therapeutic agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic
- the therapeutic agent is suitable to treat a disorder, selected from a dermatological disorder, a cosmetic disorder, a gynecological disorder, a disorder of a body cavity, wound and burn.
- a foamable oil in water nano emulsion composition wherein the HLB or mean HLB value of said non-ionic surfactant is between about 2 and about 9.
- the stabilizing agent is a polymeric agent selected from the group consisting of a water-soluble cellulose ether naturally-occurring polymeric material, microcrystalline cellulose, hydrophobically-modified ethoxylated urethane, and a carbomer.
- the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, xanthan gum, guar gum, carrageenin gum, locust bean gum and tragacanth gum.
- the surfactant is selected from the group consisting of steareth 2, steareth 21, ceteth-20, span 80, behenyl alcohol, glyceryl monostearate, PEG 40 stearate, polyoxyl 100 monostearate, methyl glucose seasquit stearate and polysorbate 80.
- a foamable oil in water nano emulsion composition wherein the density of the foam is selected from the group consisting of (1) less than 0.12 g/mL; (2) the range between 0.02 and 0.12; (3) the range between 0.04 and 0.10; (4) the range between 0.06 and 0.10.
- a foamable oil in water nano emulsion composition wherein the viscosity is selected from the group consisting of (1) between about 6000 cP and about 4000 cP (2) between about 4000 cP and about 2000 cP (3) between about 2000 cP and about 500 cP (4) between about 500 cP and about 1 cP.
- the viscosity is preferably between about 500 cP and about 1 cP and the foam is of good or excellent quality.
- the viscosity is above 20,000 cP.
- polymeric agent is a carbomer.
- carbomer is the sole polymeric agent.
- composition further comprises an active agent effective to treat a disorder and wherein the disorder is selected from the group consisting of a vaginal disorder, a vulvar disorder, an anal disorder, a disorder of a body cavity, an ear disorder, a disorder of the nose, a disorder of the respiratory system, a bacterial infection, fungal infection, viral infection, dermatosis, dermatitis, parasitic infections, disorders of hair follicles and sebaceous glands, scaling papular diseases, benign tumors, malignant tumors, reactions to sunlight, bullous diseases, pigmentation disorders, disorders of cornification, pressure sores, disorders of sweating, inflammatory reactions, xerosis, ichthyosis, allergy, burn, wound, cut, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis,
- the active agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid,
- a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface, wherein said disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors comprising:
- composition further comprises an active agent effective to treat a disorder and wherein the disorder is selected from the group described above.
- a method of promoting the penetration of an active agent into the surface layers of the skin and mucosal membranes comprising: apply a foamable composition to the surface layers of a stem or mucosal membrane, the foamable composition comprising:
- the active agent is selected from the group listed above.
- a foamable oil in water nano emulsion composition for use as a medicament or in the manufacture of a medicament.
- the foamable oil in water nano emulsion composition includes:
- the foamable composition forms an expanded foam suitable for topical administration.
- oil globules are oil bodies.
- Oil bodies also termed “oleosomes”, “lipid bodies” and “spherosomes”, are small discrete oleaginous particles, ranging in size from about 1 to about 3 ⁇ m along one dimension.
- Oil bodies consist of triacylglycerols (TAG) surrounded by phospholipids (PL) and alkaline proteins, termed oleosins.
- TAG triacylglycerols
- PL phospholipids
- alkaline proteins termed oleosins.
- Triacylglycerides are chemically defined as glycerol esters of fatty acids.
- the seed oil present in the oil body fraction of plant species is a mixture of various triacylglycerides, of which the exact composition depends on the plant species from which the oil is derived.
- Oleosins are highly lipophilic small proteins of about 15 to 26 kD. They are expressed at high levels in many seeds and are specifically targeted to oil-bodies. Oleosins completely cover the surface of the subcellular oil bodies.
- Oil-bodies are abundant in plant seeds and are among the simplest organelles present in eukaryotes. They are remarkably stable both inside the cells and in isolated preparations.
- Oil bodies are prepared from plant seeds.
- Exemplary plant seeds include (alphabetically) almond (Prunus dulcis); anise (Pimpinella anisum); avocado (Persea spp.); beach nut (Fagus sylvatica); borage (also known as evening primrose) (Boragio officinalis); Brazil nut (Bertholletia excelsa); candle nut (Aleuritis tiglium); carapa (Carapa guineensis); cashew nut (Ancardium occidentale); castor (Ricinus communis); coconut (Cocus nucifera); coriander (Coriandrum sativum); cottonseed (Gossypium spp.); crambe (Crambe abyssinica); Crepis alpina; croton (Croton tiglium); Cuphea spp.; dill (Anethum gravealis); Euphorbia lagascae; Dimorph
- Stable artificial oil bodies can be reconstituted with triacylglycerol, phospholipid, and oleosin via sonication, as described, for example in J. T. C. Tzen, Y. Z. Cao, P. Laurent, C. Ratnayake, and A. H. C. Huang. 1993. Lipids, proteins, and structure of seed oil bodies from diverse species. Plant Physiol. 101:267-276.
- the skin-beneficial effects of oil bodies include, but are not limited to (1) antioxidant effects (resulting from the presence of tocopherol and other antioxidants naturally present in the oil bodies); (2) occlusivity, as determined by improved skin barrier function and reduced trans-epidermal water loss; and (3) emolliency.
- the oil bodies building blocks the triacylglycerides and the phospholipids—contain unsaturated or polyunsaturated fatty acids.
- Exemplary unsaturated fatty acids are omega-3 and omega-6 fatty acids.
- polyunsaturated fatty acids examples include linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
- GLA gamma-linoleic acid
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- oil bodies contain phospholipids and oleosins, which concurrently carry hydrophobic and hydrophilic moieties, they act as emulsifiers and, as a result, upon dilution with water with mild mixing, they spontaneously form an emulsion.
- the oil globules are sub-micron oil globules, i.e., oil globules, which have a number-average size of less than 1,000 nm.
- An emulsion, comprising sub-micron globules or nano-size globules is called sub-micron emulsion (“SME”) or microemulsion or nanoemulsion, respectively.
- the oil globules have a number-average size of less than 500 nm; or less than 200 nm; or less than 100 nm. In certain embodiments, the oil globules have number-average size in the following ranges: (i) 40 nm to 1,000 nm. (ii) 40 nm to 500 nm; (iii) 40 nm to 200 nm; or (iv) 40 nm to 100 nm.
- SMEs are dispersions of oil and water. With reference to conventional emulsions, SMEs are more stable, making them a favorable vehicle for pharmaceutical compositions, which have to maintain stability for long periods of time. SMEs may be used in vehicles for transporting nutraceuticals, medicaments, peptides or proteins. The decrease in size of the globules makes it possible to promote the penetration of the active agents into the surface layers of the skin and mucosal membranes.
- the production of SMEs and nanoemulsion involves very-high sheer homogenizers.
- An exemplary homogenizer, suitable for producing nano-emulsions is the commercially-available “Microfluidizer®”.
- Microfluidizer® fluid processors are built for deagglomeration and dispersion of uniform submicron particles and creation of stable emulsions and dispersions.
- Microfluidizer processors overcome limitations of conventional processing technologies by utilizing high-pressure streams that collide at ultra-high velocities in precisely defined microchannels. Combined forces of shear and impact act upon products to attain uniform particle and droplet size reduction (often submicron), deagglomeration and high yield cell disruption.
- any other very-high sheer homogenizer capable of producing submicron particles is suitable for use in the production of a microemulsions or a nanoemulsion according to the present invention.
- the SMEs form spontaneously with gentle mixing such as hand shaking.
- the sub-micron particles contain at least one organic carrier, preferably a hydrophobic organic carrier.
- the composition may contain one or more of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%, or about 10% to about 20%, or about 20% to about 50% by weight.
- hydrophobic organic carrier refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL. It is liquid at ambient temperature.
- the identification of a hydrophobic organic carrier or “hydrophobic solvent”, as used herein, is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. Rather, such information is provided to aid in the identification of materials suitable for use as a hydrophobic carrier in the foamable compositions described herein.
- hydrophobic solvents are liquid oils originating from vegetable, marine or animal sources.
- Suitable liquid oil includes saturated, unsaturated or polyunsaturated oils.
- the unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
- Suitable hydrophobic solvents also include polyunsaturated oils containing poly-unsaturated fatty acids.
- said unsaturated fatty acids are selected from the group of omega-3 and omega-6 fatty acids.
- examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
- GLA gamma-linoleic acid
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- the hydrophobic solvent can include at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
- oils that possess therapeutically beneficial properties are termed “therapeutically active oil.”
- hydrophobic solvents Another class of hydrophobic solvents is the essential oils, which are also considered therapeutically active oil, which contain active biologically occurring molecules and, upon topical application, exert a therapeutic effect, which is conceivably synergistic to the beneficial effect of the NSAID in the composition.
- Another class of therapeutically active oils includes liquid hydrophobic plant-derived oils, which are known to possess therapeutic benefits when applied topically.
- Silicone oils also may be used and are desirable due to their known skin protective and occlusive properties.
- Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. These are chosen from cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms. Volatile silicones such as cyclomethicones can also be used. Silicone oils are also considered therapeutically active oil, due to their barrier retaining and protective properties.
- the organic carrier may be a mixture of two or more of the above hydrophobic solvents in any proportion.
- a further class of organic carriers includes “emollients” that have a softening or soothing effect, especially when applied to body areas, such as the skin and mucosal surfaces.
- Emollients are not necessarily hydrophobic.
- suitable emollients include hexyleneglycol, propylene glycol, isostearic acid derivatives, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated oil bodies alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol
- the organic carrier includes a mixture of a hydrophobic solvent and an emollient.
- the foamable composition is a mixture of mineral oil and an emollient in a ratio between 2:8 and 8:2 on a weight basis.
- a “polar solvent” is an organic solvent, typically soluble in both water and oil.
- polar solvents include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, esters, such as
- the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200(MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
- PEG polyethylene glycol
- PEG derivative that is liquid at ambient temperature
- the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols.
- Short chain alcohols having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect.
- the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- the composition includes a stabilizing agent, which may be a polymeric agent.
- the polymeric agent serves to stabilize the foam composition and to control drug residence in the target organ.
- Exemplary polymeric agents are classified below in a non-limiting manner. In certain cases, a given polymer can belong to more than one of the classes provided below.
- the polymeric agent may be a gelling agent.
- a gelling agent controls the residence of a therapeutic composition in the target site of treatment by increasing the viscosity of the composition, thereby limiting the rate of its clearance from the site.
- Many gelling agents are known in the art to possess mucoadhesive properties.
- hydroxyethyl cellulose methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose
- guar gum hydroxypropyl guar gum
- soluble starch cationic celluloses, cationic guars, and the like
- synthetic polymeric materials such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Mixtures of the above compounds are contemplated.
- Further exemplary gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol® resins. These resins consist essentially of a colloidal water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Carbopol® 934, Carbopol® 940, Carbopol® 950, Carbopol® 980, Carbopol® 951 and Carbopol® 981. Carbopol® 934 is a water-soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
- the gelling agent may be a water-soluble cellulose ether.
- the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose and carboxymethylhydroxyethylcellulose. More preferably, the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose (Methocel).
- the composition includes a combination of a water-soluble cellulose ether; and a naturally-occurring polymeric materials, selected from the group including xanthan gum, guar gum, carrageenan gum, locust bean gum and tragacanth gum.
- the gelling agent includes inorganic gelling agents, such as silicone dioxide (fumed silica).
- the polymeric agent may be a mucoadhesive agent.
- Mucoadhesion/bioadhesion is defined as the attachment of synthetic or biological macromolecules to a biological tissue.
- Mucoadhesive agents are a class of polymeric biomaterials that exhibit the basic characteristic of a hydrogel, i.e. swell by absorbing water and interacting by means of adhesion with the mucous that covers epithelia.
- Compositions of the present invention may contain a mucoadhesive macromolecule or polymer in an amount sufficient to confer bioadhesive properties.
- the bioadhesive macromolecule enhances the delivery of biologically active agents on or through the target surface.
- the mucoadhesive macromolecule may be selected from acidic synthetic polymers, preferably having at least one acidic group per four repeating or monomeric subunit moieties, such as poly(acrylic)- and/or poly(methacrylic) acid (e.g., Carbopol®, Carbomer®), poly(methylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC); neutral synthetically modified natural polymers, such as (hydroxypropyl)methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral synthetic polymers, such as polyvinyl alcohol or their mixtures.
- acidic synthetic polymers preferably having at least one acidic group per four repeating or monomeric subunit moie
- An additional group of mucoadhesive polymers includes natural and chemically modified cyclodextrin, especially hydroxypropyl- ⁇ -cyclodextrin.
- Such polymers may be present as free acids, bases, or salts, usually in a final concentration of about 0.01% to about 0.5% by weight.
- a suitable bioadhesive macromolecule is the family of acrylic acid polymers and copolymers, (e.g., Carbopol®). These polymers contain the general structure —[CH 2 —CH(COOH)—] n . Hyaluronic acid and other biologically-derived polymers may be used.
- Exemplary bioadhesive or mucoadhesive macromolecules have a molecular weight of at least 50 kDa, or at least 300 kDa, or at least 1,000 kDa.
- Favored polymeric ionizable macromolecules have not less than 2 mole percent acidic groups (e.g., COOH, SO3H) or basic groups (NH2, NRH, NR2), relative to the number of monomeric units.
- the acidic or basic groups can constitute at least 5 mole percent, or at least 10 mole percent, or at least 25, at least 50 mole percent, or even up to 100 mole percent relative to the number of monomeric units of the macromolecule.
- mucoadhesive agent includes inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSIL 200 (DEGUSSA).
- inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSIL 200 (DEGUSSA).
- the polymeric agent may be a film forming component.
- the film forming component may include at least one water-insoluble alkyl cellulose or hydroxyalkyl cellulose.
- Exemplary alkyl cellulose or hydroxyalkyl cellulose polymers include ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, hydroxypropyl cellulose, hydroxybutyl cellulose, and ethylhydroxyethyl cellulose, alone or in combination.
- a plasticizer or a cross linking agent may be used to modify the polymer's characteristics.
- esters such as dibutyl or diethyl phthalate, amides such as diethyldiphenyl urea, vegetable oils, fatty acids and alcohols such as oleic and myristyl acid may be used in combination with the cellulose derivative.
- the polymeric agent may be a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface. Such phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca 2+ ).
- phase change polymers include poly(N-isopropylamide), Poloxamer 407® and Smart-Gel® (Poloxamer+PAA).
- the polymeric agent is present in an amount in the range of about 0.01% to about 5.0% by weight of the foam composition. In one or more embodiments, it is typically less than about 1 wt % of the foamable composition.
- the stabilizing agent may also be a surface-active agent.
- Surface-active agents include any agent linking oil and water in the composition, in the form of emulsion.
- a surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil.
- HLB hydrophilic/lipophilic balance
- the HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
- Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions.
- the HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
- a single surfactant may suffice.
- a combination of two or more surfactants is desired.
- Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants is usually preferable where the vehicle is an emulsion.
- a combination of surfactants can be significant in producing breakable forms of good quality. It has been further discovered that the generally thought considerations for HLB values for selecting a surfactant or surfactant combination are not always binding for emulsions and that good quality foams can be produced with a surfactant or surfactant combination both where the HLB values are in or towards the lipophilic side of the scale and where the HLB values are in or towards the hydrophilic side of the scale. Surfactants also play a role in foam formation where the foamable formulation is a single phase composition.
- the composition contains a single surfactant having an HLB value between about 2 and 9, or more than one surfactant and the weighted average of their HLB values is between about 2 and about 9.
- Lower HLB values may in certain embodiments be more applicable to water in oil emulsions.
- the composition contains a single surfactant having an HLB value between about 7 and 14, or more than one surfactant and the weighted average of their HLB values is between about 7 and about 14.
- Mid range HLB values may in certain embodiments be more suitable for oil in water nano emulsion s.
- the composition contains a single surfactant having an HLB value between about 9 and about 19, or more than one surfactant and the weighted average of their HLB values is between about 9 and about 19.
- HLB values In a waterless or substantially waterless environment a wide range of HLB values may be suitable.
- the composition of the present invention contains a non-ionic surfactant.
- non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21, brij 721, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglyceride, isocete
- surfactants are selected which can provide a close packed surfactant layer separating the oil and water phases.
- combinations of at least two surfactants are selected.
- they should be complex emulgators and more preferably they should both be of a similar molecular type.
- POE esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with wax formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
- dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable. [Hong-Rong Wang and Keng-Ming Chen, Colloids and Surfaces A: Physicochemical and Engineering Aspects Volume 281, Issues 1-3, 15 Jun. 2006, Pages 190-193].
- Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB ⁇ 4.9); glyceryl monostearate/PEG 100 stearate (Av HLB ⁇ 11.2); stearate Laureth 4 (HLB ⁇ 9.7) and cetomacrogol ether (e.g., polyethylene glycol 1000 monocetyl ether).
- Non-limiting examples of preferred surfactants which have a HLB of 4-19 are set out in the Table below:
- HLB steareth 2 ⁇ 4.9 glyceryl monostearate/PEG 100 stearate Av ⁇ 11.2 Glyceryl Stearate ⁇ 4 Steareth-21 ⁇ 15.5 peg 40 stearate ⁇ 16.9 polysorbate 80 ⁇ 15 sorbitan stearate ⁇ 4.7 laureth 4 ⁇ 9.7 Sorbitan monooleate (span 80) ⁇ 4.3 ceteareth 20 ⁇ 15.7 steareth 20 ⁇ 15.3 Ceteth 20 ⁇ 15.7 Macrogol Cetostearyl Ether ⁇ 15.7 Ceteth 2 (Lipocol C-2) ⁇ 5.3 PEG-30 Dipolyhydroxystearate ⁇ 5.5 sucrose distearate (Sisterna SP30) ⁇ 6 polyoxyethylene (100) stearate ⁇ 18.8
- the surfactant is a complex emulgator in which the combination of two or more surfactants can be more effective than a single surfactant and provides a more stable emulsion or improved foam quality than a single surfactant.
- the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
- surfactant systems are, combinations of polyoxyethylene alkyl ethers, such as Brij 59/Brij10; Brij 52/Brij 10; Steareth 2/Steareth 20; Steareth 2/Steareth 21 (Brij 72/Brij 721); combinations of polyoxyethylene stearates such as Myrj 52/Myrj 59; combinations of sucrose esters, such as Surphope 1816/Surphope 1807; combinations of sorbitan esters, such as Span 20/Span 80; Span 20/Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, such as Tween 80/PEG-40 stearate; methyl glucaso sequistearate; polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121), Stepan (Mild RM1), Nikomules
- the surfactant is preferably one or more of the following: a combination of steareth-2 and steareth-21 on their own or in combination with glyceryl monostearate (GMS); in certain other embodiments the surfactant is a combination of polysorbate 80 and PEG-40 stearate. In certain other embodiments the surfactant is a combination of glyceryl monostearate/PEG 100 stearate. In certain other embodiments the surfactant is a combination of two or more of stearate 21, PEG 40 stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80.
- the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21, ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60
- the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
- non-ionic surfactants with significant hydrophobic and hydrophilic components, increase the emulsifier or foam stabilization characteristics of the composition.
- using combinations of surfactants with high and low HLB's to provide a relatively close packed surfactant layer may strengthen the emulsion.
- the stability of the composition can be improved when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed.
- the ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4.
- the resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
- a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
- the surfactant is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
- amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of the two parts. Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect
- the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals.
- Surfactants which tend to form liquid crystals may improve the quality of foams.
- Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are: phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
- the at least one surfactant is liquid.
- the liquid surfactant is a polysorbate, preferably polysorbate 80 or 60.
- the at least one surfactant is solid, semi solid or waxy.
- HLB values may not be so applicable to non ionic surfactants, for example, with liquid crystals or with silicones. Also HLB values may be of lesser significance in a waterless or substantially non-aqueous environment.
- the surfactant can be, a surfactant system comprising of a surfactant and a co surfactant, a waxy emulsifier, a liquid crystal emulsifier, an emulsifier which is solid or semi solid at room temperature and pressure, or combinations of two or more agents in an appropriate proportion as will be appreciated a person skilled in the art.
- a solid or semi solid emulsifier combination it can also comprise a solid or semi solid emulsifier and a liquid emulsifier.
- the surface-active agent includes at least one non-ionic surfactant.
- Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. Non-ionic surfactants alone can provide formulations and foams of good or excellent quality in the carriers and compositions of the present invention.
- the surfactant contains a non-ionic surfactant.
- the composition includes a mixture of non-ionic surfactants as the sole surfactant.
- the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1.
- the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1.
- surfactant comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1
- a combination of a non-ionic surfactant and an ionic surfactant is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1; for example, about 1:1, about 4:1, about 8:1, about 12:1, about 16:1and about 20:1 or at a ratio of 4:1 to 10:1, for example, about 4:1, about 6:1, about 8:1 and about 10:1.
- the upper amount of surfactant that may be used may be limited by the shakability of the composition. If the surfactant is non liquid, it can make the formulation to viscous or solid. This can be particularly significant if the formulation has high molecular weight, e.g., a high molecular weight PEG or polymeric agents or petroleum or if the surfactants are large. Solvents and polymeric agents which have high molecular weight and are very viscous or solid or waxy (e.g., Peg 1500, 2000, etc.
- the shakability of the formulation reduces until a limitation point is reached where the formulation becomes non shakable and unsuitable.
- an effective amount of surfactant may be used provided the formulation remains shakable.
- the upper limit may be determined by flowability such as in circumstances where the composition is marginally or apparently non-shakable.
- the formulation is sufficiently flowable to be able to flow through an actuator valve and be released and still expand to form a good quality foam.
- the amount of surfactant or combination of surfactants is between about 0.05% to about 20%; between about 0.05% to about 15%. or between about 0.05% to about 10%.
- the concentration of surfactant is between about 0.2% and about 8%.
- the concentration of surfactant is between about 1% and about 6%.
- the surfactant oil ratio is relatively high ranging from about of the order of 1:1 to about 1: 10. Nevertheless lower levels are possible.
- the surfactant does not contain a polyoxyethylene (POE) moiety, such as polysorbate surfactants, POE fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surfactants.
- POE polyoxyethylene
- the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surfactants are employed.
- POE—free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
- non-ethoxylated sorbitan esters such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan mono
- composition as formulated is a substantially non shakable composition it is nevertheless possible as an exception in the scope of the present invention for the formulation to be flowable to a sufficient degree to be able to flow through an actuator valve and be released and still expand to form a good quality foam.
- This surprising and unusual exception may be due one or more of a number of factors such as the high viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the composition.
- the propellant can change a merely flowable composition into a shakable one.
- the surface-active agent includes mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), prepared from sucrose and esters of fatty acids or by extraction from sucro-glycerides.
- sucrose esters include those having high monoester content, which have higher HLB values.
- the surface-active agent is selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants.
- the surfactant can be the phospholipids or the oil bodies.
- the total surfactant is usually in the range of about 0.1 to about 5% of the foamable composition, and is typically less than about 2% or less than about 1%.
- the total surfactant may be in the range of about 5% to about 25% and may preferably be in the range of about 6% to about 12%. In another preferred embodiment the total is about 8%.
- the surfactant plays a role in the determination of the viscosity of the formulation.
- the surfactants may have an inherent role in the surprising loss or reduction of viscosity to less than 500 cP even though the viscosity of the formulation can be much higher prior to nano processing with say up to six cycles with a high pressure homogenizer.
- the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols.
- Short chain alcohols having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect.
- the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- ‘Shakability’ means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases possibly aided by the presence of silicone it may exceptionally be possible to have a foamable composition which is flowable but not apparently shakable.
- a breakable foam is one that is thermally stable, yet breaks under sheer force.
- the breakable foam of the present invention is not “quick breaking”, i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, since it allows comfortable application and well directed administration to the target area.
- foam adjuvant is included in the foamable compositions of the present invention to increase the foaming capacity of surfactants and/or to stabilize the foam.
- the foam adjuvant agent includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof).
- fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50).
- Fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents.
- the amount of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains.
- Foam adjuvants, as defined herein are also useful in facilitating improved spreadability and absorption of the composition.
- the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
- fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
- fatty acids having 16 or more carbons in their carbon chain such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic
- the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond.
- a further class of foam adjuvant agent includes a branched fatty alcohol or fatty acid.
- the carbon chain of the fatty acid or fatty alcohol also can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
- fatty alcohols and fatty acids used in context of the composition of the present invention is related to their therapeutic properties per se.
- Long chain saturated and mono unsaturated fatty alcohols e.g., stearyl alcohol, erucyl alcohol, arachidyl alcohol and behenyl alcohol (docosanol) have been reported to possess antiviral, antiinfective, antiproliferative and antiinflammatory properties (see, for example, U.S. Pat. No. 4,874,794).
- Longer chain fatty alcohols e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc.
- tetracosanol hexacosanol
- heptacosanol heptacosanol
- octacosanol triacontanol, etc.
- Long chain fatty acids have also been reported to possess anti-infective characteristics.
- a combined and enhanced therapeutic effect is attained by including both a nonsteroidal immunomodulating agent and a therapeutically effective foam adjuvant in the same composition, thus providing a simultaneous anti-inflammatory and antiinfective effect from both components.
- the composition concurrently comprises a nonsteroidal immunomodulating agent, a therapeutically effective foam adjuvant and a therapeutically active oil, as detailed above.
- the foamable carrier, containing the foam adjuvant provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
- the foam adjuvant according to preferred embodiments of the present invention includes a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass. More preferably, the total amount is 0.4%-2.5% (w/w) of the carrier mass.
- the foam of the present invention may further optionally include a variety of formulation excipients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and modify their consistency.
- formulation excipients may be selected, for example, from stabilizing agents, antioxidants, humectants, preservatives, colorant and odorant agents and other formulation components, used in the art of formulation.
- Aerosol propellants are used to generate and administer the foamable composition as a foam.
- Suitable propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof.
- the propellant is AP 70 which is a mixture of propane, isobutene and butane.
- the propellant is AP 46 which is a similar mixture of propane, isobutene and butane but having a lower pressure.
- AP 70 offers about 50% higher pressure than AP 46.
- the propellant makes up about 3-25 wt % of the foamable composition. In some circumstances the propellant may be up to 35%.
- the propellants are used to generate and administer the foamable composition as a foam.
- the total composition including propellant, foamable compositions and optional ingredients can be referred to as the foamable composition.
- Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons.
- HFC hydrofluorocarbon
- Exemplary non-flammable propellants according to this aspect include propellants made by DuPont under the registered trademark Dymel, such as 1,1,1,2 tetrafluorethane (Dymel 134), and 1,1,1,2,3,3,3 heptafluoropropane (Dymel 227).
- HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
- foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
- foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbom propellants such as propane, isobutane and butane.
- a hydrocarbon propellant such as n-butane or mixtures of hydrocarbom propellants such as propane, isobutane and butane.
- compositions can subjected to a number of tests, including centrifugation to look for resistance to creaming, phase separation; one or more freeze thaw cycles, standing at room and higher temperatures as an indicator of resistance to aging.
- the foamable composition of the present invention is a carrier of a cosmetically or pharmaceutically active agent(s).
- the agents may be introduced into an aqueous phase (i.e., water), or a hydrophobic phase (e.g., hydrophobic solvent or oil globules).
- non binding and cosmetically or pharmaceutically active agents include, but are not limited to an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic
- one or more components of the oil bodies or sub-micron globules act possess a therapeutic property, such as detailed hereinabove, and thus, in such embodiments, the oil bodies or sub-micron globules can be considered herein as active agents.
- a pharmaceutical or cosmetic composition manufactured using the foam carrier according to one or more embodiments of the present invention is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
- the foam composition of the present invention creates a stable formulation having an acceptable shelf-life of at least one year, or at least two years at ambient temperature.
- a feature of a product for cosmetic or medical use is long term stability.
- Propellants which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions. It has been observed, however, that foam compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
- composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam.
- Foam quality can be graded as follows:
- Grade E excellent: very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery;
- Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery;
- Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity;
- Grade F very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery;
- Grade P no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance
- Grade VP dry foam, large very dull bubbles, difficult to spread on the skin.
- Topically administratable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
- a further aspect of the foam is breakability.
- the foam of the present invention is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally-induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
- foams have specific gravity of (1) less than 0.12 g/mL; or (2) the range between 0.02 and 0.12; or (3) the range between 0.04 and 0.10; or (4) the range between 0.06 and 0.10.
- compositions of the present invention are useful in treating an animal or a human patient having any one of a variety of dermatological disorders that include dry and/or scaly skin as one or their etiological factors (also termed “dermatoses”), such as classified in a non-limiting exemplary manner according to the following groups:
- Dermatitis including contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash;
- Bacterial infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, erythrasma;
- Fungal Infections including dermatophyte infections, yeast Infections; parasitic Infections including scabies, pediculosis, creeping eruption;
- hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsutism), alopecia, including male pattern baldness, alopecia areata, alopecia universalis and alopecia totalis; pseudofolliculitis barbae, keratinous cyst;
- Scaling papular diseases including psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris;
- Benign tumors including moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dermatofibroma, keratoacanthoma, keloid;
- Malignant tumors including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, paget's disease of the nipples, kaposi's sarcoma;
- Bullous diseases including pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear immunoglobulin A disease;
- Pigmentation disorders including hypopigmentation such as vitiligo, albinism and postinflammatory hypopigmentation and hyperpigmentation such as melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation;
- Inflammatory reactions including drug eruptions, toxic epidermal necrolysis; erythema multiforme, erythema nodosum, granuloma annulare.
- compositions are also useful in the therapy of non-dermatological disorders by providing transdermal delivery of an active nonsteroidal immunomodulating agent that is effective against non-dermatological disorders.
- composition is topically applied to a body cavity or mucosal surface (e.g., the mucosa of the nose, mouth, eye, ear, vagina or rectum) to treat conditions such as chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis,
- foamable compositions are described in: U.S. Publication No. 05-0232869, published on Oct. 20, 2005, entitled NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0205086, published on Sep. 22, 2005, entitled RETINOID IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0018937, published on Jan. 26, 2006, entitled STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on Dec.
- Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine.
- Pressurizing is carried out using a hydrocarbon gas or gas mixture
- Canisters are filled and then warmed for 30 sec in a warm bath at 50° C. and well shaken immediately thereafter.
- Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 60° C. water bath for 2 minutes.
- Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
- Oil Phase (A) The ingredients of the Oil Phase were preheated to the same temperature, e.g., 40-75° C., and then were combined with mixing. Oil soluble cosmetic or pharmaceutical active ingredients and optional oil soluble formulation ingredients are added with agitation to the Oil Phase mixture.
- the warm Oil Phase was gradually poured into the warm Aqueous Phase, with agitation, followed by Ultraturax homogenization.
- the mixture was allowed to cool down to ambient temperature.
- the active ingredient can be added with agitation to the mixture after cooling to ambient temperature.
- the mixture at ambient temperature, was added to an aerosol container, the container was sealed and appropriate amount of propellant (5-25 w % of the composition mass) was added under pressure into the container.
- micearoscopic observation of the resulting emulsion revealed mean particle size of 2 to 4 microns.
- the emulsion was passed through a microfluidizer, Microfluidics M-110Y Microfluidizer® M-110Y about 10 cycles, using ice to avoid heating the formula.
- a nanoemulsion composition (46 gram) was introduced into a 60 ml monoblock aluminum can.
- the can was sealed with an aerosol valve and 4 gram of liquefied propellant (propane butane isobutene mixture) was added through the valve.
- An emulsion (46 gram) was added into a 60 ml monoblock aluminum can.
- the can was closed with an aerosol valve and 4 gram of liquefied propellant (propane/butane mix) was added through the valve.
- the propellant can be any compressed and liquefied gas, currently used as aerosol propellant.
- the final concentration of propellant can vary from 3% to 25%.
- compositions NATO1 included the following steps:
- compositions NATO2 included the following steps:
- compositions of NATO3 included the following steps:
- compositions of NAT04 included the following steps:
- % w/w % w/w Caprylic/capric triglyceride 5.00 (MCT oil) Stearyl alcohol 0.90 — Natrulon OSF* 10.00 10.00 Methylcellulose 0.25 0.25 Xanthan gum 0.25 0.25 PEG-40 stearate 2.50 2.50 Polysorbate 80 0.90 0.90 Preservative 0.50 0.50 Purified water to 100% to 100% Propellant 8.00
- Emulsion visual test Uniform Uniform Viscosity (Spindle SC4-31)(cP) 1,428 868.5 Centrifugation (prior to propellant addition) Stable Stable (10 min/3,000 rpm) PH (direct, prior to propellant addition) 6.04 6.72 Foam Quality G E Density 0.0337 0.0339
- NEP002 NEP006 Isopropyl myristate 6.00 6.00 light Mineral oil 6.00 6.00 Glyceryl 0.50 1.00 monostearate PEG-40 stearate 3.00 6.00 Stearyl alcohol 1.00 1.00 Xanthan gum 0.30 0.30 Methocel K100M 0.30 0.30 Polysorbate 80 1.00 2.00 Water, purified 81.30 76.80 Sharomix 824 0.60 0.60 Total 100.00 100.00 Propellant 8.00 8.00 Cycles 4 3 Pressure (Bar) 1000-1500 Comments inter alia Emulsion broke after Emulsion still as to non suitability first cycle broke after first for nano emulsion cycle with double preparation surfactant that of 002.
- DISPA Diisopropyl adipate
- PPG Stearyl ether
- Steareth-2 3.67 4.00 Steareth 21 2.33 1.00 Carboxy methyl cellulose 0.50 0.50 Water, purified 72.90 73.90 Sharomix 824 0.60 0.60 Total 100.00 100.00 Propellant 8.00 8.00 Cycles 5 6 Pressure (Bar) 1000-1500 1000-1500 Visual Inspection Homogeneous Homogeneous Shakability Yes Yes F.Q.
- NEP011-4C NEP011-6C Isopropyl myristate 5.00 5.00 Octyl dodecanol 5.00 5.00 Cetearyl alcohol 3.00 3.00 Polyoxyl 100 monostearate 2.50 2.50 Methocel K100 LV 0.20 0.20 Carbomer 934P 0.40 0.40 Polysorbate 80 0.50 0.50 Propylene glycol 3.34 3.34 Water, purified 79.81 79.81 TEA, q.s.
- NEP013 NEP015 NEP014 Isopropyl myristate 10.00 10.00 10.00 light Mineral oil 10.00 10.00 10.00 Glyceryl monostearate 0.50 0.50 0.50 PEG-40 stearate 3.20 2.40 1.60 Stearyl alcohol 1.50 1.50 1.50 Carbomer 934P 0.40 0.40 0.40 Polysorbate 80 4.80 3.60 2.4 Propylene glycol 3.00 3.00 3.00 Water, purified 66.00 68.00 70.10 TEA, q.s.
- FIGS. 1A through 5C Notes to FIGS. 1A through 5C:
- nano emulsions surprisingly produced foam with a substantially larger foam bubble size ranging from an increase of about a third to an increase of almost four fold in magnitude, when the identical same formulation was subject to nano processing.
- foam of quality with a larger bubble size, which may intern positively influence the cosmetic elegance of the foam in that the formulation may have a more foam like feel with less of the sensation and greasy feeling that might be experienced with a cream or mousse
- the increased bubble size may contribute to ease of spreadability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum, and methods of using such a composition to treat, alleviate, or prevent a disorder of the skin, body cavity, or mucosal surface. The foamable oil in water nano emulsion composition includes: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent selected from (i) a non-ionic surfactant, (ii) an ionic surfactant, or (iii) a polymeric agent; and (c) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration.
Description
- This application is continuation of and claims benefit of priority to U.S. application Ser. No. 11/975,621, filed on Oct. 19, 2007, which is a continuation-in-part application of co-pending U.S. patent application Ser. No. 11/389,742, filed on Mar. 27, 2006, which (i) is a continuation-in-part of Ser. No. 10/911,367, filed on Aug. 4, 2004, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/492,385, filed on Aug. 4, 2003; (ii) claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/717,058, filed Sep. 14, 2005 and (iii) is a continuation-in-part of Ser. No. 10/532,618, filed on Dec. 22, 2005, which is a continuation-in-part of PCT/IB03/05527, filed on Oct. 24, 2003, which claims priority to U.S. Provisional Application No. 60/429,546, filed on Nov. 29, 2002 and Israeli Application No. 152486, filed on Oct. 25, 2002, all of which are incorporated in their entirety by reference.
- Foams and, in particular, foam emulsions are complex dispersion systems which do not form under all circumstances. Slight shifts in foam emulsion composition, such as by the addition of active ingredients, may destabilize the foam.
- Micro emulsions and nano emulsion can be monophasic, transparent (or slightly translucent) dispersions of oil and water. Unlike conventional emulsions, micro emulsions and nano emulsion can be thermodynamically stable, making them a favorable vehicle for pharmaceutical compositions, which have to maintain stability for long periods of time. Micro emulsions are sometimes said to be misleadingly called micro emulsions since they can form clear solutions devoid of the opaque color of regular emulsions. Micro emulsions can be oil external, water external and middle phase. Nano emulsions in contrast can be very fine oil in water dispersions. Droplet diameters can be as low as smaller than 100 nm. They can be in a metastable state and their structure can depend on the system history. They can be very fragile systems and can therefore be problematic in trying to formulate pharmaceutical and cosmetic compositions. If destabilized they can become opaque or exhibit creaming. On the other hand they can provide useful applications in skin care in that they may exhibit good textural and sensural properties due to the very fine droplet or globule size. Likewise for similar reasons they may provide more rapid penetration than conventional emulsions and can offer hydrating capabilities.
- Foams are very complex and sensitive systems and are not formed at will. Mere addition of basic ingredients like oil, water, surfactant and propellant is far from sufficient to produce foams of quality that are homogenous, stable, breakable upon mechanical force and can be used to provide a shelf stable pharmaceutical or cosmetic composition. Small deviations may lead to foam collapse. Much consideration needs to be given to facilitate the introduction of an active agent, such as examining compatibility and non reactivity with the various excipients and container and determining shelf life chemical stability. All these considerations become a greater and more non obvious challenge when trying to formulate a foamable nano-emulsion composition, which demands the symbiosis and compatibility of a complex, sensitive system with a fragile and metastable system to produce a homogenous, stable, breakable shelf stable nano foam. Moreover, nano droplets can be sterilized by filtration.
- Storage triacylglycerols (TAG) in plant seeds are present in small discrete intracellular organelles ranging from 1 to 2 μm, which are called oil-bodies. An oil body has a matrix of TAG, which is surrounded by phospholipids (PL) and alkaline proteins, termed oleosins. Oleosins are highly lipophilic proteins, are expressed at high levels in many seeds and are specifically targeted to oil-bodies. Oil-bodies are abundant in plant seeds and are among the simplest organelles present in eukaryotes. They are remarkably stable both inside the cells and in isolated preparations.
- Oil bodies are also termed in the literature as “oleosomes”, “lipid bodies” and “spherosomes”.
- The present invention relates to foamable compositions comprising oil in water nano emulsions which produce foam having an improved bubble size compared to the foam produced form a regular oil in water emulsion; to methods of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface using the foamable compositions; and to methods of producing a foam having an improved bubble size.
- In one aspect, the present invention provides a foamable oil in water nano emulsion composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging; wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In another aspect, the present invention provides a foamable oil in water nano emulsion composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging and wherein the viscosity of the nano emulsion is substantially reduced than the viscosity of the a macro emulsion having substaintially the same composition; wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer forcea; and wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In yet another aspect, the present invention provides a foamable oil in water nano emulsion composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging; wherein the composition prior to addition of propellant is translucent with a blue tint; wherein if the composition is contained in a pressurized container and further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 35% by weight of the total composition it is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In one aspect there is provided a foamable oil in water nano emulsion, composition containing small oil globules including an oil globule system, selected from the group consisting of oil bodies and sub-micron oil globules, about 0.1% to about 5% by weight of at least one stabilizing agent selected from the group consisting of a non-ionic surfactant having an HLB value between 9 and 16, an ionic surfactant, and a polymeric agent water, as well as a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- According to further embodiments of the foamable composition of present invention, the oil globule system consists of oil bodies and the stabilizing agent consists of a polymeric agent.
- According to still further embodiments of the foamable composition of present invention, the oil globule system consists of oil bodies and the stabilizing agent consists of an ionic surfactant.
- According to yet further embodiments of the present invention the surface-active agent is a phospholipid.
- According to still further embodiments of the present invention, the oil bodies are discrete oleaginous particles ranging from about 1 to about 3 μm in dimension. Oil bodies contain triacylclycerols (TAG), surrounded by phospholipids (PL) and oleosins.
- According to further embodiments of the present invention, the phospholipids are selected from the group consisting of phosphatidylethanolamine, phosphatidylcholine, lecithin, phosphatidylserine, phosphatidylglycerol and phosphatidylinositol.
- According to still further embodiments of the present invention, the oleosins are highly lipophilic small proteins of about 25 to 26 kD.
- In one or more embodiments, the oil bodies are derived from the seeds of a plant, selected from the group consisting of almond (Prunus dulcis), anise (Pimpinella anisum), avocado (Persea spp.), beach nut (Fagus sylvatica), borage (also known as evening primrose) (Boragio officinalis), Brazil nut (Bertholetia excelsa), candle nut (Aleuritis tiglium), carapa (Carapa guineensis), cashew nut (Ancardium occidentale), castor (Ricinus communis), coconut (Cocus nucifera), coriander (Coriandrum sativum), cottonseed (Gossypium spp.), crambe (Crambe abyssinica), Crepis alpina, croton (Croton tiglium), Cuphea spp., dill (Anethum gravealis), Euphorbia lagascae, Dimorphoteca pluvialis, false flax (Camolina sativa), fennel (Foeniculum vulgaris), groundnut (Arachis hypogaea), hazelnut (coryllus avellana), hemp (Cannabis sativa), honesty plant (lunnaria annua), jojoba (Simmiondsia chinensis), kapok fruit (Ceiba pentandra), kukui nut (Aleuritis moluccana), Lesquerella spp., linseed/flax (Linum usitatissimum), macademia nut (Macademia spp.), maize (Zea mays), meadow foam (Limnanthes alba), mustard (Brassica spp. and Sinapis alba), oil palm (Elaeis guineeis), oiticia (Licania rigida), paw paw (Assimina triloba), pecan (Juglandaceae ssp.), perilla (Perilla futescens), physic nut (Gairopha curcas), pilinut (Canariuim ovatum), pine nut (pine spp.), pistachio (Pistachia vera), pongam (Bongamin glabra), poppy seed (Papaver soniferum), rapeseed (Brassica spp.), safflower (Carthamus tinctorius), sesame seed (Sesamum indicum), soybean (Glycine max), squash (Cucurbita maxima), sal tree (Shorea rubusha), Stokes aster (Stokesia laevis), sunflower (Helianthus annuus), tukuma (Astocarya spp.), tung nut (Aleuritis cordata), and vernolnia (Verzonia galamensis).
- According to a further embodiment of the foamable composition, the foamable composition further includes about 0.1% to about 5% by weight of a foam adjuvant selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain, a fatty acid having 16 or more carbons in their carbon chain, fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, a fatty alcohol having at least one double bond, a fatty acid having at least one double bond, a branched fatty alcohol, a branched fatty acid, and a fatty acid substituted with a hydroxyl group and mixtures thereof.
- According to further embodiments of the present invention, the foamable composition is substantially alcohol-free.
- According to still further embodiments of the present invention, the concentration range of oil globules is selected from the group of (i) about 0.05% and about 2% and about 5%, (ii) about 2% (iii) about 5% and about 12%, and (iv) about 12% and about 24%.
- According to further embodiments of the present invention, the polymeric agent is selected from the group consisting of a water-soluble cellulose ether and naturally-occurring polymeric material.
- According to still further embodiments of the present invention, the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, xanthan gum, guar gum, carrageenin gum, locust bean gum and tragacanth gum.
- According to yet further embodiments of the present invention, the foamable composition further includes at least one therapeutic agent.
- According to further embodiments of the present invention, the therapeutic agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal anti-inflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agen, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, an anti-wrinkle agent, a radical scavenger, a metal oxide (e.g., titanium dioxide, zinc oxide, zirconium oxide, iron oxide, silicone oxide, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof).
- According to still further embodiments of the present invention, the therapeutic agent is selected from the components of the oil bodies or sub-micron oil globules.
- According to further embodiments of the present invention, the therapeutic agent is suitable to treat a disorder selected from the group consisting of dermatological disorder, a cosmetic disorder, a gynecological disorder, a disorder of a body cavity, wound and burn.
- In a further aspect, the present invention provides methods of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface using the foamable compositions described herein.
- In one aspect, the present invention provides a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface, wherein said disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors, comprising: administering topically to a subject having said disorder, a foamed composition comprising: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging and wherein the viscosity of the pre foam formulation remains substantially high after it has been subject to nano processing; wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- According to a further embodiment of the present invention, there is provided a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface, wherein the disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors. The method includes administering topically to a subject having the disorder, a foamed composition containing (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- According to a further embodiment of the method, the composition further includes an active agent effective to treat a disorder, and wherein the disorder is selected from the group consisting of a vaginal disorder, a vulvar disorder, an anal disorder, a disorder of a body cavity, an ear disorder, a disorder of the nose, a disorder of the respiratory system, a bacterial infection, fungal infection, viral infection, dermatosis, dermatitis, parasitic infections, disorders of hair follicles and sebaceous glands, scaling papular diseases, benign tumors, malignant tumors, reactions to sunlight, bullous diseases, pigmentation disorders, disorders of cornification, pressure sores, disorders of sweating, inflammatory reactions, xerosis, ichthyosis, allergy, burn, wound, cut, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, osteoarthritis, joint pain, hormonal disorder, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
- According to a further embodiment of the present invention, there is provided a method to promote the penetration of an active agent into the surface layers of the skin and mucosal membranes. The method includes applying a foamable composition to the surface layers of a skin or mucosal membrane the foamable composition, comprising (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- According to a further embodiment of the present invention, there is provided a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface, wherein said disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors. The method includes applying a foamable composition to the surface layers of a skin, body cavity or mucosal membrane the foamable composition, comprising (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; (c) water; and (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. In certain embodiments, the composition prior to addition of propellant is translucent with a blue tint.
- In one aspect, the present invention provides a method of producing a foam having improved foam bubble size comprising: (i) preparing a pre foam oil in water emulsion formulation, wherein the pre foam oil comprises (a) oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent selected from the group consisting of a non-ionic surfactant, an ionic surfactant, and a polymeric agent; and (c) water; (ii) subjecting the pre foam formulation to high pressure mechanical stress to produce a nano emulsion; (iii) storing the nano emulsion in a sealed pressurized container that further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 25% by weight of the total composition and having an outlet capable of releasing the pressurized product as a foam; and (iv) releasing the foam, wherein the bubble size of the resultant foam is significantly greater than the bubble size of a resultant foam from the pre foam oil in water emulsion formulation stored in a sealed pressurized container that further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 25% by weight of the total composition and having an outlet capable of releasing the pressurized product as a foam.
-
FIG. 1A shows pictures of a sample section of the foam produced from composition 13 of Example 9 before nano processing. -
FIG. 1B shows pictures of a sample section of the foam produced from composition 13 of Example 9 after 6 cycles of nano processing. -
FIG. 2A shows pictures of a sample section of the foam produced from composition 11 of Example 8 before nano processing. -
FIG. 2B shows pictures of a sample section of the foam produced from composition 11 of Example 8 after 6 cycles of nano processing. -
FIG. 3A shows pictures of a sample section of the foam produced from composition 7 of Example 7 before nano processing. -
FIG. 3B shows pictures of a sample section of the foam produced from composition 10 of Example 7 after 6 cycles of nano processing. -
FIG. 4A shows pictures of a sample section of the foam produced from composition 14 of Example 9 before nano processing. -
FIG. 4B shows pictures of a sample section of the foam produced from composition 14 of Example 9 after 6 cycles of nano processing. -
FIG. 5A shows pictures of a sample section of the foam produced from composition 15 of Example 9 before nano processing, which foam comprises propellant having 50% more pressure than that of the foam as shown inFIG. 5B . -
FIG. 5B shows pictures of a sample section of the foam produced from composition 15 of Example 9 before nano processing. -
FIG. 5C shows pictures of a sample section of the foam produced from composition 15 of Example 9 after 6 cycles of nano processing. - The present invention provides a foamable oil in water nano emulsion, composition including small oil globules. As used herein, the terms droplets, globules and particles, when referencing an emulsion, are used interchangeably. All % values are provided on a weight (w/w) basis.
- According to one or more embodiments of the present invention, the foamable oil in water nano emulsion composition is intended for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein “target site”).
- In an embodiment there is provided a foamable oil in water nano emulsion composition comprising:
-
- (a) A nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent;
- (c) water; and
- (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging;
- wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In another embodiment the oil globule system consists of oil globules with an average diameter size in the range of about 1000 nanometers to about 10 nanometers; and the stabilizing agent consists of a polymeric agent.
- In an embodiment there is provided a foamable oil in water nano emulsion composition comprising a non-ionic surfactant having an HLB value between 9 and 16; and/or an ionic surfactant.
- In another embodiment the oil globules are discrete particles with the majority having a size ranging from about 300 to about 20 nanometers in at least one dimension.
- In another embodiment the oil globule system consists of sub-micron oil globules; and the stabilizing agent consists of a surfactant, having an HLB value or a mean HLB value between 9 and 16.
- In a further embodiment the ratio of surfactant to oil is high being in the range of the order of about 1:1 to about 1:10
- In another embodiment the sub-micron oil globules contain at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof.
- In a further embodiment said submicron oil globules are about 50% to about 100% of the composition.
- In another embodiment the sub-micron oil globules have a number-average size range, selected from (i) 40 nm to 1,000 nm. (ii) 40 nm to 500 nm; (iii) 40 nm to 200 nm; (iv) 40 nm to 100 nm (v) less than 500 nm; (vi) less than 200 nm; and (vii) less than 100 nm.
- In an embodiment the sub-micron oil globules are produced by high sheer homogenization.
- In an embodiment there is provided a foamable oil in water nano emulsion composition further comprising about 0.1% to about 5% by weight of a foam adjuvant selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain; fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain; a fatty alcohol having at least one double bond; a fatty acid having at least one double bond; a branched fatty alcohol; a branched fatty acid; and a fatty acid substituted with a hydroxyl group and mixtures thereof.
- In an embodiment said foamable composition is substantially alcohol-free.
- In an embodiment there is provided a foamable oil in water nano emulsion composition further containing at least one therapeutic agent.
- In an embodiment the therapeutic agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, an anti-wrinkle agent, a radical scavenger, a metal oxide (e.g., titanium dioxide, zinc oxide, zirconium oxide, iron oxide), silicone oxide, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof.
- In an embodiment the therapeutic agent is suitable to treat a disorder, selected from a dermatological disorder, a cosmetic disorder, a gynecological disorder, a disorder of a body cavity, wound and burn.
- In an embodiment there is provided a foamable oil in water nano emulsion composition wherein the HLB or mean HLB value of said non-ionic surfactant is between about 2 and about 9.
- In an embodiment the stabilizing agent is a polymeric agent selected from the group consisting of a water-soluble cellulose ether naturally-occurring polymeric material, microcrystalline cellulose, hydrophobically-modified ethoxylated urethane, and a carbomer.
- In an embodiment the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, xanthan gum, guar gum, carrageenin gum, locust bean gum and tragacanth gum.
- In an embodiment the surfactant is selected from the group consisting of steareth 2, steareth 21, ceteth-20, span 80, behenyl alcohol, glyceryl monostearate, PEG 40 stearate, polyoxyl 100 monostearate, methyl glucose seasquit stearate and polysorbate 80.
- In an embodiment there is provided a foamable oil in water nano emulsion composition wherein the density of the foam is selected from the group consisting of (1) less than 0.12 g/mL; (2) the range between 0.02 and 0.12; (3) the range between 0.04 and 0.10; (4) the range between 0.06 and 0.10.
- In an embodiment there is provided a foamable oil in water nano emulsion composition comprising:
-
- (a) A nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent;
- (c) water; and
- (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging and wherein the viscosity of the pre foam formulation is substantially reduced after it has been subject to nano processing;
- wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In an embodiment there is provided a foamable oil in water nano emulsion composition wherein the viscosity is selected from the group consisting of (1) between about 6000 cP and about 4000 cP (2) between about 4000 cP and about 2000 cP (3) between about 2000 cP and about 500 cP (4) between about 500 cP and about 1 cP.
- In an embodiment the viscosity is preferably between about 500 cP and about 1 cP and the foam is of good or excellent quality.
- In another embodiment the viscosity is above 20,000 cP.
- In another embodiment the polymeric agent is a carbomer. In another embodiment the carbomer is the sole polymeric agent.
- In a further embodiment the carbomer substantially contributes to the viscosity and exhibits resistant to viscosity reduction on nano processing
- In a further embodiment there is provided a foamable oil in water nano emulsion composition comprising:
-
- (a) A nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent comprising a carbomer polymeric agent, and a second stabilizing agent selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent;
- (c) water; and
- (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging and wherein the viscosity of the pre foam formulation remains substantially high after it has been subject to nano processing;
- wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In a still further embodiment there is provided a foamable oil in water nano emulsion composition comprising:
-
- (a) a nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent; and
- (c) water;
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging;
- wherein the composition prior to addition of propellant is translucent with a blue tint;
- wherein if the composition is contained in a pressurized container and further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 35% by weight of the total composition it is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In another embodiment there is provided a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface, wherein said disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors, comprising:
-
- administering topically to a subject having said disorder, a foamed composition comprising:
- (a) a nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent;
- (c) water; and
- (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging;
- wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In an additional embodiment the composition further comprises an active agent effective to treat a disorder and wherein the disorder is selected from the group consisting of a vaginal disorder, a vulvar disorder, an anal disorder, a disorder of a body cavity, an ear disorder, a disorder of the nose, a disorder of the respiratory system, a bacterial infection, fungal infection, viral infection, dermatosis, dermatitis, parasitic infections, disorders of hair follicles and sebaceous glands, scaling papular diseases, benign tumors, malignant tumors, reactions to sunlight, bullous diseases, pigmentation disorders, disorders of cornification, pressure sores, disorders of sweating, inflammatory reactions, xerosis, ichthyosis, allergy, burn, wound, cut, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, osteoarthritis, joint pain, hormonal disorder, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
- In one or more embodiments there is provided a method of promoting the penetration of an active agent into the surface layers of the skin and mucosal membranes, comprising: apply a foamable composition to the surface layers of a stem or mucosal membrane, the foamable composition comprising:
-
- (a) a nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent;
- (c) water; and
- (d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging;
- wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In a further embodiment of the method of promoting penetration the active agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, an anti-wrinkle agent, a radical scavenger, a metal oxide (e.g., titanium dioxide, zinc oxide, zirconium oxide, iron oxide), silicone oxide, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent and a refatting agent.
- In a further embodiment there is provided a method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface, wherein said disorder involves insufficient hydration of skin or a mucosal surface as one of its etiological factors, comprising:
-
- administering topically to a subject having said disorder, a foamed composition comprising:
- (a) a nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent; and
- (c) water;
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging;
- wherein the composition prior to addition of propellant is translucent with a blue tint;
- wherein if the composition is contained in a pressurized container and further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 35% by weight of the total composition it is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In a further embodiment of the method of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface the composition further comprises an active agent effective to treat a disorder and wherein the disorder is selected from the group described above.
- In a further embodiment there is provided a method of promoting the penetration of an active agent into the surface layers of the skin and mucosal membranes, comprising: apply a foamable composition to the surface layers of a stem or mucosal membrane, the foamable composition comprising:
-
- (a) a nano oil globule system, comprising substantially of sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
- i. a non-ionic surfactant,
- ii. an ionic surfactant, and
- iii. a polymeric agent; and
- (c) water;
- wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging;
- wherein the composition prior to addition of propellant is translucent with a blue tint;
- wherein if the composition is contained in a pressurized container and further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 35% by weight of the total composition it is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
- In a further embodiment of the method of promoting the penetration of an active agent the active agent is selected from the group listed above.
- In one or more other embodiments there is provided a foamable oil in water nano emulsion composition for use as a medicament or in the manufacture of a medicament.
- In one or more embodiments there is also provided a method of producing a foam having improved foam bubble size comprising
-
- i. preparing a pre foam oil in water emulsion formulation;
- ii. subjecting the pre foam formulation to high pressure mechanical stress to produce a nano emulsion;
- iii. storing the nano emulsion in a sealed pressurized container that further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 25% by weight of the total composition and having an outlet capable of releasing the pressurized product as a foam; and
- iv. releasing the foam;
- wherein the bubble size of the resultant foam is significantly greater than the bubble size of a resultant foam from the pre foam oil in water emulsion formulation stored in a sealed pressurized container that further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 25% by weight of the total composition and having an outlet capable of releasing the pressurized product as a foam.
- The foamable oil in water nano emulsion composition includes:
-
- (a) an oil globule system selected from the group consisting of oil bodies and sub-micron oil globules;
- (b) about 0.1% to about 5% by weight of at least one stabilizing agent selected from the group consisting of a non-ionic surfactant selected from the group consisting of a non-ionic surfactant, having an HLB value between 9 and 16, an ionic surfactant; and a polymeric agent; and
- (c) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- Water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms an expanded foam suitable for topical administration.
- In one or more embodiments, the oil globules are oil bodies. Oil bodies, also termed “oleosomes”, “lipid bodies” and “spherosomes”, are small discrete oleaginous particles, ranging in size from about 1 to about 3 μm along one dimension. Oil bodies consist of triacylglycerols (TAG) surrounded by phospholipids (PL) and alkaline proteins, termed oleosins.
- Triacylglycerides (also termed triglycerides) are chemically defined as glycerol esters of fatty acids. The seed oil present in the oil body fraction of plant species is a mixture of various triacylglycerides, of which the exact composition depends on the plant species from which the oil is derived.
- Phospolipids possess a structure that is very similar to that of the triacylglycerides except that a terminal carbon of the glycerol backbone is esterified to phosphoric acid. Substitution of the hydrogen atom of phosphatidic acid results in additional phospholipids classes, including but not limited to the following:
-
Substitution Phospholipid Ethanolamine Phosphatidylethanolamine Choline Phosphatidylcholine, also called lecithins Serine Phosphatidylserine Glycerol Phosphatidylglycerol Myo-inositol Phosphatidylinositol - Oleosins are highly lipophilic small proteins of about 15 to 26 kD. They are expressed at high levels in many seeds and are specifically targeted to oil-bodies. Oleosins completely cover the surface of the subcellular oil bodies.
- Oil-bodies are abundant in plant seeds and are among the simplest organelles present in eukaryotes. They are remarkably stable both inside the cells and in isolated preparations.
- Oil bodies are prepared from plant seeds. Exemplary plant seeds include (alphabetically) almond (Prunus dulcis); anise (Pimpinella anisum); avocado (Persea spp.); beach nut (Fagus sylvatica); borage (also known as evening primrose) (Boragio officinalis); Brazil nut (Bertholletia excelsa); candle nut (Aleuritis tiglium); carapa (Carapa guineensis); cashew nut (Ancardium occidentale); castor (Ricinus communis); coconut (Cocus nucifera); coriander (Coriandrum sativum); cottonseed (Gossypium spp.); crambe (Crambe abyssinica); Crepis alpina; croton (Croton tiglium); Cuphea spp.; dill (Anethum gravealis); Euphorbia lagascae; Dimorphoteca pluvialis; false flax (Camolina sativa); fennel (Foeniculum vulgaris); groundnut (Arachis hypogaea); hazelnut (coryllus avellana); hemp (Cannabis sativa); honesty plant (Lunnaria annua); jojoba (Simmiondsia chinensis); kapok fruit (Ceiba pentandra); kukui nut (Aleuritis moluccana); Lesquerella spp., linseed/flax (Linum usitatissimum); macademia nut (Macademia spp.); maize (Zea mays); meadow foam (Limnanthes alba); mustard (Brassica spp. and Sinapis alba); oil palm (Elaeis guineeis); oiticia (Licania rigida); paw paw (Assimina triloba); pecan (Juglandaceae spp.); perilla (Perilla frutescens); physic nut (Gairopha curcas); pilinut (Canariuim ovatum); pine nut (pine spp.); pistachio (Pistachia vera); pongam (Bongamin glabra); poppy seed (Papaver soniferum); rapeseed (Brassica spp.); safflower (Carthamus tinctorius); sesame seed (Sesamum indicum); soybean (Glycine max); squash (Cucurbita maxima); sal tree (Shorea rubusha); Stokes aster (Stokesia laevis); sunflower (Helianthus annuus); tukuma (Astocarya spp.); tung nut (Aleuritis cordata); and vernolnia (Verzonia galamensis). Isolation of oil bodies from plant sources is well known. See, for example, U.S. Pat. No. 5,650,554.
- Stable artificial oil bodies can be reconstituted with triacylglycerol, phospholipid, and oleosin via sonication, as described, for example in J. T. C. Tzen, Y. Z. Cao, P. Laurent, C. Ratnayake, and A. H. C. Huang. 1993. Lipids, proteins, and structure of seed oil bodies from diverse species. Plant Physiol. 101:267-276.
- The skin-beneficial effects of oil bodies include, but are not limited to (1) antioxidant effects (resulting from the presence of tocopherol and other antioxidants naturally present in the oil bodies); (2) occlusivity, as determined by improved skin barrier function and reduced trans-epidermal water loss; and (3) emolliency. Furthermore, the oil bodies building blocks—the triacylglycerides and the phospholipids—contain unsaturated or polyunsaturated fatty acids. Exemplary unsaturated fatty acids are omega-3 and omega-6 fatty acids. Other examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Such unsaturated fatty acids are known for their skin-conditioning and anti-inflammatory effects, which contribute to the therapeutic benefit of the present foamable composition.
- Because oil bodies contain phospholipids and oleosins, which concurrently carry hydrophobic and hydrophilic moieties, they act as emulsifiers and, as a result, upon dilution with water with mild mixing, they spontaneously form an emulsion.
- In one or more embodiments, the oil globules are sub-micron oil globules, i.e., oil globules, which have a number-average size of less than 1,000 nm. An emulsion, comprising sub-micron globules or nano-size globules is called sub-micron emulsion (“SME”) or microemulsion or nanoemulsion, respectively. In one or more embodiments, the oil globules have a number-average size of less than 500 nm; or less than 200 nm; or less than 100 nm. In certain embodiments, the oil globules have number-average size in the following ranges: (i) 40 nm to 1,000 nm. (ii) 40 nm to 500 nm; (iii) 40 nm to 200 nm; or (iv) 40 nm to 100 nm.
- SMEs are dispersions of oil and water. With reference to conventional emulsions, SMEs are more stable, making them a favorable vehicle for pharmaceutical compositions, which have to maintain stability for long periods of time. SMEs may be used in vehicles for transporting nutraceuticals, medicaments, peptides or proteins. The decrease in size of the globules makes it possible to promote the penetration of the active agents into the surface layers of the skin and mucosal membranes.
- In SMEs, the active compounds can be solubilized. The general concept of solubilization of active components and its utilization may be found in the following review articles: 1. Solans, C., Pons, R., Kunieda, H “Overview of basic aspects of microemulsions” Industrial Applications of Microemulsions, Solans, C., Kunieda, H., Eds. Dekker, New York (1997); 66: 1-17, 2. Dungan, S. R., “Microemulsions in foods: properties and application” ibid 148-170; 3. Holmberg, K. “Quarter century progress and new horizons in microemulsions” in Micelles, Microemulsions and Monolayers, Shah, O. Ed.; Dekker: New York (1998) 161-192; 4. Garti, N. “Microemulsions, emulsions, double emulsions and emulsions in food” in Formulation Science (proceeding from formulation forum '97 association of formulation chemists) (1998) 1, 147-219; 5. Ezrahi, S., Aserin, A. Garti, N. in Micoremulsions-fundamental wad applied aspects Kumar, P. and Mittal, K. L. Eds. Marcel Dekker, Inc. New York (1999) “Aggregation behavior in one-phase (Winsor IV) systems” 185-246; 6. Garti, N. Clement, V., Leser, M., Aserin, A. Fanun, M. “Sucrose esters microemulsions J. Molec. Liquids (1999) 80, 253-296.
- In certain embodiments, the production of SMEs and nanoemulsion involves very-high sheer homogenizers. An exemplary homogenizer, suitable for producing nano-emulsions is the commercially-available “Microfluidizer®”. Microfluidizer® fluid processors are built for deagglomeration and dispersion of uniform submicron particles and creation of stable emulsions and dispersions. Microfluidizer processors overcome limitations of conventional processing technologies by utilizing high-pressure streams that collide at ultra-high velocities in precisely defined microchannels. Combined forces of shear and impact act upon products to attain uniform particle and droplet size reduction (often submicron), deagglomeration and high yield cell disruption.
- Notwithstanding the above, any other very-high sheer homogenizer, capable of producing submicron particles is suitable for use in the production of a microemulsions or a nanoemulsion according to the present invention.
- In additional embodiments, the SMEs form spontaneously with gentle mixing such as hand shaking.
- The sub-micron particles contain at least one organic carrier, preferably a hydrophobic organic carrier. In addition, the composition may contain one or more of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%, or about 10% to about 20%, or about 20% to about 50% by weight.
- A “hydrophobic organic carrier” as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL. It is liquid at ambient temperature. The identification of a hydrophobic organic carrier or “hydrophobic solvent”, as used herein, is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. Rather, such information is provided to aid in the identification of materials suitable for use as a hydrophobic carrier in the foamable compositions described herein.
- In one or more embodiments, the hydrophobic organic carrier is an oil, such as mineral oil. Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that derive from petroleum. It is typically liquid; its viscosity is in the range of between about 35 CST and about 100 CST (at 40° C.), and its pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming so preventing flow) is below 0° C. In one or more embodiments, the term hydrophobic organic carrier does not include thick or semi-solid materials, such as white petrolatum, also termed “Vaseline”, which, in certain compositions is disadvantageous due to its waxy nature and semi-solid texture.
- According to one or more embodiments, hydrophobic solvents are liquid oils originating from vegetable, marine or animal sources. Suitable liquid oil includes saturated, unsaturated or polyunsaturated oils. By way of example, the unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
- Suitable hydrophobic solvents also include polyunsaturated oils containing poly-unsaturated fatty acids. In one or more embodiments, said unsaturated fatty acids are selected from the group of omega-3 and omega-6 fatty acids. Examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Such unsaturated fatty acids are known for their skin-conditioning effect, which contribute to the therapeutic benefit of the present foamable composition. Thus, the hydrophobic solvent can include at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof. In the context of the present invention, oils that possess therapeutically beneficial properties are termed “therapeutically active oil.”
- Another class of hydrophobic solvents is the essential oils, which are also considered therapeutically active oil, which contain active biologically occurring molecules and, upon topical application, exert a therapeutic effect, which is conceivably synergistic to the beneficial effect of the NSAID in the composition.
- Another class of therapeutically active oils includes liquid hydrophobic plant-derived oils, which are known to possess therapeutic benefits when applied topically.
- Silicone oils also may be used and are desirable due to their known skin protective and occlusive properties. Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. These are chosen from cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms. Volatile silicones such as cyclomethicones can also be used. Silicone oils are also considered therapeutically active oil, due to their barrier retaining and protective properties.
- The organic carrier may be a mixture of two or more of the above hydrophobic solvents in any proportion.
- A further class of organic carriers includes “emollients” that have a softening or soothing effect, especially when applied to body areas, such as the skin and mucosal surfaces. Emollients are not necessarily hydrophobic. Examples of suitable emollients include hexyleneglycol, propylene glycol, isostearic acid derivatives, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated oil bodies alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, sucrose esters of fatty acids, octyl hydroxystearate and mixtures thereof.
- According to one or more embodiments of the present invention, the organic carrier includes a mixture of a hydrophobic solvent and an emollient. According to one or more embodiments, the foamable composition is a mixture of mineral oil and an emollient in a ratio between 2:8 and 8:2 on a weight basis.
- A “polar solvent” is an organic solvent, typically soluble in both water and oil. Examples of polar solvents include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglycerides, octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketones; amides, such as acetamide oleates such as triolein; various alkanoic acids such as caprylic acid; lactam compounds, such as azone; alkanols, such as dialkylamino acetates, and admixtures thereof.
- According to one or more embodiments, the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200(MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
- According to one or more embodiments, the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect. Thus, the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- The composition includes a stabilizing agent, which may be a polymeric agent. The polymeric agent serves to stabilize the foam composition and to control drug residence in the target organ. Exemplary polymeric agents are classified below in a non-limiting manner. In certain cases, a given polymer can belong to more than one of the classes provided below.
- The polymeric agent may be a gelling agent. A gelling agent controls the residence of a therapeutic composition in the target site of treatment by increasing the viscosity of the composition, thereby limiting the rate of its clearance from the site. Many gelling agents are known in the art to possess mucoadhesive properties.
- The gelling agent can be a natural gelling agent, a synthetic gelling agent and an inorganic gelling agent. Exemplary gelling agents that can be used in accordance with one or more embodiments of the present invention include, for example, microcrystalline cellulose, Aculyn a Hydrophobically-modified Ethoxylated Urethane, naturally-occurring polymeric materials, such as locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g. hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose), guar gum, hydroxypropyl guar gum, soluble starch, cationic celluloses, cationic guars, and the like, and synthetic polymeric materials, such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Mixtures of the above compounds are contemplated.
- Further exemplary gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol® resins. These resins consist essentially of a colloidal water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Carbopol® 934, Carbopol® 940, Carbopol® 950, Carbopol® 980, Carbopol® 951 and Carbopol® 981. Carbopol® 934 is a water-soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
- The gelling agent may be a water-soluble cellulose ether. Preferably, the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose and carboxymethylhydroxyethylcellulose. More preferably, the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose (Methocel). In one or more embodiments, the composition includes a combination of a water-soluble cellulose ether; and a naturally-occurring polymeric materials, selected from the group including xanthan gum, guar gum, carrageenan gum, locust bean gum and tragacanth gum.
- Yet, in other embodiments, the gelling agent includes inorganic gelling agents, such as silicone dioxide (fumed silica).
- The polymeric agent may be a mucoadhesive agent. Mucoadhesion/bioadhesion is defined as the attachment of synthetic or biological macromolecules to a biological tissue. Mucoadhesive agents are a class of polymeric biomaterials that exhibit the basic characteristic of a hydrogel, i.e. swell by absorbing water and interacting by means of adhesion with the mucous that covers epithelia. Compositions of the present invention may contain a mucoadhesive macromolecule or polymer in an amount sufficient to confer bioadhesive properties. The bioadhesive macromolecule enhances the delivery of biologically active agents on or through the target surface. The mucoadhesive macromolecule may be selected from acidic synthetic polymers, preferably having at least one acidic group per four repeating or monomeric subunit moieties, such as poly(acrylic)- and/or poly(methacrylic) acid (e.g., Carbopol®, Carbomer®), poly(methylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC); neutral synthetically modified natural polymers, such as (hydroxypropyl)methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral synthetic polymers, such as polyvinyl alcohol or their mixtures. An additional group of mucoadhesive polymers includes natural and chemically modified cyclodextrin, especially hydroxypropyl-β-cyclodextrin. Such polymers may be present as free acids, bases, or salts, usually in a final concentration of about 0.01% to about 0.5% by weight.
- A suitable bioadhesive macromolecule is the family of acrylic acid polymers and copolymers, (e.g., Carbopol®). These polymers contain the general structure —[CH2—CH(COOH)—]n. Hyaluronic acid and other biologically-derived polymers may be used.
- Exemplary bioadhesive or mucoadhesive macromolecules have a molecular weight of at least 50 kDa, or at least 300 kDa, or at least 1,000 kDa. Favored polymeric ionizable macromolecules have not less than 2 mole percent acidic groups (e.g., COOH, SO3H) or basic groups (NH2, NRH, NR2), relative to the number of monomeric units. The acidic or basic groups can constitute at least 5 mole percent, or at least 10 mole percent, or at least 25, at least 50 mole percent, or even up to 100 mole percent relative to the number of monomeric units of the macromolecule.
- Yet, another group of mucoadhesive agent includes inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSIL 200 (DEGUSSA).
- Many mucoadhesive agents are known in the art to also possess gelling properties.
- The polymeric agent may be a film forming component. The film forming component may include at least one water-insoluble alkyl cellulose or hydroxyalkyl cellulose. Exemplary alkyl cellulose or hydroxyalkyl cellulose polymers include ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, hydroxypropyl cellulose, hydroxybutyl cellulose, and ethylhydroxyethyl cellulose, alone or in combination. In addition, a plasticizer or a cross linking agent may be used to modify the polymer's characteristics. For example, esters such as dibutyl or diethyl phthalate, amides such as diethyldiphenyl urea, vegetable oils, fatty acids and alcohols such as oleic and myristyl acid may be used in combination with the cellulose derivative.
- The polymeric agent may be a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface. Such phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca2+). Non-limiting examples of phase change polymers include poly(N-isopropylamide), Poloxamer 407® and Smart-Gel® (Poloxamer+PAA). The polymeric agent is present in an amount in the range of about 0.01% to about 5.0% by weight of the foam composition. In one or more embodiments, it is typically less than about 1 wt % of the foamable composition.
- The stabilizing agent may also be a surface-active agent. Surface-active agents (also termed “surfactants”) include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions. The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average). In many cases a single surfactant may suffice. In other cases a combination of two or more surfactants is desired. Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants is usually preferable where the vehicle is an emulsion. In an emulsion environment a combination of surfactants can be significant in producing breakable forms of good quality. It has been further discovered that the generally thought considerations for HLB values for selecting a surfactant or surfactant combination are not always binding for emulsions and that good quality foams can be produced with a surfactant or surfactant combination both where the HLB values are in or towards the lipophilic side of the scale and where the HLB values are in or towards the hydrophilic side of the scale. Surfactants also play a role in foam formation where the foamable formulation is a single phase composition.
- The relationship between oil and surfactant is indicated by the required predicted HLB for the oil and the parallel theoretical HLB of the surfactant as shown in the non limiting examples below.
- According to one or more embodiments the composition contains a single surfactant having an HLB value between about 2 and 9, or more than one surfactant and the weighted average of their HLB values is between about 2 and about 9. Lower HLB values may in certain embodiments be more applicable to water in oil emulsions.
- According to one or more embodiments the composition contains a single surfactant having an HLB value between about 7 and 14, or more than one surfactant and the weighted average of their HLB values is between about 7 and about 14. Mid range HLB values may in certain embodiments be more suitable for oil in water nano emulsion s.
- According to one or more other embodiments the composition contains a single surfactant having an HLB value between about 9 and about 19, or more than one surfactant and the weighted average of their HLB values is between about 9 and about 19. In a waterless or substantially waterless environment a wide range of HLB values may be suitable.
- Preferably, the composition of the present invention contains a non-ionic surfactant. Nonlimiting examples of possible non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21, brij 721, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglyceride, isoceteth-20 and mono-, di- and tri-esters of sucrose with fatty acids. In certain embodiments, suitable sucrose esters include those having high monoester content, which have higher HLB values.
- In certain embodiments with wax as emollient, surfactants are selected which can provide a close packed surfactant layer separating the oil and water phases. To achieve such objectives combinations of at least two surfactants are selected. Preferably, they should be complex emulgators and more preferably they should both be of a similar molecular type. For example, a pair of ethers like steareth 2 and steareth 21, or a pair of esters for example, PEG-40 stearate and polysorbate 80. In certain circumstances POE esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with wax formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
- It has been discovered also that by using a derivatized hydrophilic polymer with hydrophobic alkyl moieties as a polymeric emulsifier such as pemulen it is possible to stabilize the emulsion better about or at the region of phase reversal tension. Other types of derivatized polymers like silicone copolymers, derivatized starch [Aluminum Starch Octenylsuccinate (ASOS)]/[DRY-FLO AF Starch], and derivatized dexrin may also a similar stabilizing effect.
- A series of dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable. [Hong-Rong Wang and Keng-Ming Chen, Colloids and Surfaces A: Physicochemical and Engineering Aspects Volume 281, Issues 1-3, 15 Jun. 2006, Pages 190-193].
- Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB˜4.9); glyceryl monostearate/PEG 100 stearate (Av HLB˜11.2); stearate Laureth 4 (HLB˜9.7) and cetomacrogol ether (e.g., polyethylene glycol 1000 monocetyl ether).
- Non-limiting examples of preferred surfactants, which have a HLB of 4-19 are set out in the Table below:
-
Surfactant HLB steareth 2 ~4.9 glyceryl monostearate/PEG 100 stearate Av~11.2 Glyceryl Stearate ~4 Steareth-21 ~15.5 peg 40 stearate ~16.9 polysorbate 80 ~15 sorbitan stearate ~4.7 laureth 4 ~9.7 Sorbitan monooleate (span 80) ~4.3 ceteareth 20 ~15.7 steareth 20 ~15.3 Ceteth 20 ~15.7 Macrogol Cetostearyl Ether ~15.7 Ceteth 2 (Lipocol C-2) ~5.3 PEG-30 Dipolyhydroxystearate ~5.5 sucrose distearate (Sisterna SP30) ~6 polyoxyethylene (100) stearate ~18.8 - In one or more embodiments the surfactant is a complex emulgator in which the combination of two or more surfactants can be more effective than a single surfactant and provides a more stable emulsion or improved foam quality than a single surfactant. For example and by way of non-limiting explanation it has been found that by choosing say two surfactants, one hydrophobic and the other hydrophilic the combination can produce a more stable emulsion than a single surfactant. Preferably, the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
- Specific non limiting examples of surfactant systems are, combinations of polyoxyethylene alkyl ethers, such as Brij 59/Brij10; Brij 52/Brij 10; Steareth 2/Steareth 20; Steareth 2/Steareth 21 (Brij 72/Brij 721); combinations of polyoxyethylene stearates such as Myrj 52/Myrj 59; combinations of sucrose esters, such as Surphope 1816/Surphope 1807; combinations of sorbitan esters, such as Span 20/Span 80; Span 20/Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, such as Tween 80/PEG-40 stearate; methyl glucaso sequistearate; polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121), Stepan (Mild RM1), Nikomulese (41) and Montanov (68) and the like.
- In certain embodiments the surfactant is preferably one or more of the following: a combination of steareth-2 and steareth-21 on their own or in combination with glyceryl monostearate (GMS); in certain other embodiments the surfactant is a combination of polysorbate 80 and PEG-40 stearate. In certain other embodiments the surfactant is a combination of glyceryl monostearate/PEG 100 stearate. In certain other embodiments the surfactant is a combination of two or more of stearate 21, PEG 40 stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21, ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60
- In certain other embodiments the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
- Without being bound by any particular theory or mode of operation, it is believed that the use of non-ionic surfactants with significant hydrophobic and hydrophilic components, increase the emulsifier or foam stabilization characteristics of the composition. Similarly, without being bound by any particular theory or mode of operation, using combinations of surfactants with high and low HLB's to provide a relatively close packed surfactant layer may strengthen the emulsion.
- In one or more embodiments the stability of the composition can be improved when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed. The ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4. The resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
- Thus, in an exemplary embodiment, a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
- In certain cases, the surfactant is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
- Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of the two parts. Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect
- In one or more embodiments the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals. Surfactants which tend to form liquid crystals may improve the quality of foams. Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are: phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
- In one or more embodiments the at least one surfactant is liquid.
- In one or more embodiments the liquid surfactant is a polysorbate, preferably polysorbate 80 or 60.
- In one or more embodiments the at least one surfactant is solid, semi solid or waxy.
- It should be noted that HLB values may not be so applicable to non ionic surfactants, for example, with liquid crystals or with silicones. Also HLB values may be of lesser significance in a waterless or substantially non-aqueous environment.
- In one or more embodiments the surfactant can be, a surfactant system comprising of a surfactant and a co surfactant, a waxy emulsifier, a liquid crystal emulsifier, an emulsifier which is solid or semi solid at room temperature and pressure, or combinations of two or more agents in an appropriate proportion as will be appreciated a person skilled in the art. Where a solid or semi solid emulsifier combination is used it can also comprise a solid or semi solid emulsifier and a liquid emulsifier.
- In one or more embodiments of the present invention, the surface-active agent includes at least one non-ionic surfactant. Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. Non-ionic surfactants alone can provide formulations and foams of good or excellent quality in the carriers and compositions of the present invention.
- Thus, in a preferred embodiment, the surfactant, the composition contains a non-ionic surfactant. In another preferred embodiment the composition includes a mixture of non-ionic surfactants as the sole surfactant. Yet, in additional embodiments, the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1. In further embodiments, surfactant comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1
- In one or more embodiments of the present invention, a combination of a non-ionic surfactant and an ionic surfactant (such as sodium lauryl sulphate and cocamidopropylbetaine) is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1; for example, about 1:1, about 4:1, about 8:1, about 12:1, about 16:1and about 20:1 or at a ratio of 4:1 to 10:1, for example, about 4:1, about 6:1, about 8:1 and about 10:1.
- In selecting a suitable surfactant or combination thereof it should be borne in mind that the upper amount of surfactant that may be used may be limited by the shakability of the composition. If the surfactant is non liquid, it can make the formulation to viscous or solid. This can be particularly significant if the formulation has high molecular weight, e.g., a high molecular weight PEG or polymeric agents or petroleum or if the surfactants are large. Solvents and polymeric agents which have high molecular weight and are very viscous or solid or waxy (e.g., Peg 1500, 2000, etc. or petrolatum) can exacerbate the effect of a waxy or solid surfactant on shakability or flowability In general terms, as the amount of non-liquid surfactant is increased the shakability of the formulation reduces until a limitation point is reached where the formulation becomes non shakable and unsuitable. Thus in one embodiment, an effective amount of surfactant may be used provided the formulation remains shakable. In other certain exceptional embodiments the upper limit may be determined by flowability such as in circumstances where the composition is marginally or apparently non-shakable. The formulation is sufficiently flowable to be able to flow through an actuator valve and be released and still expand to form a good quality foam.
- In certain embodiments of the present invention the amount of surfactant or combination of surfactants is between about 0.05% to about 20%; between about 0.05% to about 15%. or between about 0.05% to about 10%. In a preferred embodiment the concentration of surfactant is between about 0.2% and about 8%. In a more preferred embodiment the concentration of surfactant is between about 1% and about 6%. In one or more preferred embodiments the surfactant oil ratio is relatively high ranging from about of the order of 1:1 to about 1: 10. Nevertheless lower levels are possible.
- In some embodiments, it is desirable that the surfactant does not contain a polyoxyethylene (POE) moiety, such as polysorbate surfactants, POE fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surfactants. For example, the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surfactants are employed. In an exemplary manner, POE—free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
- If the composition as formulated is a substantially non shakable composition it is nevertheless possible as an exception in the scope of the present invention for the formulation to be flowable to a sufficient degree to be able to flow through an actuator valve and be released and still expand to form a good quality foam. This surprising and unusual exception may be due one or more of a number of factors such as the high viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the composition. The propellant can change a merely flowable composition into a shakable one.
- In one or more embodiments of the present invention, the surface-active agent includes mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), prepared from sucrose and esters of fatty acids or by extraction from sucro-glycerides. Suitable sucrose esters include those having high monoester content, which have higher HLB values.
- The surface-active agent is selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants.
- In the case wherein the oil globules are oil bodies, the surfactant can be the phospholipids or the oil bodies.
- Combination of surfactants are contemplated. In regular emulsion compositions the total surfactant is usually in the range of about 0.1 to about 5% of the foamable composition, and is typically less than about 2% or less than about 1%. However in order to form nano emulsions it may be appropriate to use higher levels of surfactant, particularly if nanoemulsions are desired with a diameter size in the range of about less than 500 nanometers. Thus, the total surfactant may be in the range of about 5% to about 25% and may preferably be in the range of about 6% to about 12%. In another preferred embodiment the total is about 8%.
- In one or more embodiments the surfactant plays a role in the determination of the viscosity of the formulation. In particular without being bound by any theory the surfactants may have an inherent role in the surprising loss or reduction of viscosity to less than 500 cP even though the viscosity of the formulation can be much higher prior to nano processing with say up to six cycles with a high pressure homogenizer.
- According to one or more embodiments, the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect. Thus, the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- ‘Shakability’ means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases possibly aided by the presence of silicone it may exceptionally be possible to have a foamable composition which is flowable but not apparently shakable.
- A breakable foam is one that is thermally stable, yet breaks under sheer force.
- The breakable foam of the present invention is not “quick breaking”, i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, since it allows comfortable application and well directed administration to the target area.
- Preferably, foam adjuvant is included in the foamable compositions of the present invention to increase the foaming capacity of surfactants and/or to stabilize the foam. In one or more embodiments of the present invention, the foam adjuvant agent includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof). Other examples of fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50). Fatty alcohols, derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents. The amount of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains. Foam adjuvants, as defined herein are also useful in facilitating improved spreadability and absorption of the composition.
- In one or more embodiments of the present invention, the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof. As for fatty alcohols, the amount of fatty acids required to support the foam system is inversely related to the length of its carbon chain.
- Optionally, the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond. A further class of foam adjuvant agent includes a branched fatty alcohol or fatty acid. The carbon chain of the fatty acid or fatty alcohol also can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
- An important property of the fatty alcohols and fatty acids used in context of the composition of the present invention is related to their therapeutic properties per se. Long chain saturated and mono unsaturated fatty alcohols, e.g., stearyl alcohol, erucyl alcohol, arachidyl alcohol and behenyl alcohol (docosanol) have been reported to possess antiviral, antiinfective, antiproliferative and antiinflammatory properties (see, for example, U.S. Pat. No. 4,874,794). Longer chain fatty alcohols, e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc., are also known for their metabolism modifying properties and tissue energizing properties. Long chain fatty acids have also been reported to possess anti-infective characteristics.
- Thus, in preferred embodiments of the present invention, a combined and enhanced therapeutic effect is attained by including both a nonsteroidal immunomodulating agent and a therapeutically effective foam adjuvant in the same composition, thus providing a simultaneous anti-inflammatory and antiinfective effect from both components. Furthermore, in a further preferred embodiment, the composition concurrently comprises a nonsteroidal immunomodulating agent, a therapeutically effective foam adjuvant and a therapeutically active oil, as detailed above. Such combination provides an even more enhanced therapeutic benefit. Thus, the foamable carrier, containing the foam adjuvant provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
- The foam adjuvant according to preferred embodiments of the present invention includes a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass. More preferably, the total amount is 0.4%-2.5% (w/w) of the carrier mass.
- The foam of the present invention may further optionally include a variety of formulation excipients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and modify their consistency. Such excipients may be selected, for example, from stabilizing agents, antioxidants, humectants, preservatives, colorant and odorant agents and other formulation components, used in the art of formulation.
- Aerosol propellants are used to generate and administer the foamable composition as a foam. Suitable propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof.
- In an embodiment of the present invention the propellant is AP 70 which is a mixture of propane, isobutene and butane. In another embodiment the propellant is AP 46 which is a similar mixture of propane, isobutene and butane but having a lower pressure. AP 70 offers about 50% higher pressure than AP 46.
- The propellant makes up about 3-25 wt % of the foamable composition. In some circumstances the propellant may be up to 35%. The propellants are used to generate and administer the foamable composition as a foam. The total composition including propellant, foamable compositions and optional ingredients can be referred to as the foamable composition.
- Alcohol and organic solvents render foams inflammable. It has been surprisingly discovered that fluorohydrocarbon propellants, other than chloro-fluoro carbons (CMOs), which are non-ozone-depleting propellants, are particularly useful in the production of a non-flammable foamable composition. A test according to European Standard prEN 14851, titled “Aerosol containers—Aerosol foam flammability test” revealed that compositions containing an organic carrier that contains a hydrophobic organic carrier and/or a polar solvent, which are detected as inflammable when a hydrocarbon propellant is used, become non-flammable, while the propellant is an HFC propellant.
- Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons. Exemplary non-flammable propellants according to this aspect include propellants made by DuPont under the registered trademark Dymel, such as 1,1,1,2 tetrafluorethane (Dymel 134), and 1,1,1,2,3,3,3 heptafluoropropane (Dymel 227). HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
- Notably, the stability of foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
- In one or more embodiments foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbom propellants such as propane, isobutane and butane.
- In order to project the potential shelf life and stability of the compositions and their ingredients particularly active or benefit agents the compositions can subjected to a number of tests, including centrifugation to look for resistance to creaming, phase separation; one or more freeze thaw cycles, standing at room and higher temperatures as an indicator of resistance to aging.
- In one or more embodiments, the foamable composition of the present invention is a carrier of a cosmetically or pharmaceutically active agent(s). The agents may be introduced into an aqueous phase (i.e., water), or a hydrophobic phase (e.g., hydrophobic solvent or oil globules). Exemplary, non binding and cosmetically or pharmaceutically active agents include, but are not limited to an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, an anti-wrinkle agent, a radical scavenger, a metal oxide (e.g., titanium dioxide, zinc oxide, zirconium oxide, iron oxide), silicone oxide, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof. Yet, in certain embodiments, one or more components of the oil bodies or sub-micron globules act possess a therapeutic property, such as detailed hereinabove, and thus, in such embodiments, the oil bodies or sub-micron globules can be considered herein as active agents.
- A pharmaceutical or cosmetic composition manufactured using the foam carrier according to one or more embodiments of the present invention is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
- The foam composition of the present invention creates a stable formulation having an acceptable shelf-life of at least one year, or at least two years at ambient temperature. A feature of a product for cosmetic or medical use is long term stability. Propellants, which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions. It has been observed, however, that foam compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
- The composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam.
- Foam quality can be graded as follows:
- Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery;
- Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery;
- Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity;
- Grade F (fair): very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery;
- Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance; and
- Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
- Topically administratable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
- A further aspect of the foam is breakability. The foam of the present invention is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally-induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
- Another property of the foam is density (specific gravity), as measured upon release from the aerosol can. Typically, foams have specific gravity of (1) less than 0.12 g/mL; or (2) the range between 0.02 and 0.12; or (3) the range between 0.04 and 0.10; or (4) the range between 0.06 and 0.10.
- By including oil bodies or sub-micron globules and optionally, additional active agents in the compositions of the present invention, the composition are useful in treating an animal or a human patient having any one of a variety of dermatological disorders that include dry and/or scaly skin as one or their etiological factors (also termed “dermatoses”), such as classified in a non-limiting exemplary manner according to the following groups:
- Dermatitis including contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash;
- Bacterial infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, erythrasma;
- Fungal Infections including dermatophyte infections, yeast Infections; parasitic Infections including scabies, pediculosis, creeping eruption;
- Viral Infections;
- Disorders of hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsutism), alopecia, including male pattern baldness, alopecia areata, alopecia universalis and alopecia totalis; pseudofolliculitis barbae, keratinous cyst;
- Scaling papular diseases including psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris;
- Benign tumors including moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dermatofibroma, keratoacanthoma, keloid;
- Malignant tumors including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, paget's disease of the nipples, kaposi's sarcoma;
- Reactions to sunlight including sunburn, chronic effects of sunlight, photosensitivity;
- Bullous diseases including pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear immunoglobulin A disease;
- Pigmentation disorders including hypopigmentation such as vitiligo, albinism and postinflammatory hypopigmentation and hyperpigmentation such as melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation;
- Disorders of cornification including ichthyosis, keratosis pilaris, calluses and corns, actinic keratosis;
- Pressure sores;
- Disorders of sweating; and
- Inflammatory reactions including drug eruptions, toxic epidermal necrolysis; erythema multiforme, erythema nodosum, granuloma annulare.
- According to one or more embodiments of the present invention, the compositions are also useful in the therapy of non-dermatological disorders by providing transdermal delivery of an active nonsteroidal immunomodulating agent that is effective against non-dermatological disorders.
- The same advantage is expected when the composition is topically applied to a body cavity or mucosal surface (e.g., the mucosa of the nose, mouth, eye, ear, vagina or rectum) to treat conditions such as chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
- Other foamable compositions are described in: U.S. Publication No. 05-0232869, published on Oct. 20, 2005, entitled NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0205086, published on Sep. 22, 2005, entitled RETINOID IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0018937, published on Jan. 26, 2006, entitled STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on Dec. 8, 2005, entitled VASOACTIVE KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0269485, published on Nov. 30, 2006, entitled ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 07-0020304, published on Jan. 25, 2007, entitled NON-FLAMMABLE INSECTICIDE COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0193789, published on Aug. 31, 2006, entitled FILM FORMING FOAMABLE COMPOSITION; U.S. patent application Ser. No. 11/732547, filed on Apr. 4, 2007, entitled ANTI-INFECTION AUGMENTATION OF FOAMABLE COMPOSITIONS AND KIT AND USES THEREOF; U.S. Provisional Patent Application No. 60/789186, filed on Apr. 4, 2006, KERATOLYTIC ANTIFUNGAL FOAM; U.S. Provisional Patent Application No. 0/815948, filed on Jun. 23, 2006, entitled FOAMABLE COMPOSITIONS COMPRISING A CALCIUM CHANNEL BLOCKER, A CHOLINERGIC AGENT AND A NITRIC OXIDE DONOR; U.S. Provisional Patent Application No. 60/818634, filed on Jul. 5, 2006, entitled DICARBOXYLIC ACID FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF; U.S. Provisional Patent Application No. 60/843140, filed on Sep. 8, 2006, entitled FOAMABLE VEHICLE AND VITAMIN PHARMACEUTICAL COMPOSITIONS THEREOF, all of which are incorporated herein by reference in their entirety with reference to any of the active ingredients; penetration enhancers; humectants; moisturizers; listed therein can be applied herein and are incorporated by reference.
- The following examples further exemplify the benefit agent foamable pharmaceutical carriers, pharmaceutical compositions thereof, methods for preparing the same, and therapeutic uses of the compositions. The examples are for the purposes of illustration only and are not intended to be limiting. Many variations may be carried out by one of ordinary skill in the art and are contemplated within the full scope of the present invention.
- A general procedure for preparing foamable compositions is set out in WO 2004/037225, which is incorporated herein by reference.
- Nano Emulsion Foam Stabilized with Hydrocolloids polymers
-
- 1. Mix oily phase ingredients and heat to 75° C. to melt all ingredients and obtain homogeneous mixture.
- 2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
- 3. Add all other water soluble ingredients to water-polymer solution and heat to 75° C.
- 4. Add slowly external phase to internal phase at 75° C. under vigorous mixing and homogenize to obtain fine emulsion.
- 5. Cool to below 40° C. and add sensitive ingredients with mild mixing.
- 6. The fine emulsion oily droplets are further finely dispersed using high pressure homogenizer (Model M-110Y Microfluidezer® processor, Microfluidics Corp, USA) at 1000-1500 bars pressure, 4 to 8 cycles. The temperature is kept above 40° C. during homogenization process until viscosity drops.
Nano Emulsion Foam Stabilized With Acrylates polymers - 1. Mix oily phase ingredients and heat to 60° C. to melt all ingredients and obtain homogeneous mixture.
- 2. Disperse the Acrylate polymer in the oily phase.
- 3. Mix all water soluble ingredients to water solution and heat to 60° C.
- 4. Add slowly external phase to internal phase at 60° C. under vigorous mixing and homogenize to obtain fine emulsion.
- 5. Cool to below 40° C. and add sensitive ingredients with mild mixing.
- 6. The fine emulsion oily droplets are further finely dispersed using high pressure homogenizer (Model M-110Y Microfluidezer® processor, Microfluidics Corp, USA) at 1000-1500 bars pressure, 4 to 8 cycles. The temperature is kept above 40° C. during homogenization process until viscosity drops.
-
-
- 1. Mix oily phase ingredients and heat to 75° C. to melt all ingredients and obtain homogeneous mixture.
- 2. Mix polymers in water with heating or cooling as appropriate for specific polymer. Whilst the polymers may be added instead into the oily phase it was found to be advantageous to prepare them in the water phase.
- 3. Add all other water soluble ingredients to water-polymer solution and heat to 75° C.
- 4. Add slowly internal phase to external phase at 75° C. under vigorous mixing and homogenize to obtain fine emulsion. Alternatively the external phase is added slowly to the internal phase.
- 5. Cool to below 40° C. and add sensitive ingredients with mild mixing.
- 6. Cool to room temperature.
-
-
- 1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 75° C. to melt and dissolve the various ingredients.
- 2. Cool to below 40° C. and add sensitive ingredients with mild mixing.
- 3. Cool to room temperature.
-
-
- 1. Mix all ingredients excluding polymers and heat to 75° C. to melt and dissolve and obtain homogeneous mixture.
- 2. Mix well and cool to below 40° C. and add the polymers and sensitive ingredients with moderate mixing.
- 3. Cool to room temperature.
Oily Foam With phospholipids and/or Water - 1. Swell the phospholipids in the main oily solvent under mixing for at least 20 minutes until uniform suspension is obtained.
- 2. Add all other ingredients excluding polymers and heat to 75° C. to melt and dissolve and obtain homogeneous mixture.
- 3. Mix well and cool to below 40° C. and add the polymers and sensitive ingredients with moderate mixing.
- 4. Cool to room temperature.
- 5. In case of polymers dissolved in water or organic solvent, dissolve the polymers in the solvent with heating or cooling as appropriate for specific polymer and add to the oily mixture under vigorous mixing at ˜40° C.
- Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine.
- Propellant Filling
- Pressurizing is carried out using a hydrocarbon gas or gas mixture
- Canisters are filled and then warmed for 30 sec in a warm bath at 50° C. and well shaken immediately thereafter.
- Closure Integrity Test.
- Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 60° C. water bath for 2 minutes.
- Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
- By way of non limiting example the objectives of hardness, collapse time, viscosity, bubble size, nano size and FTC stability tests are briefly set out below as would be appreciated by a person of the art.
- Hardness
-
- LFRA100 instrument is used to characterize hardness. A probe is inserted into the test material. The resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display. Preferably at least three repeat tests are made. The textural characteristics of a dispensed foam can effect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness. Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
- Collapse Time
-
- Collapse time (CT) is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36° C. It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 min.
- Viscosity
-
- Viscosity is measured with Brookfield LVDV-II +PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10RPM. However, at about the apparent upper limit for the spindle of ˜>50,000CP, the viscosity at 1RPM may be measured, although the figures are of a higher magnitude. Unless otherwise stated viscosity of the pre foam formulation is provided.
- FTC (Freeze Thaw Cycles)
-
- To check the foam appearance under extreme conditions of repeated cycles of cooling, heating, (first cycle) cooling, heating (second cycle) etc., commencing with −10° C. (24 hours) followed by +40° C. (24 hours) measuring the appearance and again repeating the cycle for up to four times.
- Creaming by Centrifugation:
-
- 1. Principle of test
- The centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion.
- 2. Procedure
- 2.1. Following preparation of the experimental formulation/s, allow to stand at room temperature for ≧24 h.
- 2.2. Handle pentane in the chemical hood. Add to each experimental formulation in a 20-mL glass vial a quantity of pentane equivalent to the specified quantity of propellant for that formulation, mix and allow formulation to stand for at least 1 h and not more than 24 h.
- 2.3. Transfer each mixture to 1.5 mL microtubes. Tap each microtube on the table surface to remove entrapped air bubbles.
- 2.4. Place visually balanced microtubes in the centrifuge rotor and operate the centrifuge at one or more of 10,000 rpm for 10 min, 3,000 rpm for 10 min or at 1,000 rpm for 10 min.
- 1. Principle of test
- Bubble Size:
-
- Foams are made of gas bubbles entrapped in liquid. The bubble size and distribution reflects in the visual texture and smoothness of the foam. Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template. Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software. The camera used was a Nikon D40X Camera (resolution 10 MP) equipped with Sigma Macro Lens (ref: APO MACRO 150 mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels×400 pixels.
- Nano Size:
-
- The light microscope enables observing and measuring particles from few millimeters down to one micron. Light microscope is limited by the visible light wavelength and therefore is useful to measuring size of particles above 800 nanometers and practically from 1 micron (1,000 nanometers).Measuring smaller particle, nano size range, is performed by a Dynamic light scattering (DLS), sometimes referred to as Photon Correlation Spectroscopy (PCS) or Quasi-Elastic Light Scattering (QELS). The method is a non-invasive, well-established technique for measuring the size of molecules and particles typically in the sub micron region, and with the latest technology lower than 1 nanometer. Measurements are usually made without a vacuum, but wherever appropriate a vacuum can be applied. A Malvern nano sizeris SB-A-018 nano zs Serial num: MAL 50041 for example may be used.
- The following examples exemplify the compositions and methods described herein. The examples are for the purposes of illustration only and are not intended to be limiting. Many variations will suggest themselves and are within the full intended scope of the appended claims.
-
-
% w/w A Mineral oil (oil) 5.60 Isopropyl myristate (emollient) 5.60 Glyceryl monostearate (emollient) 0.45 PEG-40 Stearate (surfactant) 2.60 Stearyl alcohol (foam adjuvant) 0.85 B Xanthan gum (gelling agent) 0.26 Methocel K100M (gelling agent) 0.26 Polysorbate 80 (surfactant) 0.90 Water 74.88 C Preservative 0.60 D Propellant 8.00 100.00 - Oil Phase (A): The ingredients of the Oil Phase were preheated to the same temperature, e.g., 40-75° C., and then were combined with mixing. Oil soluble cosmetic or pharmaceutical active ingredients and optional oil soluble formulation ingredients are added with agitation to the Oil Phase mixture.
- Aqueous Phase (B): Water gelling agent and surfactant were dissolved in water, with agitation. The solution was warmed to 50-70° C. Water soluble cosmetic or pharmaceutical active ingredients and optional water soluble ingredients were added with agitation to the Aqueous Phase mixture.
- The warm Oil Phase was gradually poured into the warm Aqueous Phase, with agitation, followed by Ultraturax homogenization. The mixture was allowed to cool down to ambient temperature. In case of heat sensitive active ingredients, the active ingredient can be added with agitation to the mixture after cooling to ambient temperature. The mixture, at ambient temperature, was added to an aerosol container, the container was sealed and appropriate amount of propellant (5-25 w % of the composition mass) was added under pressure into the container.
- Microscopic observation of the resulting emulsion revealed mean particle size of 2 to 4 microns.
- The emulsion was passed through a microfluidizer, Microfluidics M-110Y Microfluidizer® M-110Y about 10 cycles, using ice to avoid heating the formula.
- A nanoemulsion composition (46 gram) was introduced into a 60 ml monoblock aluminum can. The can was sealed with an aerosol valve and 4 gram of liquefied propellant (propane butane isobutene mixture) was added through the valve.
- Particle size distribution was determined using a Malvern nanosizer™ instrument. The pre-foam composition showed two peaks of 188 and 59 nanometers. Four days after packaging and pressurizing of the composition, foam was released from the aerosol can and light microscope observation revealed small population of ˜1 micron globules and substantial Brownian movement indicating that majority of oil droplets are of sub-micron or nano-scale.
- An emulsion (46 gram) was added into a 60 ml monoblock aluminum can. The can was closed with an aerosol valve and 4 gram of liquefied propellant (propane/butane mix) was added through the valve. The propellant can be any compressed and liquefied gas, currently used as aerosol propellant. The final concentration of propellant can vary from 3% to 25%.
-
-
NAT01 NAT02 NAT03 NAT04 % w/w % w/w % w/w % w/w Natural Oleosomes 30.00 30.00 30.00 30.00 (Natrulon OSF)* Hydroxypropylmethycellulose 0.25 0.25 — — (gelling agent) Xanthan Gum (gelling agent) 0.25 0.25 — — Cocamide DEA (surfactant) 1.00 1.00 Polsorbate 20 (surfactant) — — — 1.00 Water pure 68.50 69.50 69.00 69.00 100.00 100.00 100.00 100.00 Foam Properties Foam Quality E E E G Stability RT Stable Stable Creaming Creaming After 72 After 72 Hr. Hr. *Natrulon OSF is the trade name of Lonza Inc. - The production of the compositions NATO1 included the following steps:
-
- 1. Add the polymeric agents (Hydroxypropylmethycellulose and Xanthan Gum) to the Natrulon OSF at 50° C. and mix during 10 minutes while the preparation cools down to Room Temperature.
- 2. Add the Cocamide DEA with mixing.
- 3. Fill the composition aerosol canisters and add 8% of propellant.
- The production of the compositions NATO2 included the following steps:
-
- 1. Add the polymeric agents (Hydroxypropylmethycellulose and Xanthan Gum) to the Natrulon OSF at 50° C. and mix during 10 minutes while the preparation cools down to Room Temperature.
- 2. Fill the composition aerosol canisters and add 8% of propellant.
- The production of the compositions of NATO3 included the following steps:
-
- 1. Add the cool water to the Natrulon OSF and mix during 10 minutes.
- 2. Add the Cocamide DEA with mixing.
- 3. Fill the composition aerosol canisters and add 8% of propellant.
- The production of the compositions of NAT04 included the following steps:
-
- 1. Add the cool water to the Natrulon OSF and mix during 10 minutes.
- 2. Add Polysorbate 20 with mixing.
- 3. Fill the composition aerosol canisters and add 8% of propellant.
-
-
% w/w % w/w Caprylic/capric triglyceride 5.00 — (MCT oil) Stearyl alcohol 0.90 — Natrulon OSF* 10.00 10.00 Methylcellulose 0.25 0.25 Xanthan gum 0.25 0.25 PEG-40 stearate 2.50 2.50 Polysorbate 80 0.90 0.90 Preservative 0.50 0.50 Purified water to 100% to 100% Propellant 8.00 -
-
Emulsion visual test Uniform Uniform Viscosity (Spindle SC4-31)(cP) 1,428 868.5 Centrifugation (prior to propellant addition) Stable Stable (10 min/3,000 rpm) PH (direct, prior to propellant addition) 6.04 6.72 Foam Quality G E Density 0.0337 0.0339 -
-
Ingredients NEP002 NEP006 Isopropyl myristate 6.00 6.00 light Mineral oil 6.00 6.00 Glyceryl 0.50 1.00 monostearate PEG-40 stearate 3.00 6.00 Stearyl alcohol 1.00 1.00 Xanthan gum 0.30 0.30 Methocel K100M 0.30 0.30 Polysorbate 80 1.00 2.00 Water, purified 81.30 76.80 Sharomix 824 0.60 0.60 Total 100.00 100.00 Propellant 8.00 8.00 Cycles 4 3 Pressure (Bar) 1000-1500 Comments inter alia Emulsion broke after Emulsion still as to non suitability first cycle broke after first for nano emulsion cycle with double preparation surfactant that of 002. - Comment: None of the above two formulations were found suitable for preparation of a nano emulsion using a high pressure homogenizer. This indicates that the selection of surfactants that can hold the emulsion together whilst being subject to the effects of being processed in a high speed homogenizer is of importance in the preparation of nano emulsions. Formulations were also prepared with a combination of high and medium levels of petrolatum and mineral oil (42% and 18% respectively) and with medium levels of petrolatum (25%). In both cases the formulation was found to be too viscous to be used with the nano emulsion. None of the above formulations were found suitable for preparation of a nano emulsion using a high pressure homogenizer primarily because of their high viscosity. Nevertheless, it is believed that the issue of viscosity may be overcome-able by warming the formulation and or reducing the levels of petrolatum. A formulation containing a powder suspension was also found to be unsuitable due to sedimentation. Accordingly, to the extent a formulation is to comprise a suspension that element may be introduced after a stable nano emulsion carrier is produced rather than during the process. For satisfactory processing the emulsion should have sufficient stability to withstand gentle heating.
-
-
Ingredients NEP007 NEP008 Diisopropyl adipate (DISPA) 20.00 PPG 15 Stearyl ether (PPG) 20.00 Steareth-2 3.67 4.00 Steareth 21 2.33 1.00 Carboxy methyl cellulose 0.50 0.50 Water, purified 72.90 73.90 Sharomix 824 0.60 0.60 Total 100.00 100.00 Propellant 8.00 8.00 Cycles 5 6 Pressure (Bar) 1000-1500 1000-1500 Visual Inspection Homogeneous Homogeneous Shakability Yes Yes F.Q. Good Fairly Good Cetrif: 3000 RPM Stable Stable Cetrif: 10000 RPM 30% 90% Creaming Creaming Density 0.057 N/R Viscosity(cP) 10 RPM 4734.99 3775.19 Collapse Time (sec.) >300 >300 PFF Size Study: Diameter (nm)/% volume-25 C. 718/92.4% 2590/86.8% 147/7.6% * 243/13.2 * Dilution 1:80 w/w with 1:80 w/w with vacuum vacuum FOAM Size Study: Diameter (nm)/% volume-25 C. 2790/82.4% 328/17.6% Dilution 1:80 w/w with 1:80 w/w with vacuum * vacuum * *-example of *-example of results results achieved achieved FTC (4 cycles) Quality Good Density 0.046 Collapse time (sec.) >300 >300 1 Month 40 C. Quality Excellent Fairly Good Density 0.045 Collapse time (sec.) >300 Diameter (nm)/% volume-25 C. 3410/100% Dilution 1:80 w/w with vacuum * - Comment: After 5 or 6 cycles of high pressure homogenization the emulsion appears to behave differently depending on which oil is used. In the presence of 20% DISPA a good quality foam is produced containing large nano particles primarily in the region of 700 nanometers and which can withstand four freeze thaw cycles (FTC) but which reverts to form globules of over 3 microns after a month. In contrast in the presence of 20% PPG foam quality is fairly good and the oil droplets have a diameter primarily in the region of 2600 nanometers or 2.6 microns.
-
-
Ingredients NEP010 White Petrolatum (sofmetic) 7.14 Steareth-2 1.43 Steareth 21 4.29 Carboxy methyl cellulose 0.36 Water, purified 86.18 TEA, q.s. to pH: to pH 4.77 Sharomix 824 0.60 Total 100.00 Propellant 8.00 Cycles 6 Pressure (Bar) 1000-1500 Visual Inspection Homogeneous Shakability Yes F.Q. Excellent* Cetrif: 3000 RPM Stable Cetrif: 10000 RPM 98% translucent Viscosity(cP) 10 RPM 7.00 Collapse Time (sec.) >300 PFF Size Study: Diameter (nm)/% volume- 125/100% 25 C. Dilution 1:10 v/v FOAM Size Study: Diameter (nm)/% volume- 275/22.1% 25 C. 96.8/16.1% 26.2/55.4% Dilution 1:10 w/w * After 2 weeks FG FTC (4 cycles) Quality Good Density 0.036 Collapse Time (sec.) >300 - Comment: Petrolatum produces formulations with higher viscosity as it is a viscous material. Nevertheless, by reducing the content of petrolatum and by gentle warming it is possible to make nano emulsions with petrolatum. Not only was the above formula homogenous and stable to centrifugation but it produced foam of excellent quality having pre foam nano particles size primarily in the region of 125 nanometers and the majority of the foam nano particles being in the region of 26 nanometers. Remarkably, the formulation viscosity showed a dramatic reduction. Without being bound by any theory this may be connected to the high pressure mechanical manipulation of petrolatum and possible breakdown of polymer and further it seems that there can be a close connection between reduction of viscosity and successful smaller nano emulsion formulations. On the other hand by using a different polymer carbomer an acrylic polymer it was possible to achieve a successful larger nano emulsion with high viscosity that remained stable for a month at 40C; stable to centrifugation and stable to FTC as can be seen in Formula 12 Example 8
-
-
NEP011-4C NEP011-6C Isopropyl myristate 5.00 5.00 Octyl dodecanol 5.00 5.00 Cetearyl alcohol 3.00 3.00 Polyoxyl 100 monostearate 2.50 2.50 Methocel K100 LV 0.20 0.20 Carbomer 934P 0.40 0.40 Polysorbate 80 0.50 0.50 Propylene glycol 3.34 3.34 Water, purified 79.81 79.81 TEA, q.s. to pH: to pH 4.60 to pH 4.70 Propyl Paraben 0.10 0.10 Methyl paraben 0.15 0.15 Total 100.00 100.00 Propellant 8.00 8.00 Cycles 4 6 Pressure (Bar) 1000-1500 1000-1500 Visual Inspection Homogenous Homogenous Shakability Yes Yes F.Q. Excellent Excellent Cetrif: 3000 RPM Stable Stable Cetrif: 10000 RPM Stable Stable Density 0.041 Viscosity(cP) 10 RPM 5198.89 52.99 Collapse Time (sec.) >300 PFF Size Study: * Diameter (nm)/% volume-25 oC 570/100% 251/100% Dilution 1:80 w/w 1:80 w/w FOAM Size Study: Diameter (nm)/% volume-25 C. 667/85.2% 99.1/4% 5220/10.4% 297/100% Dilution 1:80 w/w 1:80 w/w FTC (4 cycles) Quality Excellent Density 0.038 *Separation after 5 days, reversible - Comment: The question of how many cycles are preferable was examined. Using too few cycles may not produce emulsions with oil droplets in the lower nanometer range. On the other hand there is some concern that using too many cycles may destroy the ability to make good quality stable homogenous nano foam. Nano emulsions are fragile and metastable. Much energy work is required to reduce oil droplets size. The energy is invested in creating large interfacial area between the two immiscible phases. At first the energy input contributes to creation of the interfacial area and particle size reduction. At some point, an extra energy does not contribute any more to size reduction and instead causes particle collapse, increases in particle size and reduction in interfacial area. Every process of emulsification and energy input has an optimum which will be related for example to formulation, mean of energy input, homogenization and other criteria. It was noted that in general three cycles was insufficient and that signs of nano emulsion qualities of translucent foam with a blue tint became more recognizable from four cycles. Thus a study was made to compare four with six cycles. It can be seen that after four cycles the pre foam formulation had a nano size primarily in the region of 570 nanometers and a reasonable viscosity in the range of 5000 Cp. However, when the processing was extended to six cycles there was a remarkable reduction in viscosity of about a hundred fold to the range of 50 cP and that the nano size of the pre foam formulation was halved. Interestingly, when foam was produced the nano size was substantially the same, suggesting that conversion to foam does not disturb the nano particle size to any significant extent. On the other hand as can be seen below there a dramatic effect on bubble size is observed between a pre and post nano processed formulation. Also of note is the observation that dramatic reduction in viscosity is seen with the polymeric combination of methocel and carbomer. However, as seen in Example 8 below, when the polymeric agent is only pH adjusted carbomer the formulation remains with high viscosity after 6 cycles
-
-
Ingredients NEP012 Isopropyl myristate 20.00 Steareth-2 4.34 Steareth 21 2.66 Carbomer 934P 0.50 Propylene glycol 3.00 Water, purified 69.00 TEA, q.s. to pH: to pH 4.66 Sharomix 824 0.50 Total 100.00 Propellant 8.00 Cycles 6 Pressure (Bar) 1000-1500 Visual Inspection Homogenous Shakability Yes F.Q. Excellent Centrifugation: 3000 RPM Stable Centrifugation: 10000 RPM Stable Density 0.065 Viscosity(cP) 10 RPM 21595.39 Collapse Time (sec.) >300 PFF Size Study: Diameter (nm)/% volume-25 oC 802/100% Dilution 1:80 w/w FOAM Size Study: Diameter (nm)/% volume-25 oC 688/90.8% 5240/7.3% 110/1.8% Dilution 1:80 w/w FTC Quality Excellent Density 0.073 Collapse Time (sec.) >300 1 month 40 C. Quality Excellent Density 0.048 Collapse Time (sec.) >300 Diameter (nm)/% volume-25 C. 831//71.4% 154/3.3% 5040/25.3% Dilution 1:80 w/w - Comment: Like the formulations discussed in Example 5, this example is based on 20% oil. The oil is isopropyl myristate, which is a third type of oil. Here the formula was pH adjusted with triethanolamine (TEA). The oil droplet size for the pre-foam formulation was of the order of 800 nanometers and that of the foam was of the order of 700 namometers indicating that isopropyl myristate is not dissimilar from DISPA in relation to the size of resultant nano particles. Moreover, after a month at 40 C most of the globules were of the order 830 nanometers. Of the three formulations isopropyl myristate, made the best quality foam, which likewise may more suit nano emulsion preparation albeit at the higher end of the scale. The viscosity of the pre foam formulation is high primarily due to the level of carbomer and the pH. At this viscosity the composition is flowable but not really shakable. However, upon addition of propellant the formulation is shakable.
-
-
NEP013 NEP015 NEP014 Isopropyl myristate 10.00 10.00 10.00 light Mineral oil 10.00 10.00 10.00 Glyceryl monostearate 0.50 0.50 0.50 PEG-40 stearate 3.20 2.40 1.60 Stearyl alcohol 1.50 1.50 1.50 Carbomer 934P 0.40 0.40 0.40 Polysorbate 80 4.80 3.60 2.4 Propylene glycol 3.00 3.00 3.00 Water, purified 66.00 68.00 70.10 TEA, q.s. to pH: to pH 4.66 to pH 4.71 to pH 4.60 Sharomix 824 0.60 0.60 0.50 Total 100.00 100.00 100.00 Propellant 8.00 8.00 8.00 Cycles 6 6 6 Presion (Bar) 1000-1500 1000-1500 1000-1500 Visual Inspection Homogenous Homogenous Homo- (highly genous translucent) Shakability Yes Yes Yes F.Q. Excellent Excellent Excellent Centrifugation: 3000 RPM Stable Stable Stable Centrifugation: 10000 RPM Stable Stable Stable Density 0.052 0.045 0.042 Viscosity(cP) 10 RPM 241.95 207.96 107.96 Collapse Time (sec.) >300 >300 >300 PFF Size Study: Diameter (nm)/% volume- 80.2/100% 105/100% 149/100% 25 C. Dilution 1:15 v/v 1:20 v/v 1:20 v/v FOAM Size Study: Diameter (nm)/% volume- 104 nm/88.7%, 120/88.2% 179/84.8 25 C. 4660 nm/11.3% 4740/11.8% 5280/15.2% Dilution 1:15 w/w 1:20 w/w 1:20 w/w with vacuum FTC Quality Good Density 0.050 Collapse Time (sec.) >300 Diameter (nm)/% volume- 117/62.1% 25 C. 822/8% 3400/29.9% 1-Month 40 C. Quality Good Density 0.045 Collapse Time (sec.) >300 Diameter (nm)/% volume- 72.8/76.3% 25 C. 3290/23.7% Dilution 1:15 w/w - Comment: The surfactant concentrations of PEG-40 stearate and Polysorbate 80 were decreased from 8% to 6% to 4% to examine the effect of surfactant levels on nano sizing of the formulations and foam. Whilst all the formulations produced foam of excellent quality there was a clear and consistant effect on oil droplet size. As the level of surfactant was reduced there was a corresponding increase in nano size. Thus higher levels of surfactant support a lower nano size. Approximately parallel reductions were also observed in viscosity and in density as the surfactant levels were reduced. It is also noteworthy that after a month at 40 C the globules size remained substantially the same
- Notes to
FIGS. 1A through 5C: -
- C0 means the formulation was not subject to nano processing.
- C6 means the formulation was subject to 6 cycles of nano processing.
- AP 70 and AP 46 are propellants comprising similar mixtures of propane, butane and isobutane but the former offers about 50% more pressure.
- In all cases observed as shown in
FIGS. 1A through 5C , nano emulsions surprisingly produced foam with a substantially larger foam bubble size ranging from an increase of about a third to an increase of almost four fold in magnitude, when the identical same formulation was subject to nano processing. Thus, by creating a nano emulsion it is possible to generate foam of quality with a larger bubble size, which may intern positively influence the cosmetic elegance of the foam in that the formulation may have a more foam like feel with less of the sensation and greasy feeling that might be experienced with a cream or mousse Also, the increased bubble size may contribute to ease of spreadability. It was also discovered that it is possible to manipulate bubble size by propellant selection. So for example, bubble size was seen to increase by about a third when a higher pressure hydrocarbon propellant was substituted in the same formulation -
- Comment: In the above three cases formation of nano emulsions having nano size particles resulted in a substantial reduction in the formulation viscosity even though chemically the formulation constituents were unchanged. No significant change of collapse time was observed. Formulations which were non shakable prior to processing were became shakable following processing. Also remarkably formulations that produced only fairly good foam prior to processing were improved such that, for example, excellent foam may be formed. True nano emulsions appeared translucent with a blue hint whereas prior to processing the emulsions were generally opaque.
Claims (26)
1. A foamable oil in water nano emulsion composition comprising:
(a) a nano oil globule system, comprising substantially of sub-micron oil globules;
(b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of
i. a non-ionic surfactant,
ii. an ionic surfactant, and
iii. a polymeric agent;
(c) water; and
(d) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition
wherein the oil, stabilizer and water are selected to provide a composition that is substantially homogenous and resistant to aging;
wherein the composition is contained in a pressurized container is substantially flowable and provides a breakable foam upon release, which is thermally stable, yet breaks under sheer force; and
wherein the bubble size of the resultant foam is significantly greater than the bubble size of the resultant foam from a composition with the same ingredients which has not been subject to nano processing.
2-20. (canceled)
1-20. (canceled)
21. A foamable nano-emulsion composition comprising a carrier and a propellant, the carrier comprising:
a. one or more of a hydrophobic solvent, a polar solvent, an emollient, and a mixture thereof, at a concentration of about 2% to about 50% by weight of the carrier;
b. a stabilizing agent selected from the group consisting of a surface-active agent, a polymeric agent and a mixture thereof, wherein the surface-active agent comprises a polyoxyethylene alkyl ether, and wherein the polymeric agent comprises a water-soluble cellulose ether;
c. water;
d. optionally a foam adjuvant; and
wherein the carrier comprises submicron oil globules;
wherein the propellant is a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the nano-emulsion composition; and
wherein the composition is contained in a pressurized container and provides a breakable foam upon release.
22. The composition of claim 21 , wherein the polar solvent is selected from the group consisting of a polyol, glycerol, propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, a glycol, sulfoxide, dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, monooleate of ethoxylated glycerides with 8 to 10 ethylene oxide units, azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglyceride, octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketone, an amide, acetamide oleate, triolein, an alkanoic acid, caprylic acid, a lactam compound, azone, an alkanol, a dialkylamino acetate, a polyethylene glycol, PEG200, PEG300, PEG400, PEG600, and a mixture of any two or more thereof.
23. The composition of claim 21 , wherein the emollient is selected from the group consisting of hexyleneglycol, propylene glycol, an isostearic acid derivative, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated oil bodies alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, a wheat germ glyceride, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, sucrose esters of fatty acids, octyl hydroxystearate, and a mixture of any two or more thereof.
24. The composition of claim 21 , wherein the hydrophobic solvent is selected from the group consisting of liquid oil, a vegetable oil, a marine oil, an animal oil, saturated oil, unsaturated oil, polyunsaturated oil, olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oil, poly-unsaturated fatty acid, omega-3 fatty acid, omega-6 fatty acids, linoleic acid, linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an essential oil, a therapeutically active oil, a silicone oil, a non-volatile silicone, polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers, cyclic or linear polydimethylsiloxanes containing from about 3 to about 9 silicon atoms, a volatile silicone, cyclomethicone and a mixture of any two or more thereof.
25. The composition of claim 21 , wherein the surface-active agent u her comprises a non-ionic surface-active agent.
26. The composition of claim 21 , wherein the surface-active agent further comprises a surfactant selected from the group consisting of a polysorbate, a polyoxyethylene fatty acid ester, a polyoxyethylene alkyl ether, a steareth, a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, a monoglyceride, a diglyceride, isoceteth-20, mono-, di-, and tri-esters of sucrose with fatty acids, steareth 2, steareth 21, ceteth-20, sorbitan monooleate, glyceryl monostearate, PEG 40 stearate, polyoxyl 100 monostearate, methyl glucose sesquistearate, polysorbate 80, a phospholipid, sodium lauryl sulphate, cocamidopropylbetaine, and a mixture of any two or more thereof.
27. The composition of claim 21 , wherein the polymeric agent further comprises a polymeric agent selected from the group consisting of a naturally-occurring polymeric material, microcrystalline cellulose, hydrophobically-modified ethoxylated urethane, a carbomer, methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, methylhydroxyethylcellulose, hydroxyethyl carboxymethylcellulose, carboxymethylcellulose, xanthan gum, guar gum, carrageenin gum, locust bean gum, tragacanth gum, and a mixture of any two or more thereof.
28. The composition of claim 21 , wherein the foam adjuvant is selected from the group consisting of a fatty alcohol having 15 or more carbons in its carbon chain; a fatty acid having 16 or more carbons in its carbon chain; a fatty alcohol derived from beeswax; a mixture of alcohols, a majority of which have at least 20 carbon atoms in a carbon chain; a fatty alcohol having at least one double bond; a fatty acid having at least one double bond; a branched fatty alcohol; a branched fatty acid; a fatty acid substituted with a hydroxyl group; and a mixture of any two or more thereof.
29. The composition of claim 28 , wherein the foam adjuvant is selected from the group consisting of cetyl alcohol, stearyl alcohol, cetostearyl alcohol, and a mixture thereof.
30. The composition of claim 21 , wherein the carrier further comprises an active agent.
31. The composition of claim 30 , wherein the active agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, an allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, an anti-wrinkle agent, a radical scavenger, a metal oxide, titanium dioxide, zinc oxide, zirconium oxide, iron oxide, silicone oxide, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent, and a mixture of any two or more thereof.
32. The composition of claim 21 , wherein the oil globules have an average size selected from the group consisting of (i) about 40 nm to about 1,000 nm; (ii) about 40 nm to about 500 nm; (iii) about 40 nm to about 200 nm; (iv) about 40 nm to about 100 nm; (v) less than about 500 nm; (vi) less than about 200 nm; and (vii) less than about 100 nm.
33. The composition of claim 21 , wherein the breakable foam has a density selected from the group consisting of (i) less than about 0.12 g/mL; (ii) between about 0.02 g/mL and about 0.12 g/mL; (iii) between about 0,04 g/mL and about 0.10 g/mL; and (iv) between about 0.06 g/mL and about 0.10 g/mL.
34. The composition of claim 23 , wherein the emollient is diisopropyl adipate.
35. The composition of claim 24 , wherein the hydrophobic solvent is mineral oil.
36. The composition of claim 35 , wherein the carrier comprises a mixture of mineral oil and the emollient in a ratio between 2:8 and 8:2 on a weight basis.
37. A method of promoting penetration of an active agent into a skin or a mucosal membrane, comprising
a. releasing the nano-emulsion composition of claim 30 from the pressurized container;
b. applying the resultant breakable foam obtained from the composition to a skin or mucosal membrane; and
c. spreading the foam so it is absorbed into the skin or mucosal membrane.
38. A method of treating or alleviating a disorder of a skin, body cavity, and/or mucosal surface, comprising topically administering a breakable foam produced from the composition of claim 30 to a subject having said disorder, wherein:
(a) the active agent comprises an antifungal agent and the disorder is an fungal disorder; or
(b) the active agent comprises a retinoid and the disease is a sebaceous gland disorder.
39. A method of producing a foam composition having improved foam bubble size comprising: (i) providing an oil in water emulsion formulation, wherein the emulsion comprises (a) oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent selected from the group consisting of a non-ionic surfactant, an ionic surfactant, and a polymeric agent; and (c) water; (ii) subjecting the emulsion to high pressure mechanical stress to produce a nano emulsion; and (iii) filling a sealed pressurized container with the nano emulsion, wherein the container further comprises a liquefied hydrocarbon gas propellant at a concentration of about 3% to about 25% by weight of the composition and has an outlet capable of releasing the nano emulsion as a foam; wherein upon release of the foam, the bubble size is significantly greater than the bubble size of a foam from an oil in water emulsion formulation that is not subjected to high pressure mechanical stress to produce a nano emulsion.
40. The composition of claim 21 , wherein the carrier comprises one or more of a hydrophobic solvent, a polar solvent, an emollient, and a mixture thereof, at a concentration of about 2% to about 5% by weight of the carrier.
41. The composition of claim 21 , wherein the carrier comprises one or more of a hydrophobic solvent, a polar solvent, an emollient, and a mixture thereof, at a concentration of about 5% to about 10% by weight of the carrier.
42. The composition of claim 21 , wherein the carrier comprises one or more of a hydrophobic solvent, a polar solvent, an emollient, and a mixture thereof, at a concentration of about 10% to about 20% by weight of the carrier.
43. The composition of claim 21 , wherein the carrier comprises one or more of a hydrophobic solvent, a polar solvent, an emollient, and a mixture thereof, at a concentration of about 20% to about 50% by weight of the carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/368,236 US20170231909A1 (en) | 2002-10-25 | 2016-12-02 | Foam prepared from nanoemulsions and uses |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15248602A IL152486A0 (en) | 2002-10-25 | 2002-10-25 | Alcohol-free cosmetic and pharmaceutical foam carrier |
IL152486 | 2002-10-25 | ||
US42954602P | 2002-11-29 | 2002-11-29 | |
US49238503P | 2003-08-04 | 2003-08-04 | |
PCT/IB2003/005527 WO2004037225A2 (en) | 2002-10-25 | 2003-10-24 | Cosmetic and pharmaceutical foam |
US10/532,618 US20060140984A1 (en) | 2002-10-25 | 2003-10-24 | Cosmetic and pharmaceutical foam |
US10/911,367 US20050069566A1 (en) | 2003-08-04 | 2004-08-04 | Foam carrier containing amphiphilic copolymeric gelling agent |
US71705805P | 2005-09-14 | 2005-09-14 | |
US11/389,742 US20060233721A1 (en) | 2002-10-25 | 2006-03-27 | Foam containing unique oil globules |
US11/975,621 US20080138296A1 (en) | 2002-10-25 | 2007-10-19 | Foam prepared from nanoemulsions and uses |
US14/172,466 US9539208B2 (en) | 2002-10-25 | 2014-02-04 | Foam prepared from nanoemulsions and uses |
US15/368,236 US20170231909A1 (en) | 2002-10-25 | 2016-12-02 | Foam prepared from nanoemulsions and uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/172,466 Continuation US9539208B2 (en) | 2002-10-25 | 2014-02-04 | Foam prepared from nanoemulsions and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170231909A1 true US20170231909A1 (en) | 2017-08-17 |
Family
ID=39498294
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/975,621 Abandoned US20080138296A1 (en) | 2002-10-25 | 2007-10-19 | Foam prepared from nanoemulsions and uses |
US14/172,466 Expired - Lifetime US9539208B2 (en) | 2002-10-25 | 2014-02-04 | Foam prepared from nanoemulsions and uses |
US15/368,236 Abandoned US20170231909A1 (en) | 2002-10-25 | 2016-12-02 | Foam prepared from nanoemulsions and uses |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/975,621 Abandoned US20080138296A1 (en) | 2002-10-25 | 2007-10-19 | Foam prepared from nanoemulsions and uses |
US14/172,466 Expired - Lifetime US9539208B2 (en) | 2002-10-25 | 2014-02-04 | Foam prepared from nanoemulsions and uses |
Country Status (1)
Country | Link |
---|---|
US (3) | US20080138296A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
KR101108439B1 (en) | 2002-10-25 | 2012-01-31 | 포믹스 리미티드 | Cosmetic and pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
WO2006100154A1 (en) | 2005-03-24 | 2006-09-28 | Nolabs Ab | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor |
ES2407407T3 (en) | 2005-06-01 | 2013-06-12 | Glaxosmithkline Intellectual Property Development Limited | Vitamin formulation |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
CA2683746A1 (en) * | 2007-04-13 | 2008-10-23 | Mmp Inc. | Naturally-derived emulsifier system |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
EP2349209A2 (en) | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
DE102009028156A1 (en) * | 2009-07-31 | 2011-02-03 | Evonik Stockhausen Gmbh | Foamable O / W emulsion |
CN102695528B (en) | 2009-08-21 | 2016-07-13 | 诺万公司 | Wound dressing, its using method and forming method thereof |
ES2958410T3 (en) | 2009-08-21 | 2024-02-08 | Novan Inc | Topical gels |
CA2780898A1 (en) * | 2009-11-13 | 2011-05-19 | University Of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
US9186324B2 (en) * | 2010-02-07 | 2015-11-17 | J.P.M.E.D. Ltd. | Hair follicle targeting compositions |
US20110212035A1 (en) * | 2010-02-26 | 2011-09-01 | Collegium Pharmaceutical, Inc. | Emollient foams for treatment of dermatoses |
GB2479891A (en) * | 2010-04-27 | 2011-11-02 | David Chamberlain | Foaming solution to provide acoustic dampening in the ear canal |
US9161531B2 (en) * | 2011-02-23 | 2015-10-20 | Donald R. Korb | High alcohol content sanitizer |
ES2804263T3 (en) | 2011-07-05 | 2021-02-05 | Novan Inc | Topical compositions |
WO2013006613A1 (en) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for same |
EP2794577A4 (en) * | 2011-12-20 | 2015-05-20 | Map Pharmaceuticals Inc | Excipient-free aerosol formulation |
EP2833721B1 (en) | 2012-03-14 | 2021-02-17 | Novan Inc. | Nitric oxide releasing pharmaceutical compositions |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
JP2015000871A (en) * | 2013-06-18 | 2015-01-05 | ロレアル | Foam aerosol cosmetic composition |
ES2836132T3 (en) | 2013-08-08 | 2021-06-24 | Novan Inc | Topical compositions and methods of using them |
WO2015042679A1 (en) * | 2013-09-26 | 2015-04-02 | Ultrapan Ind. E Com. Ltda | Nanosalt, cryogenic grinding process, aerosol and use of said aerosol |
WO2015066777A1 (en) * | 2013-11-08 | 2015-05-14 | L'oreal | Cosmetic compositions in the form of oil-in-water nanoemulsions, comprising solid fatty alcohol(s), liquid fatty ester(s), other oil(s) and non-ionic surfactant(s) |
JP2017506671A (en) | 2014-02-14 | 2017-03-09 | ホアン,ジンジュン | Composition of nanoemulsion delivery system |
MX363626B (en) | 2014-06-16 | 2019-03-28 | Procter & Gamble | Method of treating hair with a concentrated conditioner. |
JP2017517554A (en) | 2014-06-16 | 2017-06-29 | ザ プロクター アンド ギャンブル カンパニー | Method for treating hair using a concentrated conditioner |
CN107072927A (en) | 2014-06-16 | 2017-08-18 | 宝洁公司 | The method that hair is handled using concentrated type conditioner |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
AU2015287674B2 (en) | 2014-07-11 | 2019-11-21 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
WO2016010988A1 (en) | 2014-07-14 | 2016-01-21 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
CA2919733A1 (en) | 2014-08-08 | 2016-02-08 | Novan, Inc. | Topical compositions and methods of using the same |
KR101673692B1 (en) * | 2014-11-07 | 2016-11-07 | 현대자동차주식회사 | Phase-change material suspension fluid Composition containing fumed silica and method for manufacturing the same |
SI3265140T1 (en) * | 2015-03-02 | 2021-11-30 | Medlab Clinical U.S., Inc. | Transmucosal and transdermal delivery systems |
CA2977737C (en) | 2015-03-24 | 2020-08-18 | The Procter & Gamble Company | Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin |
US10258548B2 (en) | 2015-04-23 | 2019-04-16 | The Procter And Gamble Company | Hair care conditioning composition |
WO2017019614A1 (en) | 2015-07-28 | 2017-02-02 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
US9872832B2 (en) * | 2015-10-23 | 2018-01-23 | LG Bionano, LLC | Nanoemulsions having reversible continuous and dispersed phases |
US10265255B2 (en) | 2015-12-15 | 2019-04-23 | The Procter And Gamble Company | Method of treating hair |
US10322072B2 (en) | 2015-12-15 | 2019-06-18 | The Procter And Gamble Company | Method of treating hair |
US10265251B2 (en) | 2015-12-15 | 2019-04-23 | The Procter And Gamble Company | Method of treating hair |
US10124951B2 (en) | 2015-12-15 | 2018-11-13 | The Procter And Gamble Company | Method of treating hair |
WO2017106404A1 (en) | 2015-12-15 | 2017-06-22 | The Procter & Gamble Company | Method of treating hair |
CN108430432A (en) | 2015-12-15 | 2018-08-21 | 宝洁公司 | The method for handling hair |
US10294013B2 (en) | 2015-12-21 | 2019-05-21 | The Procter And Gamble Plaza | Package to dispense a foaming composition |
WO2017151905A1 (en) | 2016-03-02 | 2017-09-08 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
JP6899845B2 (en) | 2016-04-13 | 2021-07-07 | ノヴァン,インコーポレイテッド | Compositions, systems, kits and methods for treating infectious diseases |
US10835480B2 (en) | 2016-04-22 | 2020-11-17 | The Procter And Gamble Company | Method of forming a silicone layer |
US10828248B2 (en) | 2016-04-22 | 2020-11-10 | The Procter And Gamble Company | Method of forming a silicone layer |
BR112018073125B1 (en) | 2016-05-11 | 2022-09-13 | Bayer Healthcare Llc | FORMULATION, METHODS FOR PREPARING A FOAMING FORMULATION AND FOR USING A FOAMING FORMULATION, AND, PRESSURIZED PACKAGING |
US11612551B2 (en) | 2016-05-11 | 2023-03-28 | Formulated Solutions, Llc | Whipped formulations |
DE102016222160A1 (en) * | 2016-11-11 | 2018-05-17 | Beiersdorf Ag | Facial cleansing product with special foam quality and sensor technology |
MX2019013454A (en) | 2017-05-11 | 2020-08-03 | Beiersdorf Ag | Gel formulations. |
CN112165935A (en) | 2018-03-01 | 2021-01-01 | 诺万公司 | Nitric oxide-releasing suppository and method of use |
JP2019151566A (en) * | 2018-03-01 | 2019-09-12 | ロレアル | Sprayable composition |
EP3793524A4 (en) * | 2018-05-11 | 2022-03-30 | Formulytica Pty Ltd | Sub-micron emulsions |
JP7199528B2 (en) | 2018-11-08 | 2023-01-05 | ザ プロクター アンド ギャンブル カンパニー | Low shear stress conditioner composition with spherical gel network vesicles |
JP2022541874A (en) | 2019-06-11 | 2022-09-28 | サイファイ エス.ピー.エー. | Microemulsion composition |
Family Cites Families (1128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1159250A (en) | 1914-05-01 | 1915-11-02 | Frank Moulton | Vaginal irrigator. |
US1666684A (en) | 1926-01-15 | 1928-04-17 | Carstens Mfg Co H | Vaginal douche |
US1924972A (en) | 1929-04-15 | 1933-08-29 | Carl J Beckert | Stabilized egg product |
US2085733A (en) | 1935-07-15 | 1937-07-06 | John C Bird | Shaving cream |
US2390921A (en) | 1943-03-23 | 1945-12-11 | Ethel Hudson Clark | Applicator for facial creams |
US2524590A (en) | 1946-04-22 | 1950-10-03 | Carsten F Boe | Emulsion containing a liquefied propellant gas under pressure and method of spraying same |
US2586287A (en) | 1948-12-11 | 1952-02-19 | Colagte Palmolive Peet Company | Aluminum sulfamate antiperspirant preparation |
US2617754A (en) | 1949-08-29 | 1952-11-11 | Procter & Gamble | Cosmetic cream |
US2772427A (en) * | 1952-01-18 | 1956-12-04 | Brock & Rankin Inc | Book backbone structure with concealed rivet means and method of making same |
US3062715A (en) | 1953-11-18 | 1962-11-06 | George S Pfaus | Vaginal tablet |
US2767712A (en) | 1954-03-01 | 1956-10-23 | Neil S Waterman | Medicinal applicator |
GB808104A (en) | 1955-01-04 | 1959-01-28 | Udylite Res Corp | Electrodeposition of copper from aqueous alkaline cyanide solutions |
GB808105A (en) | 1956-06-15 | 1959-01-28 | Ici Ltd | New pharmaceutical compositions |
US3092555A (en) | 1958-04-21 | 1963-06-04 | Roy H Horn | Relatively collapsible aerosol foam compositions |
US3144386A (en) | 1958-05-09 | 1964-08-11 | Merck & Co Inc | Mastitis aerosol foam |
US2968628A (en) | 1958-10-17 | 1961-01-17 | Shulton Inc | Propellant composition |
US3178352A (en) | 1959-02-27 | 1965-04-13 | Erickson Roy | Shaving method and composition therefor |
US3141821A (en) | 1959-03-17 | 1964-07-21 | Lehn & Fink Products Corp | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis |
US3004894A (en) | 1959-04-07 | 1961-10-17 | Upjohn Co | Therapeutic composition comprising tetracycline and a dioxolane |
GB922930A (en) | 1959-09-21 | 1963-04-03 | Sunnen Joseph | Spermicidal composition and method of making same |
US3142420A (en) | 1959-11-09 | 1964-07-28 | Neotechnic Eng Ltd | Metering dispenser for aerosol with fluid pressure operated piston |
US3092255A (en) | 1960-02-05 | 1963-06-04 | Robert F Hohman | Sorting apparatus |
US3067784A (en) | 1960-04-14 | 1962-12-11 | Esta Medical Lab Inc | Adapter connecting aerosol container valve stem to dispenser for filling said dispenser |
NL270627A (en) | 1960-10-26 | |||
US3154075A (en) | 1960-11-02 | 1964-10-27 | Norwich Pharma Co | Vaginal applicator |
GB998490A (en) | 1961-06-03 | 1965-07-14 | Albert Fritz Albach | A foam projector |
DE1926796U (en) | 1961-10-12 | 1965-11-11 | Heidolph Elektro K G | FAN. |
NL128174C (en) * | 1962-02-28 | |||
US3261695A (en) | 1962-12-24 | 1966-07-19 | Gen Foods Corp | Process for preparing dehydrated foods |
US3330730A (en) | 1962-08-03 | 1967-07-11 | Colgate Palmolive Co | Pressurized emulsion quick breaking foam compositions |
US3252859A (en) | 1962-10-24 | 1966-05-24 | Masti Kure Company Inc | Colloidal silica-oil composition and method of using same |
US3244589A (en) | 1962-10-26 | 1966-04-05 | Sunnen | Alkyl phenoxy polyethoxy ether spermicidal aerosol |
US3298919A (en) | 1962-12-26 | 1967-01-17 | Dow Corning | Shaving cream containing polysiloxanes |
US3383280A (en) | 1963-01-09 | 1968-05-14 | Miles Lab | Dermatological abradant stick-type applicator |
FR1355607A (en) | 1963-01-22 | 1964-03-20 | Improvements to cannula probes and their applications | |
US3149543A (en) | 1963-03-04 | 1964-09-22 | Ingersoll Rand Co | Non-lubricated piston |
GB1026831A (en) | 1963-05-31 | 1966-04-20 | Mediline Ag | Preparations for use in feminine hygiene |
US3824303A (en) | 1963-07-24 | 1974-07-16 | Yardley Of London Inc | Collapsible foam pre-electric shave lotion containing diester lubricants |
GB1081949A (en) | 1963-08-12 | 1967-09-06 | Avon Prod Inc | Improvements in cosmetic mask |
US3333333A (en) | 1963-08-14 | 1967-08-01 | Rca Corp | Method of making magnetic material with pattern of embedded non-magnetic material |
US3236457A (en) | 1963-08-21 | 1966-02-22 | John R Kennedy | Composite spray container assembly |
US3263867A (en) | 1963-12-26 | 1966-08-02 | Valve Corp Of America | Metering button-type aerosol actuator |
US3395214A (en) | 1964-01-09 | 1968-07-30 | Scholl Mfg Co Inc | Antiperspirant composition providing a readily collapsible sprayable foam |
US3278093A (en) | 1964-01-13 | 1966-10-11 | Valve Corp Of America | Metering and non-metering aerosol actuator button |
GB1052724A (en) | 1964-04-27 | |||
US3303970A (en) | 1964-07-14 | 1967-02-14 | Jerome Marrow | Device for simultaneously dispensing from plural sources |
US3395215A (en) | 1964-10-15 | 1968-07-30 | Colgate Palmolive Co | Pressurized lotion composition |
US3384541A (en) | 1964-10-28 | 1968-05-21 | William G. Clark | Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants |
US3263869A (en) | 1964-11-03 | 1966-08-02 | Calmar Inc | Liquid dispenser with overcap |
US3342845A (en) | 1964-11-05 | 1967-09-19 | Upjohn Co | Terphenyl triisocyanates |
US3419658A (en) | 1965-01-25 | 1968-12-31 | Du Pont | Nonaqueous aerosol foams containing mineral oil |
US3346451A (en) | 1965-01-27 | 1967-10-10 | S E Massengill Company | Concentrated liquid lactic acid douche preparation containing aromatics |
US3301444A (en) | 1965-08-12 | 1967-01-31 | Oel Inc | Aerosol metering valve |
US3456052A (en) | 1965-09-28 | 1969-07-15 | Garrett Lab Inc | Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol |
GB1121358A (en) | 1965-10-21 | 1968-07-24 | Bristol Myers Co | Aerosol manufacture |
US3849569A (en) | 1965-12-02 | 1974-11-19 | Glaxo Lab Ltd | Composition containing procaine penicillin |
BE692228A (en) | 1966-01-10 | 1967-07-05 | ||
US3401849A (en) | 1966-05-24 | 1968-09-17 | Robert L. Weber | Low force metering valve |
US3886084A (en) | 1966-09-29 | 1975-05-27 | Champion Int Corp | Microencapsulation system |
US3377004A (en) | 1966-10-03 | 1968-04-09 | Gen Mills Inc | Metered dispensing container |
GB1201918A (en) | 1966-12-21 | 1970-08-12 | Bespak Industries Ltd | Improvements in or relating to valves for pressurised dispensers |
US3527559A (en) | 1967-01-05 | 1970-09-08 | Standard Pharmacal Corp | Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent |
US3366494A (en) | 1967-02-15 | 1968-01-30 | Du Pont | Pressurized aerosol food emulsions |
US3561262A (en) | 1967-10-26 | 1971-02-09 | Magnaflux Corp | Water soluble developer |
US3540448A (en) | 1968-01-17 | 1970-11-17 | Joseph Sunnen | Rechargeable applicator for dispensing substances in a foam condition |
US3563098A (en) | 1968-06-28 | 1971-02-16 | Rex Chainbelt Inc | Automatic quick release mechanism |
US3559890A (en) | 1968-09-03 | 1971-02-02 | William R Brooks | Foam dispenser |
US3878118A (en) | 1968-09-06 | 1975-04-15 | Wilkinson Sword Ltd | Self-heating chemical compositions |
US3667461A (en) | 1968-11-05 | 1972-06-06 | Paul A Zamarra | Disposable syringe |
CA975500A (en) | 1969-02-06 | 1975-09-30 | Joseph G. Spitzer | Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same, and process |
US3866800A (en) | 1969-02-12 | 1975-02-18 | Alberto Culver Co | Non-pressurized package containing self-heating products |
US3966090A (en) | 1969-02-17 | 1976-06-29 | Dart Industries Inc. | Package for dispensing an antiseptic composition |
US4001391A (en) | 1969-04-18 | 1977-01-04 | Plough, Inc. | Means for depositing aerosol sprays in buttery form |
US3819524A (en) | 1969-06-17 | 1974-06-25 | Colgate Palmolive Co | Cosmetic composition for thermal dispensing |
US3577518A (en) | 1969-07-18 | 1971-05-04 | Nat Patent Dev Corp | Hydrophilic hairspray and hair setting preparations |
US3787566A (en) | 1969-07-29 | 1974-01-22 | Holliston Labor Inc | Disinfecting aerosol compositions |
BE759520A (en) | 1969-11-28 | 1971-04-30 | Aspro Nicholas Ltd | ASPIRIN COMPOSITIONS |
GB1353381A (en) | 1971-02-04 | 1974-05-15 | Wilkinson Sword Ltd | Substituted p-menthanes and compositions containing them |
GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
GB1351762A (en) | 1971-02-14 | 1974-05-01 | Wilkinson Sword Ltd | Tobacco and tobacco-containing manufactures |
CA958338A (en) | 1971-03-08 | 1974-11-26 | Chung T. Shin | Antiperspirant powder aerosol compositions containing aluminum chloride and water soluble aluminum compounds and methods of preparation |
US3770648A (en) | 1971-07-12 | 1973-11-06 | Bristol Myers Co | Anhydrous aerosol foam |
US3912667A (en) | 1971-09-13 | 1975-10-14 | Spitzer Joseph G | Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same and process |
BE788788A (en) | 1971-09-13 | 1973-03-13 | Treuhandvereinigung Ag | PRODUCT FOR PRESERVING, PROMOTING AND RESTORING HAIR AND METHOD OF MANUFACTURING THIS PRODUCT |
US3997467A (en) | 1971-11-26 | 1976-12-14 | Pharmacia Aktiebolag | Foam forming composition |
SE358308B (en) | 1971-11-26 | 1973-07-30 | Pharmacia Ab | |
CH1917171A4 (en) | 1971-12-30 | 1975-04-30 | ||
US3963833A (en) | 1972-06-02 | 1976-06-15 | Colgate-Palmolive Company | Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt |
US3841525A (en) | 1972-06-14 | 1974-10-15 | N Siegel | Aerosol spray device with cam activator |
US3849580A (en) | 1972-09-05 | 1974-11-19 | American Home Prod | Aerosol dispensing system for anhydrous edible fat compositions |
US3751562A (en) | 1972-09-22 | 1973-08-07 | Princeton Biomedix | Medicated gelled oils |
US3970584A (en) | 1973-02-14 | 1976-07-20 | S. C. Johnson & Son, Inc. | Aerosol package containing a foam-forming emulsion and propellent system |
US4439416A (en) | 1973-03-23 | 1984-03-27 | Colgate-Palmolive Company | Self-heating shaving composition |
GB1423179A (en) | 1973-05-16 | 1976-01-28 | Wilkinson Sword Ltd | Pressurised shaving foam dispensers |
YU36328B (en) | 1973-07-18 | 1983-06-30 | Elastin Werk Ag | Method of manufacturing red foils for packing sausages |
US4110426A (en) | 1973-07-24 | 1978-08-29 | Colgate-Palmolive Company | Method of treating skin and hair with a self-heated cosmetic |
US3865275A (en) | 1973-07-30 | 1975-02-11 | Raymond Lee Organization Inc | Apparatus for operating an aerosol can |
US3929985A (en) | 1974-01-18 | 1975-12-30 | Richardson Merrell Inc | Anhydrous candicidin foam compositions |
DE2501548A1 (en) | 1974-01-25 | 1975-07-31 | Procter & Gamble | ORAL TREATMENT PRODUCTS |
GB1457671A (en) | 1974-01-31 | 1976-12-08 | Wilkinson Sword Ltd | Flavour |
US3923970A (en) | 1974-03-29 | 1975-12-02 | Carter Wallace | Stable aerosol shaving foams containing mineral oil |
US3962150A (en) | 1974-04-10 | 1976-06-08 | Richardson-Merrell Inc. | Foam producing cleansing compositions |
US3953591A (en) | 1974-04-29 | 1976-04-27 | The Procter & Gamble Company | Fatty acid, polysiloxane and water-soluble polymer containing skin conditioning emulsion |
US3966632A (en) | 1974-06-06 | 1976-06-29 | G. D. Searle & Co. | Vegetable oil emulsion |
US4145411A (en) | 1974-09-05 | 1979-03-20 | Colgate-Palmolive Company | Pressurized foaming shaving composition |
JPS5729213B2 (en) | 1974-11-12 | 1982-06-21 | ||
US4052513A (en) * | 1974-12-13 | 1977-10-04 | Plough, Inc. | Stable topical anesthetic compositions |
US3952916A (en) | 1975-01-06 | 1976-04-27 | Warner-Lambert Company | Automatic dispenser for periodically actuating an aerosol container |
US3970219A (en) | 1975-03-03 | 1976-07-20 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols and process |
US4019657A (en) | 1975-03-03 | 1977-04-26 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols |
US4018396A (en) | 1975-05-05 | 1977-04-19 | Bechtel International Corporation | Embedded housing for ore crusher |
US3993224A (en) | 1975-09-08 | 1976-11-23 | Aerosol Investments, Ltd. | Spout for two-component resin dispenser |
DE2608226A1 (en) | 1976-02-28 | 1977-09-08 | Haarmann & Reimer Gmbh | AGENTS WITH PHYSIOLOGICAL COOLING EFFECT |
US4102995A (en) | 1976-05-13 | 1978-07-25 | Westwood Pharmaceuticals Inc. | Tar gel formulation |
US4124149A (en) | 1976-07-19 | 1978-11-07 | Spitzer Joseph G | Aerosol container with position-sensitive shut-off valve |
CA1089368A (en) | 1976-08-02 | 1980-11-11 | Daniel C. Geary | Polyethoxylated fatty alcohol in antiperspirant sticks |
IL52045A (en) | 1976-08-25 | 1979-12-30 | Mundipharma Ag | Sprayable germicidal foam compositions |
US4252787A (en) | 1976-12-27 | 1981-02-24 | Cambridge Research And Development Group | Anti-fertility composition and method |
US4310510A (en) | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
US4083974A (en) | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
JPS5744429Y2 (en) | 1977-04-14 | 1982-10-01 | ||
IT1114950B (en) | 1977-12-30 | 1986-02-03 | Porro Marcella | COMPOSITIONS FOR ACNE TREATMENT AND THERAPY |
US4386104A (en) | 1977-04-19 | 1983-05-31 | Nazzaro Porro Marcella | Process for the treatment of acne |
GB2004746B (en) | 1977-10-03 | 1982-03-10 | Scherico Ltd | Stable hopical anaesthetic compositions |
JPS5639815Y2 (en) | 1977-11-25 | 1981-09-17 | ||
SE7713618L (en) | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | LOCAL ANESTHETIC MIXTURE |
US4160827A (en) | 1978-02-06 | 1979-07-10 | The Upjohn Company | Metronidazole phosphate and salts |
US4229432A (en) | 1978-04-19 | 1980-10-21 | Bristol-Myers Company | Antiperspirant stick composition |
US4603812A (en) | 1978-06-27 | 1986-08-05 | The Dow Chemical Company | Foam-generating pump sprayer |
US4178373A (en) * | 1978-08-21 | 1979-12-11 | William H. Rorer, Inc. | Coal tar gel composition |
US4214000A (en) | 1978-10-30 | 1980-07-22 | Johnson & Johnson | Zinc salt of all-trans-retinoic acid for the treatment of acne |
JPS5569682U (en) | 1978-11-08 | 1980-05-13 | ||
US4213979A (en) | 1978-12-18 | 1980-07-22 | Plough, Inc. | Stable sprayable hydrocortisone product |
US4954487A (en) | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4439441A (en) | 1979-01-11 | 1984-03-27 | Syntex (U.S.A.) Inc. | Contraceptive compositions and methods employing 1-substituted imidazole derivatives |
US4226344A (en) | 1979-02-06 | 1980-10-07 | Booth, Inc. | Constant flow valve actuator |
CH639913A5 (en) | 1979-03-16 | 1983-12-15 | Aerosol Service Ag | Container for receiving and delivering a liquid substance |
US4230701A (en) | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4335120A (en) | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4278206A (en) * | 1979-04-13 | 1981-07-14 | Ae Development Corporation | Non-pressurized dispensing system |
US4241048A (en) | 1979-05-01 | 1980-12-23 | Bristol-Myers Company | Suspension composition of benzocaine |
JPS55153712A (en) | 1979-05-18 | 1980-11-29 | Kao Corp | Insulin pharmaceutical preparation and its production |
US4268499A (en) | 1979-06-07 | 1981-05-19 | Dow Corning Corporation | Antiperspirant emulsion compositions |
US4241149A (en) | 1979-07-20 | 1980-12-23 | Temple University | Canal clathrate complex solid electrolyte cell |
DE2931469A1 (en) | 1979-08-02 | 1981-02-26 | Bayer Ag | SURFACE SEALED MOLDED BODIES MADE OF CELLED POLYURETHANE ELASTOMERS AND METHOD FOR THE PRODUCTION THEREOF |
US4271149A (en) | 1979-09-21 | 1981-06-02 | West Agro-Chemical, Inc. | Germicidal iodine compositions with enhanced iodine stability |
US4299826A (en) | 1979-10-12 | 1981-11-10 | The Procter & Gamble Company | Anti-acne composition |
EP0032309A3 (en) | 1980-01-10 | 1981-08-05 | Imperial Chemical Industries Plc | Production of catalyst component, catalyst and use thereof |
US4309995A (en) | 1980-01-28 | 1982-01-12 | Sacco Susan M | Vaginal irrigation apparatus |
JPS56135416A (en) | 1980-03-27 | 1981-10-22 | Mitsubishi Chem Ind Ltd | Pharmaceutical preparation for skin |
SE8004580L (en) | 1980-06-19 | 1981-12-20 | Draco Ab | PHARMACEUTICAL PREPARATION |
US4338211A (en) | 1980-06-30 | 1982-07-06 | The Procter & Gamble Company | Liquid surfactant skin cleanser with lather boosters |
US4508705A (en) | 1980-07-02 | 1985-04-02 | Lever Brothers Company | Skin treatment composition |
US4323582A (en) | 1980-07-21 | 1982-04-06 | Siegel Norman H | Method of treating animals and humans for internal and external parasites |
JPS601113Y2 (en) | 1980-07-22 | 1985-01-12 | 三菱電機株式会社 | Round lighting equipment packaging |
US4329990A (en) | 1980-08-07 | 1982-05-18 | Sneider Vincent R | Expanding swab applicator |
US4325939A (en) | 1980-09-22 | 1982-04-20 | Richardson-Vicks Inc. | Zinc derivatives and their use in dental compositions |
US4305936A (en) | 1980-10-09 | 1981-12-15 | Dermik Laboratories | Topical corticosteroid formulations |
US4292250A (en) | 1980-11-17 | 1981-09-29 | Wisconsin Alumni Research Foundation | Vitamin D derivatives |
DE3176215D1 (en) | 1980-11-19 | 1987-07-02 | Procter & Gamble | Non-yellowing topical pharmaceutical composition |
EP0065513B1 (en) | 1980-11-27 | 1985-09-18 | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. | Antimycotic synergistic pharmaceutical compositions and process for the preparation thereof |
DE3147726A1 (en) | 1980-12-03 | 1982-06-24 | Leo Pharmaceutical Products Ltd. A/S (Loevens kemiske Fabrik Produktionsaktieselskab), 2750 Ballerup | ANTIBIOTIC COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS THAT CONTAIN THESE COMPOUNDS |
US4352808A (en) | 1980-12-12 | 1982-10-05 | Schering Corporation | 3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore |
US4323694A (en) | 1981-04-13 | 1982-04-06 | Finetex, Inc. | Benzoic acid esters |
US4522948A (en) | 1981-04-24 | 1985-06-11 | Syntex (U.S.A.) Inc. | Spermicidal substituted 1-(cycloalkyl)alkylimidazoles |
US4393066A (en) | 1981-06-05 | 1983-07-12 | Garrett David M | Method for treatment of herpetic lesions |
US4607101A (en) | 1981-08-27 | 1986-08-19 | Jaye-Boern Laboratories, Inc. | Method of treating acne vulgaris with a composition containing carbamide peroxide |
US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
US4469674A (en) | 1981-09-03 | 1984-09-04 | Richardson-Vicks Inc. | Stable oral compositions containing zinc and fluoride compounds |
US4440320A (en) | 1981-11-30 | 1984-04-03 | Wernicke Steven A | Foam dispensing apparatus |
LU83876A1 (en) | 1982-01-15 | 1983-09-02 | Oreal | COSMETIC COMPOSITION FOR TREATMENT OF KERATINIC FIBERS AND METHOD FOR TREATING THE SAME |
LU83949A1 (en) | 1982-02-16 | 1983-09-02 | Oreal | COMPOSITION FOR THE TREATMENT OF KERATINIC MATERIALS CONTAINING AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ANIONIC LATEX |
US5087618A (en) | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
US4529605A (en) | 1983-01-12 | 1985-07-16 | Una E. Lynch | Bathing oil composition |
US4661340A (en) | 1983-06-06 | 1987-04-28 | Interkemia Vegyipari Gazdasagi Tarsasag | Quail egg based stabilized foam compositions for cosmetic purposes |
GB8315787D0 (en) | 1983-06-08 | 1983-07-13 | Briggs J H | Coolant spray |
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
GB8330969D0 (en) | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
GB8402748D0 (en) | 1984-02-02 | 1984-03-07 | Dunlop Ltd | Intravaginal device |
US4985459A (en) | 1984-02-08 | 1991-01-15 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
NZ207341A (en) | 1984-03-01 | 1988-02-29 | Harvey Alex Ind Ltd | Device containing chemical impregnants for insertion into a body cavity of an animal |
US4628063A (en) | 1984-03-08 | 1986-12-09 | Dana P. Brigham | Antiviral pharmaceutical preparations and methods for their use |
US4574052A (en) | 1984-05-31 | 1986-03-04 | Richardson-Vicks Inc. | Crackling aerosol foam |
GB8416638D0 (en) | 1984-06-29 | 1984-08-01 | Beecham Group Plc | Topical treatment and composition |
ATE37209T1 (en) | 1984-08-06 | 1988-09-15 | Ciba Geigy Ag | PROCESS FOR SIZING PAPER WITH ANIONIC, HYDROPHOBIC SIZES AND CATIONIC RETENTION AGENTS. |
US4595526A (en) | 1984-09-28 | 1986-06-17 | Colgate-Palmolive Company | High foaming nonionic surfacant based liquid detergent |
SE443914B (en) | 1984-10-01 | 1986-03-17 | Torkel Ingemar Fischer | MEANS OF A SENSITIVITY TEST |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
CA1261276A (en) | 1984-11-09 | 1989-09-26 | Mark B. Grote | Shampoo compositions |
US4701320A (en) | 1984-11-29 | 1987-10-20 | Lederle (Japan), Ltd. | Composition stably containing minocycline for treating periodontal diseases |
US4627973A (en) | 1984-12-14 | 1986-12-09 | Charles Of The Ritz Group Ltd. | Skin mousse |
AU5078885A (en) | 1984-12-20 | 1986-06-26 | Warner-Lambert Company | Non-irritant detergent |
US4673569A (en) | 1985-02-12 | 1987-06-16 | Faberge Incorporated | Mousse hair composition |
EP0194097B1 (en) | 1985-03-01 | 1990-04-25 | The Procter & Gamble Company | Mild cleansing mousse |
US5002680A (en) | 1985-03-01 | 1991-03-26 | The Procter & Gamble Company | Mild skin cleansing aerosol mousse with skin feel and moisturization benefits |
US4639367A (en) | 1985-03-18 | 1987-01-27 | Product Resources International, Inc. | Aerosol foam |
AU5549486A (en) | 1985-03-18 | 1986-10-13 | Product Resources International, Inc. | Exothermic stable foam compositions |
US4752465A (en) | 1985-09-20 | 1988-06-21 | Product Resources International, Inc. | Aerosol foam |
US5094853A (en) | 1985-04-26 | 1992-03-10 | S. C. Johnson & Son, Inc. | Method of preparing a water-soluble stable arthropodicidally-active foam matrix |
US4965063A (en) * | 1985-05-24 | 1990-10-23 | Irene Casey | Cleaner and disinfectant with dye |
DE3521713A1 (en) | 1985-06-18 | 1986-12-18 | Henkel KGaA, 4000 Düsseldorf | OIL-IN-WATER EMULSIONS WITH IMPROVED VISCOSITY BEHAVIOR |
US4672078A (en) | 1985-07-03 | 1987-06-09 | Schering-Plough Corporation | Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations |
GB8519426D0 (en) | 1985-08-01 | 1985-09-04 | Ici Plc | Composition for personal care products |
US4806262A (en) | 1985-08-14 | 1989-02-21 | The Procter & Gamble Company | Nonlathering cleansing mousse with skin conditioning benefits |
EP0213827A3 (en) | 1985-08-14 | 1988-04-06 | The Procter & Gamble Company | Nonfoaming cleansing mousse with skin conditioning benefits |
AU6175586A (en) | 1985-09-11 | 1987-03-12 | Chesebrough-Pond's Inc. | Petroleum jelly, mild detergent anhydrous base compositions |
FR2591331A1 (en) | 1985-12-10 | 1987-06-12 | Drevet Jean Baptiste | Device for dispensing metered portions of a product contained in a pressurised receptacle |
US4837378A (en) | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
GB8607570D0 (en) | 1986-03-26 | 1986-04-30 | Euro Celtique Sa | Vaginal pharmaceutical preparation |
JPS62241701A (en) | 1986-04-11 | 1987-10-22 | Maeda Kogyo Kk | Quick releasing device for hub for bicycle |
CA1291036C (en) | 1986-04-23 | 1991-10-22 | Edwin I. Stoltz | Nasal administration of drugs |
DE3614515A1 (en) | 1986-04-29 | 1987-11-05 | Pfeiffer Erich Gmbh & Co Kg | DISCHARGE DEVICE FOR MEDIA |
FR2598392B1 (en) | 1986-05-09 | 1988-08-26 | Oreal | PACKAGING FOR TWO PRESSURIZED CONTAINERS |
PH25150A (en) | 1986-06-05 | 1991-03-13 | Ciba Geigy Ag | Novel pharmaceutical preparation for topical application |
US4770634A (en) | 1986-06-11 | 1988-09-13 | Pellico Michael A | Method for treating teeth with foamable fluoride compositions |
JPS62299423A (en) | 1986-06-18 | 1987-12-26 | Mazda Motor Corp | Air-conditioner for vehicle |
US4837019A (en) | 1986-08-11 | 1989-06-06 | Charles Of The Ritz Group Ltd. | Skin treatment composition and method for treating burned skin |
US4906453A (en) | 1986-08-12 | 1990-03-06 | Jumpeer Nails, Inc. | Mousse product |
DE3628531A1 (en) | 1986-08-22 | 1988-02-25 | Merz & Co Gmbh & Co | FOAMABLE CREAMS |
WO1988001502A1 (en) | 1986-09-05 | 1988-03-10 | The Upjohn Company | Sebum-dissolving nonaqueous minoxidil formulation |
WO1988001863A1 (en) | 1986-09-12 | 1988-03-24 | The Upjohn Company | Foams for delivery of minoxidil |
EP0270316A3 (en) | 1986-12-04 | 1989-12-06 | Pfizer Inc. | Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne |
US4822613A (en) | 1986-12-15 | 1989-04-18 | S. C. Johnson & Son, Inc. | Water-soluble foamable insecticidally-active compositions |
US4822614A (en) | 1986-12-19 | 1989-04-18 | S. C. Johnson & Son, Inc. | Bioactive film-forming composition for control of crawling insects and the like |
US5389677B1 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
US4863900A (en) | 1987-01-15 | 1989-09-05 | The Research Foundation Of State University Of New York | Method for reducing viral transmission with poly-L-histidine |
JPS63119420U (en) | 1987-01-30 | 1988-08-02 | ||
DE3704907A1 (en) | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
US4828837A (en) | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
AU1388388A (en) * | 1987-04-01 | 1988-10-06 | Dak-Laboratoriet A/S | Benzoic acid derivatives and use thereof |
LU86839A1 (en) * | 1987-04-10 | 1988-12-13 | Oreal | DETERGENT AND FOAMING COSMETIC COMPOSITION, DELAYING RE-LUBRICATION OF HAIR |
JPH01503519A (en) | 1987-04-21 | 1989-11-30 | チャタン・ノミニーズ・プロプライアタリー・リミテッド | vaginal irrigator |
FR2615173B1 (en) | 1987-05-13 | 1989-08-18 | Valois | DOSING VALVE FOR LIQUID LOADED WITH A LIQUID OR LIQUEFIED GAS PROPELLER, FOR USE IN THE REVERSE POSITION |
US4867967A (en) | 1987-06-04 | 1989-09-19 | Crutcher Wilbert L | Method for the treatment of pseudofolliculitis barbae |
US4780309A (en) | 1987-06-16 | 1988-10-25 | Warner-Lambert Company | Edible aerosol foam compositions and method of preparing same |
US4849117A (en) | 1987-06-17 | 1989-07-18 | Sanitek Products, Inc. | Concentrated composition for forming an aqueous foam |
US4885282A (en) | 1987-07-02 | 1989-12-05 | Thornfeldt Carl R | Treatment of hyperhidrosis, ichthyosis and wrinkling |
US4898246A (en) | 1987-07-06 | 1990-02-06 | Total Walther Feuerschutz Gmbh | Quick release valve for sprinkler head |
US5196405A (en) | 1987-07-08 | 1993-03-23 | Norman H. Oskman | Compositions and methods of treating hemorrhoids and wounds |
US4847068A (en) | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
US4913893A (en) | 1987-08-28 | 1990-04-03 | Clairol Incorporated | Aerosol hair setting composition containing an alginate |
CA1273576A (en) | 1987-09-16 | 1990-09-04 | Patrick A. Beauchamp | Topical treatment for diseased skin disorders |
JPH0451958Y2 (en) | 1987-09-22 | 1992-12-07 | ||
US4981677A (en) | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US4784842A (en) | 1987-09-25 | 1988-11-15 | Jean London | Therapeutic composition for treatment of cuts, burns and abrasions |
US4772427A (en) | 1987-12-01 | 1988-09-20 | Colgate-Palmolive Co. | Post-foaming gel shower product |
US5143717A (en) | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
ES2037385T3 (en) | 1988-01-14 | 1993-06-16 | Akzo N.V. | A MANUFACTURING PROCEDURE OF A PHARMACEUTICAL PREPARATION FOR LOCAL ADMINISTRATION. |
US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
JP2643217B2 (en) | 1988-01-22 | 1997-08-20 | エーザイ株式会社 | Aqueous liquid of fat-soluble substance |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4897262A (en) | 1988-03-22 | 1990-01-30 | Playtex Jhirmack, Inc. | Non-aerosol hair spray composition |
DE3811081A1 (en) | 1988-03-30 | 1989-10-12 | Schering Ag | USE OF TOPIC APPLICABLE PREPARATIONS FOR THE TREATMENT OF AGING SKIN |
LU87187A1 (en) | 1988-03-31 | 1989-10-26 | Oreal | COMBINATION OF PYRIMIDINE DERIVATIVES AND SALICYLIC ACID DERIVATIVES FOR INDUCING AND STIMULATING HAIR GROWTH AND REDUCING HAIR LOSS |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4873078A (en) | 1988-04-22 | 1989-10-10 | Plough, Inc. | High-gloss, high-shine lipstick |
GB8811409D0 (en) | 1988-05-13 | 1988-06-15 | Unilever Plc | Cosmetic composition |
US5378730A (en) | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
US4827378A (en) | 1988-06-15 | 1989-05-02 | Rockwell International Corporation | Jack coaxial connector EMI shielding apparatus |
US5217707A (en) | 1988-06-16 | 1993-06-08 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Pharmaceutical composition and process for the preparation thereof |
US4879083A (en) | 1988-06-17 | 1989-11-07 | Macmillan Bloedel Limited | Chemically treated wood particle board |
US4902281A (en) | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US4950420A (en) | 1988-08-31 | 1990-08-21 | Nalco Chemical Company | Antifoam/defoamer composition |
US4855294A (en) | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
GB8821129D0 (en) | 1988-09-09 | 1988-10-12 | Unilever Plc | Cosmetic composition |
US5135915A (en) | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
US5186857A (en) | 1988-11-14 | 1993-02-16 | Imaginative Research Associates, Inc. | Self-foaming oil compositions and process for making and using same |
GB8828013D0 (en) | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US4970067A (en) | 1988-12-12 | 1990-11-13 | Helene Curtis, Inc. | Method and composition to condition hair and impart semi-permanent hair set retention properties |
US5262407A (en) | 1988-12-16 | 1993-11-16 | L'oreal | Use of salicylic derivatives for the treatment of skin aging |
FR2640942A1 (en) | 1988-12-23 | 1990-06-29 | Suchard Sa Jacobs | Container of the aerosol type for delivering, in the form of a foam, metered quantities of product, particularly of food product |
ES2052879T3 (en) | 1988-12-27 | 1994-07-16 | Osaka Shipbuilding | AEROSOL COMPOSITION. |
FR2641185B1 (en) | 1988-12-29 | 1991-04-05 | Oreal | SHAVING COMPOSITION FOR THE SKIN BASED ON ACYLOXYALKYL FUNCTIONAL POLYORGANOSILOXANES AND METHOD FOR IMPLEMENTING SAME |
LU87449A1 (en) | 1989-02-09 | 1990-09-19 | Oreal | PROCESS FOR THE MANUFACTURE OF FOAMS FOR USE IN THE COSMETIC AND PHARMACEUTICAL AREAS AND FOAMS OBTAINED BY THIS PROCESS |
US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
US4996193A (en) | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5019375A (en) | 1989-03-14 | 1991-05-28 | The Procter & Gamble Company | Low residue antiperspirant creams |
JP2903708B2 (en) | 1989-03-17 | 1999-06-14 | 大正製薬株式会社 | Aerosol for external use |
US5221696A (en) | 1989-03-29 | 1993-06-22 | Alcon Laboratories, Inc. | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs |
DE69020211T2 (en) | 1989-04-05 | 1995-11-02 | Kao Corp | Cosmetic double emulsion composition. |
US5204093A (en) | 1989-04-06 | 1993-04-20 | Victor Steven A | Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same |
US5071648A (en) | 1989-04-06 | 1991-12-10 | Merocel Corporation | Polymeric broad-spectrum antimicrobial materials |
US5618798A (en) | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
GB8909559D0 (en) | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
US5322683A (en) | 1989-05-01 | 1994-06-21 | Leonard Mackles | Anhydrous aerosol foam |
US5002540A (en) | 1989-05-22 | 1991-03-26 | Warren Kirschbaum | Intravaginal device and method for delivering a medicament |
GB8911853D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Co2 blown integral skin foams |
US5208031A (en) | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
CA1337279C (en) | 1989-06-06 | 1995-10-10 | Robert J. Borgman | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
US5122519A (en) | 1989-06-27 | 1992-06-16 | American Cyanamid Company | Stable, cosmetically acceptable topical gel formulation and method of treatment for acne |
MX21452A (en) | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED. |
US5560859A (en) * | 1989-07-26 | 1996-10-01 | Pfizer Inc. | Post foaming gel shaving composition |
US4981367A (en) | 1989-07-28 | 1991-01-01 | Stranco, Inc. | Portable mixing apparatus |
EP0484530B1 (en) | 1989-07-28 | 1995-07-12 | Hisamitsu Pharmaceutical Co., Inc. | Foamed aerosol preparation |
JPH0383914A (en) | 1989-08-18 | 1991-04-09 | W R Grace & Co | Drug carrier |
US5219877A (en) | 1989-09-25 | 1993-06-15 | Bristol-Myers Squibb Company | Lauryl alcohol as skin penetration enhancer for topical imidazole agents |
IL95952A0 (en) | 1989-10-19 | 1991-07-18 | Sterling Drug Inc | Aerosol composition for topical medicament |
US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5508033A (en) | 1989-12-06 | 1996-04-16 | Societe D'engrais Composes Mineraux Et Amendments | Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions |
EP0504301B1 (en) | 1989-12-07 | 2004-03-31 | Instead, Inc. | Method of collecting vaginal discharge |
US5295984A (en) | 1989-12-07 | 1994-03-22 | Ultrafem, Inc. | Vaginal discharge collection device and intravaginal drug delivery system |
WO1991008733A1 (en) | 1989-12-20 | 1991-06-27 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
US4966779A (en) | 1989-12-21 | 1990-10-30 | Basf Corporation | Stable, water miscible emulsion comprising a fat-soluble vitamin |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US4963351A (en) | 1989-12-26 | 1990-10-16 | Bhn Associates | Shaving aid |
US5100917A (en) | 1989-12-29 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | Novel a-nor-steroid-3-carboxylic acid derivatives |
US5104645A (en) | 1990-02-02 | 1992-04-14 | The Proctor & Gamble Company | Antidandruff shampoo compositions |
SE9000485D0 (en) | 1990-02-09 | 1990-02-09 | Pharmacia Ab | FOAMABLE COMPOSITION FOR PHARMACEUTICAL USE, USE THEREOF AND METHOD OF TREATMENT |
US5164367A (en) | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
US5130121A (en) | 1990-04-17 | 1992-07-14 | Isp Investments Inc. | Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of water-soluble vinyl monomer |
US5007556A (en) | 1990-04-18 | 1991-04-16 | Block Drug Company, Inc. | Metering dispenser |
US5156765A (en) | 1990-05-15 | 1992-10-20 | Fox Valley Systems, Inc. | Aerosol foam marking compositions |
US5112359A (en) | 1990-06-04 | 1992-05-12 | Clairol, Inc. | Hair colorants |
JP3649341B2 (en) | 1990-06-15 | 2005-05-18 | 株式会社資生堂 | COMPOSITE AND COMPOSITE COMPOSITION, EMULSION COMPOSITION, AND EMULSION COMPOSITION |
US5034220A (en) | 1990-06-20 | 1991-07-23 | Gaf Chemicals Corporation | Non-aerosol shaving gel |
US5336692A (en) | 1990-06-28 | 1994-08-09 | Medicis Pharmaceutical Corporation | Ointment base and method of use |
IT1243379B (en) | 1990-07-27 | 1994-06-10 | Giuliani Spa | PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL |
US5108556A (en) | 1990-09-14 | 1992-04-28 | Minnesota Mining And Manufacturing Company | Process for preparing tertiary perfluoroamines |
US5091111A (en) | 1990-09-19 | 1992-02-25 | S. C. Johnson & Son, Inc. | Aqueous emulsion and aersol delivery system using same |
US5114718A (en) | 1990-09-20 | 1992-05-19 | The Procter & Gamble Company | Sustained release compositions for treating periodontol disease |
GB9021546D0 (en) | 1990-10-04 | 1990-11-21 | Beecham Group Plc | Novel composition |
FR2668927B1 (en) | 1990-11-09 | 1993-01-08 | Oreal | COSMETIC ANHYDROUS COMPOSITION IN AEROSOL FORM FOR THE FORMATION OF A FOAM. |
US5073371A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
DE9016291U1 (en) | 1990-11-30 | 1991-03-28 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Topically applicable diclofenac preparations |
WO1992011839A1 (en) | 1991-01-08 | 1992-07-23 | Leonard Mackles | Anhydrous aerosol |
AU1411992A (en) | 1991-01-15 | 1992-08-27 | Robert A Bok | A composition containing a tetracycline and use for inhibiting angiogenesis |
US5227163A (en) | 1991-01-18 | 1993-07-13 | Clilco, Ltd. | Lice-repellant compositions |
DE4102506C2 (en) | 1991-01-29 | 1999-11-25 | Pfeiffer Erich Gmbh & Co Kg | Discharge device for media |
WO1992013602A1 (en) | 1991-02-05 | 1992-08-20 | Buil Juergen | Fire extinguishing and protection agent |
US6753167B2 (en) | 1991-02-22 | 2004-06-22 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
US5650554A (en) | 1991-02-22 | 1997-07-22 | Sembiosys Genetics Inc. | Oil-body proteins as carriers of high-value peptides in plants |
US5948682A (en) | 1991-02-22 | 1999-09-07 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
US5658956A (en) | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
US5663208A (en) | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
US5648380A (en) * | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
IT1247138B (en) * | 1991-03-06 | 1994-12-12 | Dompe Farmaceutici Spa | HYDROPHILE PHARMACEUTICAL COMPOSITION CONTAINING KETOPROFENE LYSINE SALT FOR TOPICAL USE. |
US5279819A (en) | 1991-03-18 | 1994-01-18 | The Gillette Company | Shaving compositions |
AU664178B2 (en) | 1991-03-19 | 1995-11-09 | Vithal J. Rajadhyaksha | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers |
US5389676A (en) | 1991-03-22 | 1995-02-14 | E. B. Michaels Research Associates, Inc. | Viscous surfactant emulsion compositions |
AU658608B2 (en) | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
US5167950A (en) | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
DE4110973A1 (en) | 1991-04-05 | 1992-10-08 | Haarmann & Reimer Gmbh | MEDIUM WITH A PHYSIOLOGICAL COOLING EFFECT AND EFFECTIVE COMPOUNDS SUITABLE FOR THIS MEDIUM |
HU209605B (en) | 1991-04-15 | 1994-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for production of wather-free transdermal preparation |
IT1247529B (en) | 1991-04-24 | 1994-12-17 | Poli Ind Chimica Spa | PHARMACEUTICAL COMPOSITIONS IN FOAM FORM FOR INTRAVAGINAL, SKIN AND ORAL ADMINISTRATION |
US5204090A (en) | 1991-05-30 | 1993-04-20 | Bristol Myers Squibb | Waterproof high-SPF sunscreen compositions |
US5164357A (en) | 1991-06-05 | 1992-11-17 | Appleton Papers Inc. | Thermally-responsive record material |
FR2677544B1 (en) | 1991-06-14 | 1993-09-24 | Oreal | COSMETIC COMPOSITION CONTAINING A MIXTURE OF NANOPIGMENTS OF METAL OXIDES AND MELANIC PIGMENTS. |
DE4210165A1 (en) | 1991-07-30 | 1993-02-04 | Schering Ag | TRANSDERMAL THERAPEUTIC SYSTEMS |
DE4127630A1 (en) | 1991-08-21 | 1993-02-25 | Bruno Jesswein | TWO-COMPONENT PRESSURE CAN, IN PARTICULAR FOR 2K FOAM |
GB9118028D0 (en) | 1991-08-21 | 1991-10-09 | Secr Defence Brit | Improved transdrmal formulations |
US5643600A (en) | 1991-09-17 | 1997-07-01 | Micro-Pak, Inc. | Lipid vesicles containing avocado oil unsaponifiables |
WO1993005755A1 (en) | 1991-09-27 | 1993-04-01 | Nof Corporation | Cosmetic composition and emulsion composition |
GB2260079B (en) | 1991-10-01 | 1995-08-09 | American Cyanamid Co | Pharmaceutical composition containing felbinac |
US5230897A (en) | 1991-10-31 | 1993-07-27 | G. D. Searle & Co. | Transdermal pentamidine |
US5236707A (en) | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
WO1993009761A1 (en) | 1991-11-22 | 1993-05-27 | Richardson-Vicks Inc. | Combined personal cleansing and moisturizing compositions |
DE4140474C2 (en) | 1991-12-09 | 1995-07-13 | Schuelke & Mayr Gmbh | Skincare additive |
US5294365A (en) | 1991-12-12 | 1994-03-15 | Basf Corporation | Hydroxypolyethers as low-foam surfactants |
IT1253711B (en) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS |
US5252246A (en) | 1992-01-10 | 1993-10-12 | Allergan, Inc. | Nonirritating nonionic surfactant compositions |
EP0552612A3 (en) | 1992-01-22 | 1993-10-20 | Hoffmann La Roche | Methods for determining and isolating compounds which bind directly to nucleosolic proteins |
US5318774A (en) | 1992-02-28 | 1994-06-07 | Richardson-Vicks Inc. | Composition and method for imparting an artificial tan to human skin |
UA41319C2 (en) | 1992-04-02 | 2001-09-17 | Сембайозіс Дженетікс Інк. | method for expression of DNA sequence being of interest in seedS cell, chimeric gene, expressing cassette, isolated regulatory section of transcription, a method for modification of metabolism specific for seeds, a method for obtaining new polypeptides by plant, isolated DNA, a method for expression of dna sequence being of interest by plant-host, a method for obtaining purified polypeptide being of interest, a method for obtaining polypeptide being of interest by oiL body |
US5344051A (en) | 1992-04-27 | 1994-09-06 | Insta-Foam Products, Inc. | Two-component foam dispensing apparatus |
ZA932947B (en) | 1992-04-28 | 1993-10-27 | Schering Plough Healthcare | Applicator for semisolid medications |
US5254334A (en) | 1992-05-04 | 1993-10-19 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters |
US5409706A (en) | 1992-05-04 | 1995-04-25 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters |
IL105595A0 (en) | 1992-05-15 | 1993-09-22 | Akzo Nv | Applicator for introducing a cream-type substance into a woman's vagina |
ATE158163T1 (en) | 1992-05-18 | 1997-10-15 | Procter & Gamble | COMPOSITIONS WITH COOLING EFFECT |
US5389305A (en) | 1992-06-03 | 1995-02-14 | Colgate Palmolive Co. | High foaming nonionic surfactant base liquid detergent |
US5346135A (en) | 1992-06-16 | 1994-09-13 | Vincent Edward C | Spraying apparatus for blending liquids in a gaseous spray system |
US5300286A (en) | 1992-07-14 | 1994-04-05 | Dow Corning Corporation | Silicone emulsion for personal care application |
AU4673993A (en) | 1992-07-28 | 1994-02-14 | Procter & Gamble Company, The | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
FI933979A0 (en) | 1992-09-10 | 1993-09-10 | Mcneil Ppc Inc | BIOERODERBAR ANORDNING FOER DOSERING AV AKTIVA INGREDIENSER |
JPH08501553A (en) | 1992-09-14 | 1996-02-20 | スミス・ウォルター・ピー | Skin conditioning composition, its application and manufacture |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5413775A (en) | 1992-09-29 | 1995-05-09 | Amerchol Corporation | Hairsprays and acrylic polymer compositions for use therein |
IT1255895B (en) * | 1992-10-20 | 1995-11-17 | Laura Chiodini | PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN |
ATE239431T1 (en) | 1992-10-21 | 2003-05-15 | Gynetech Lab Inc | DELIVERY SYSTEM CONSISTING OF A VAGINA SPONGE |
DE59308338D1 (en) | 1992-10-31 | 1998-05-07 | Goldschmidt Ag Th | Cosmetic or pharmaceutical preparations |
DE4238860A1 (en) | 1992-11-19 | 1994-05-26 | Medicon Gmbh | Skin protection products for the protection of human skin |
US5308643A (en) | 1992-11-30 | 1994-05-03 | Osipow Lloyd I | Self-lather generating shaving compositions |
JP3328344B2 (en) | 1992-12-22 | 2002-09-24 | タイホー工業株式会社 | Method of controlling foaming state retention time of foaming type cleaning polishes |
JPH06263630A (en) | 1993-03-10 | 1994-09-20 | Lion Corp | Vitamin as-solubilizing eye drop |
DE4309900C1 (en) | 1993-03-26 | 1994-06-30 | Goldschmidt Ag Th | Process for the preparation of amphoteric surfactants |
JPH06279228A (en) * | 1993-03-30 | 1994-10-04 | Kao Corp | Foaming composition |
US5326557A (en) | 1993-04-06 | 1994-07-05 | Dow Corning Corporation | Moisturizing compositions containing organosilicon compounds |
US5807571A (en) * | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
AU676562B2 (en) | 1993-05-19 | 1997-03-13 | Hisamitsu Pharmaceutical Co., Inc. | Solubilizing agent and external preparation containing the same |
AU6825594A (en) | 1993-05-21 | 1994-12-20 | Henkel Corporation | Mild shampoo composition |
US5635469A (en) | 1993-06-10 | 1997-06-03 | The Procter & Gamble Company | Foaming cleansing products |
US5447725A (en) | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
US5384308A (en) | 1993-06-14 | 1995-01-24 | Henkin; R. I. | Composition and method for enhancing wound healing |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5398846A (en) | 1993-08-20 | 1995-03-21 | S. C. Johnson & Son, Inc. | Assembly for simultaneous dispensing of multiple fluids |
US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
FR2709666B1 (en) * | 1993-09-07 | 1995-10-13 | Oreal | Cosmetic or dermatological composition consisting of an oil-in-water emulsion based on oily globules provided with a lamellar liquid crystal coating. |
JP2978043B2 (en) | 1993-09-16 | 1999-11-15 | 高砂香料工業株式会社 | (2S) -3-{(1R, 2S, 5R)-[5-methyl-2- (1-methylethyl) cyclohexyl] oxy} -1,2-propanediol, its production method and use |
US5766632A (en) | 1993-10-01 | 1998-06-16 | Legere Pharmaceuticals, Ltd. | Method of using lectins for contraception |
FR2710854B1 (en) | 1993-10-08 | 1995-12-01 | Oreal | Oil-in-water emulsion usable for obtaining a cream. |
US5578315A (en) | 1993-12-01 | 1996-11-26 | Rutgers, The State University Of New Jersey | Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity |
FR2713486B1 (en) | 1993-12-14 | 1996-02-09 | Scophysa | New compositions for foams, in particular rectal foams, and foams thus obtained. |
DE69426727D1 (en) | 1993-12-23 | 2001-03-29 | Procter & Gamble | ANTIMICROBIAL COMPOSITIONS FOR WIPES |
US5527822A (en) | 1993-12-29 | 1996-06-18 | Forest Laboratories, Inc. | Method of treatment of traumatic brain injury |
DE9422052U1 (en) | 1994-01-04 | 1997-10-30 | Adolf Würth GmbH & Co. KG, 74653 Künzelsau | Filling device for filling a refillable dispensing container and refillable dispensing container |
DE4405127A1 (en) | 1994-02-18 | 1995-08-31 | Henkel Kgaa | Hair treatment products |
US5514367A (en) | 1994-02-28 | 1996-05-07 | Estee Lauder, Inc. | Skin tanning compositions and methods for their preparation and use |
US5925669A (en) | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
IL109230A (en) | 1994-04-05 | 1998-08-16 | Agis Ind 1983 Ltd | Anti-fungal composition containing bifonazole and fluocinonide |
US5658749A (en) | 1994-04-05 | 1997-08-19 | Corning Clinical Laboratories, Inc. | Method for processing mycobacteria |
US5429815A (en) | 1994-04-11 | 1995-07-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Stable single-phase self-foaming cleanser |
FR2719467B1 (en) | 1994-05-05 | 1996-05-31 | Oreal | Use of flavonoids to preserve and / or strengthen the mechanical properties of the hair and method of protecting hair using these compounds. |
ES2079320B1 (en) | 1994-05-17 | 1996-10-16 | Cusi Lab | OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS. |
US5902574A (en) | 1994-05-23 | 1999-05-11 | The Gillette Company | Shaving preparation for improved shaving comfort |
US5545401A (en) | 1994-06-02 | 1996-08-13 | Shanbrom; Edward | Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine |
FR2720635B1 (en) | 1994-06-03 | 1996-07-26 | Oreal | Sunscreen cosmetic compositions and uses. |
US6221381B1 (en) | 1994-06-28 | 2001-04-24 | The University Of British Columbia | Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier |
MA23592A1 (en) | 1994-06-30 | 1995-12-31 | Procter & Gamble | COMPOSITIONS FOR BODY CARE CONTAINING THERMOPLASTIC ELASTOMERIC GRAFT COPOLYMERS |
US5679324A (en) | 1994-07-08 | 1997-10-21 | The Procter & Gamble Co. | Aerosol foamable fragrance composition |
FR2722431B1 (en) | 1994-07-12 | 1996-09-13 | Lir France Sa | DOUBLE DISPENSER FOR FLUID PRODUCTS |
US5869529A (en) | 1994-07-20 | 1999-02-09 | Agis Industries (1983) Ltd. | Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
JP3173330B2 (en) | 1994-07-20 | 2001-06-04 | トヨタ自動車株式会社 | Slip control device for vehicle lock-up clutch |
US5444092A (en) | 1994-07-20 | 1995-08-22 | Collins; Jerry | Method and composition for treating psoriasis |
GB9414699D0 (en) | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
US5512555A (en) | 1994-07-21 | 1996-04-30 | Merck & Co., Inc. | Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one |
JP3241542B2 (en) | 1994-07-29 | 2001-12-25 | 高砂香料工業株式会社 | Method for purifying (-)-n-isopulegol and citrus-based fragrance composition containing (-)-n-isopulegol obtained by the method |
DE4428096A1 (en) | 1994-08-09 | 1996-02-15 | Wella Ag | Two-chamber container |
US5656586A (en) | 1994-08-19 | 1997-08-12 | Rhone-Poulenc Inc. | Amphoteric surfactants having multiple hydrophobic and hydrophilic groups |
US5547989A (en) * | 1994-08-19 | 1996-08-20 | Schering-Plough Healthcare Products, Inc. | Compositions for treating corns and calluses |
MX9701469A (en) | 1994-08-26 | 1997-05-31 | Procter & Gamble | Personal cleansing compositions. |
US5976555A (en) | 1994-09-07 | 1999-11-02 | Johnson & Johnson Consumer Products, Inc. | Topical oil-in-water emulsions containing retinoids |
JP3604177B2 (en) | 1994-09-14 | 2004-12-22 | 日東電工株式会社 | Transdermal formulation |
US5500211A (en) | 1994-09-22 | 1996-03-19 | The Gillette Company | Soap-free self-foaming shave gel composition |
US5905092A (en) | 1994-09-27 | 1999-05-18 | Virotex Corporation Reel/Frame | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction |
US5955414A (en) | 1994-10-05 | 1999-09-21 | S. C. Johnson & Son, Inc. | Cleaning foam having fluorinated stain repellent and low flammability |
US5540853A (en) | 1994-10-20 | 1996-07-30 | The Procter & Gamble Company | Personal treatment compositions and/or cosmetic compositions containing enduring perfume |
AU3855695A (en) | 1994-11-08 | 1996-05-31 | Mochida Pharmaceutical Co., Ltd. | External preparation for skin protection |
US5567420A (en) | 1994-11-16 | 1996-10-22 | Mceleney; John | Lotion which is temporarily colored upon application |
US5788664A (en) | 1994-11-30 | 1998-08-04 | Scalise; Gaspare | Suppository applicator |
GB9424562D0 (en) | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
US5641480A (en) | 1994-12-08 | 1997-06-24 | Lever Brothers Company, Division Of Conopco, Inc. | Hair care compositions comprising heteroatom containing alkyl aldonamide compounds |
US5529770A (en) | 1994-12-09 | 1996-06-25 | West Agro, Inc. | Viscous liquid conditioning topical germicides |
DE4444238A1 (en) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
FR2728166A1 (en) | 1994-12-19 | 1996-06-21 | Oreal | TOPICAL COMPOSITION CONTAINING AN ANTAGONIST OF SUBSTANCE P |
ATE237298T1 (en) | 1994-12-21 | 2003-05-15 | Cosmederm Technologies | FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATIONS |
WO1996019921A1 (en) | 1994-12-23 | 1996-07-04 | Commonwealth Scientific And Industrial Research Organisation | Iodine biocidal material |
DE4446891A1 (en) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stable aqueous budesonide solution |
US5616136A (en) | 1995-01-09 | 1997-04-01 | Med-Safe Systems, Inc. | Quick release needle removal apparatus |
US5534261A (en) | 1995-01-17 | 1996-07-09 | University Of Southern California | Retinoid-based compositions and method for preventing adhesion formation using the same |
FR2729855A1 (en) | 1995-01-26 | 1996-08-02 | Oreal | USE OF A CGRP ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED |
US5523078A (en) | 1995-02-03 | 1996-06-04 | Michael E. Baylin | Method of preparing and composition for treatment of hair and scalp |
US5587149A (en) | 1995-02-06 | 1996-12-24 | R.P. Scherer Corporation | Topical application emulsions |
FR2730932B1 (en) | 1995-02-27 | 1997-04-04 | Oreal | TRANSPARENT NANOEMULSION BASED ON FLUID NON-IONIC AMPHIPHILIC LIPIDS AND USE IN COSMETICS OR DERMOPHARMACY |
FR2730930B1 (en) | 1995-02-27 | 1997-04-04 | Oreal | USE OF NO-SYNTHASE INHIBITORS TO REDUCE THE IRRITANT SKIN EFFECT OF PRODUCTS USED IN THE COSMETIC OR PHARMACEUTICAL FIELD |
GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
US5558872A (en) | 1995-03-07 | 1996-09-24 | Healthpoint Medical Limited Partnership | Gelled mineral oil skin protectant |
US5618850A (en) * | 1995-03-09 | 1997-04-08 | Focal, Inc. | Hydroxy-acid cosmetics |
US5783202A (en) | 1995-03-14 | 1998-07-21 | Soltec Research Pty. Ltd. | Pediculicidal mousse composition for killing head lice |
CA2215921A1 (en) | 1995-03-29 | 1996-10-03 | Hidekazu Syodai | Gelatin capsules having adjusted water activity |
US5585104A (en) | 1995-04-12 | 1996-12-17 | The Procter & Gamble Company | Cleansing emulsions |
EP0738510A3 (en) | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
FR2733417B1 (en) | 1995-04-25 | 1997-06-06 | Oreal | FOAMING OIL-IN-WATER EMULSION BASED ON NON-IONIC SURFACTANTS, A FATTY PHASE AND A CATIONIC OR ANIONIC POLYMER CROSS-LINKED AND USE IN TOPICAL APPLICATION |
GB9510856D0 (en) | 1995-05-27 | 1995-07-19 | Cussons Int Ltd | Cleaning composition |
UY24246A1 (en) | 1995-06-06 | 1996-06-14 | Neutrogena Corp | TROPIC VEHICLES CONTAINING SOLUBILIZED AND STABILIZED AZELAIC ACID |
AU715827B2 (en) | 1995-06-22 | 2000-02-10 | Minnesota Mining And Manufacturing Company | Stable hydroalcoholic compositions |
JP3542665B2 (en) | 1995-07-07 | 2004-07-14 | 株式会社資生堂 | Anti-aging skin external preparation, collagen cross-linking inhibition skin external preparation and anti-ultraviolet skin external preparation |
FR2736824B1 (en) | 1995-07-18 | 1997-10-10 | Fabre Pierre Dermo Cosmetique | MINOXIDIL HAIR COMPOSITION WITH LOW FAT SOLVENT CONTENT |
US5705472A (en) | 1995-07-18 | 1998-01-06 | Petroferm Inc. | Neutral aqueous cleaning composition |
DE29512760U1 (en) | 1995-08-08 | 1995-11-16 | Wella Ag, 64295 Darmstadt | Pressurized gas container for dispensing foam |
TW504387B (en) | 1995-09-06 | 2002-10-01 | Kao Corp | Emulsified, water-in-oil type composition and skin cosmetic preparation |
US5881493A (en) | 1995-09-14 | 1999-03-16 | D. B. Smith & Co. Inc. | Methods for applying foam |
CN1062129C (en) | 1995-09-14 | 2001-02-21 | 徐荣祥 | Medicine matrix and its use |
JPH0984855A (en) | 1995-09-25 | 1997-03-31 | Kyoto Yakuhin Kogyo Kk | Aerosol preparation for administer medicine to rectum or vagina |
US6221823B1 (en) | 1995-10-25 | 2001-04-24 | Reckitt Benckiser Inc. | Germicidal, acidic hard surface cleaning compositions |
WO1997021426A1 (en) | 1995-12-14 | 1997-06-19 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation |
FR2742986B1 (en) | 1995-12-29 | 1998-01-30 | Rhone Poulenc Chimie | COSMETIC COMPOSITIONS FOR THE HAIR OR THE SKIN BASED ON SULPHONATED COPOLYESTERS WITH POLYORGANOSILOXANE MOTIFS |
US5716611A (en) | 1996-01-02 | 1998-02-10 | Euro-Celtique, S.A. | Emollient antimicrobial formulations containing povidone iodine |
US5759524A (en) | 1996-02-09 | 1998-06-02 | The Procter & Gamble Company | Photoprotective compositions |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5889028A (en) | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5843411A (en) | 1997-02-06 | 1998-12-01 | Topix Pharmaceuticals Inc. | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5912007A (en) | 1996-02-29 | 1999-06-15 | Warner-Lambert Company | Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same |
US6251369B1 (en) | 1996-03-05 | 2001-06-26 | Sultan Dental Products | Dental fluoride foam |
FR2745716B1 (en) | 1996-03-07 | 1998-04-17 | Oreal | ULTRAFINE PRESSURIZABLE FOAMING OIL-IN-WATER EMULSIONS |
WO1997039745A1 (en) | 1996-04-19 | 1997-10-30 | Sloan-Kettering Institute For Cancer Research | Use of inhaled retinoids in the prevention of cancer |
US5910382A (en) | 1996-04-23 | 1999-06-08 | Board Of Regents, University Of Texas Systems | Cathode materials for secondary (rechargeable) lithium batteries |
IT1283042B1 (en) | 1996-05-21 | 1998-04-07 | Condea Augusta Spa | COSMETIC COMPOUNDS DEODORANT AND / OR ANTI-BREATHING |
US5797955A (en) | 1996-06-11 | 1998-08-25 | Walters; David J. | Pressure application unit for positioning vertebra |
US5833961A (en) | 1996-06-25 | 1998-11-10 | Inolex Investment Corporation | Polyester-based suncreen formulations |
EP0932401A1 (en) | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
US5716621A (en) | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
JP2002514163A (en) | 1996-07-10 | 2002-05-14 | ステリス インコーポレイテッド | Triclosan skin wash with improved efficacy |
DE19631221C2 (en) | 1996-08-02 | 1999-07-01 | Beiersdorf Ag | Foam-form sunscreen preparations containing water-soluble sunscreen filter substances and surface-active substances |
US6042848A (en) | 1996-08-15 | 2000-03-28 | The Board Of Trustees Of Southern Illinois University | Enhancement of antimicrobial peptide activity by metal ions |
US5833963A (en) | 1996-08-20 | 1998-11-10 | Bristol-Myers Squibb Company | Non-tacky and quick-drying aqueous-based antiperspirant compositions |
US5837270A (en) | 1996-08-26 | 1998-11-17 | Burgess; Nelson Leon | Topical anti-acne composition |
EP0829259A1 (en) | 1996-09-04 | 1998-03-18 | Warner-Lambert Company | Foam/gel with microbeads and/or fine particles |
US6271295B1 (en) | 1996-09-05 | 2001-08-07 | General Electric Company | Emulsions of silicones with non-aqueous hydroxylic solvents |
US5952392A (en) | 1996-09-17 | 1999-09-14 | Avanir Pharmaceuticals | Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition |
US7060253B1 (en) | 1996-09-20 | 2006-06-13 | Mundschenk David D | Topical formulations and delivery systems |
FR2754451B1 (en) | 1996-10-14 | 1998-11-06 | Oreal | SELF-FOAMING CREAM |
AU4995597A (en) | 1996-10-23 | 1998-05-15 | Vertex Pharmaceuticals Incorporated | Methods of using sucrose octasulfate to treat or prevent enveloped virus infection |
US6093408A (en) | 1996-10-25 | 2000-07-25 | The Procter & Gamble Company | Skin care compositions |
IT1287114B1 (en) | 1996-10-31 | 1998-08-04 | Recordati Chem Pharm | ANTI-HERPETIC PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATORS, CONTAINING ACICLOVIR |
WO1998019654A1 (en) | 1996-11-04 | 1998-05-14 | The Procter & Gamble Company | Hair mousse composition comprising silicone emulsion |
JP2001509137A (en) | 1996-11-12 | 2001-07-10 | タマーキン ファーマシューティカル イノベイション リミテッド | How to treat skin diseases |
FR2755854B1 (en) * | 1996-11-15 | 1998-12-24 | Oreal | NANOEMULSION BASED ON NON-IONIC AND CATIONIC AMPHIPHILIC LIPIDS AND USES |
ES2196371T3 (en) | 1996-11-16 | 2003-12-16 | Wella Ag | PRODUCT FOR DYING AND FIBER FADING. |
US5906992A (en) | 1996-11-21 | 1999-05-25 | Colgate Palmolive Company | Foam cleaning compositions |
AUPO379596A0 (en) | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
US5951544A (en) | 1996-12-04 | 1999-09-14 | Laser Industries Ltd. | Handpiece assembly for laser apparatus |
US5759579A (en) | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
US5695551A (en) | 1996-12-09 | 1997-12-09 | Dow Corning Corporation | Water repellent composition |
US5856452A (en) | 1996-12-16 | 1999-01-05 | Sembiosys Genetics Inc. | Oil bodies and associated proteins as affinity matrices |
US5672634A (en) | 1996-12-23 | 1997-09-30 | Isp Investments Inc. | Crosslinked PVP-I2 foam product |
US5879469A (en) | 1997-01-06 | 1999-03-09 | Deeay Technologies Ltd. | Dishwashing method and detergent composition therefor |
US6582711B1 (en) | 1997-01-09 | 2003-06-24 | 3M Innovative Properties Company | Hydroalcoholic compositions thickened using polymers |
SE520811C2 (en) | 1997-01-17 | 2003-08-26 | Ponsus Ab | Skin protection preparations containing lipophilic and hydrophilic components, method of preparation and use thereof |
IN186803B (en) | 1997-02-05 | 2001-11-10 | Panacea Biotec Ltd | |
ES2133090B1 (en) | 1997-02-21 | 2000-04-01 | Uriach & Cia Sa J | NEW APPLICATOR FOR THE ADMINISTRATION OF SEMI-SOLID MEDICATIONS. |
CA2280179A1 (en) | 1997-02-11 | 1998-08-13 | Bernard Salafsky | Anti-parasitic action of n,n-diethyl-m-toluamide (deet) and formulations that prolong its activity in the skin |
IL131477A0 (en) | 1997-02-24 | 2001-01-28 | Michael A Kamm | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
FR2760637B1 (en) | 1997-03-11 | 1999-05-28 | Fabre Pierre Dermo Cosmetique | COAL TAR EXTRACT WITH REDUCED AROMATIC HYDROCARBON CONTENT, PROCESS FOR OBTAINING AND DERMO-COSMETIC PREPARATIONS |
US5922331A (en) | 1997-03-26 | 1999-07-13 | Chanel, Inc. | Skin cream composition |
US5951989A (en) | 1997-04-07 | 1999-09-14 | Heymann; Warren R. | Method for the treatment of dry skin |
USH2043H1 (en) | 1997-05-23 | 2002-08-06 | The Procter & Gamble Company | Skin care compositions |
US6183762B1 (en) | 1997-05-27 | 2001-02-06 | Sembiosys Genetics Inc. | Oil body based personal care products |
US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
EP0986309B1 (en) | 1997-05-27 | 2008-02-20 | SemBioSys Genetics Inc. | Uses of oil bodies |
US6217887B1 (en) * | 1997-06-04 | 2001-04-17 | The Procter & Gamble Company | Leave-on antimicrobial compositions which provide improved immediate germ reduction |
EP0884045A1 (en) | 1997-06-06 | 1998-12-16 | Pfizer Products Inc. | Self-tanning dihydroxyacetone formulations having improved stability and providing enhanced delivery |
US20050276836A1 (en) | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
CA2293622C (en) | 1997-06-13 | 2007-08-21 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation |
FR2765799B1 (en) | 1997-07-08 | 1999-08-27 | Oreal | GLOSSY COMPOSITION CONTAINING AROMATIC OILS THICKENED BY A POLYSACCHARIDE ALKYLETHER |
EP1014916B2 (en) | 1997-08-18 | 2011-06-15 | Neubourg Skin Care GmbH & Co. KG | Foaming skin cream, uses thereof and a method for producing the same |
SE9703226D0 (en) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
US5885581A (en) | 1997-09-11 | 1999-03-23 | Merz, Incorporated | Composition and method for improvement of the appearance of scars |
US5939376A (en) | 1997-09-25 | 1999-08-17 | Colgate Palmolive Company | Liquid cleaning compositions containing an organic ester foam control agent |
US6241971B1 (en) | 1997-09-25 | 2001-06-05 | The Procter & Gamble Company | Hair styling compositions comprising mineral salt, lipophilic material, and low levels of surfactant |
US6214318B1 (en) | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
FR2769299B1 (en) | 1997-10-03 | 1999-12-31 | Oreal | BI-PRODUCTS PACKAGING AND DISTRIBUTION SET |
AUPO983897A0 (en) | 1997-10-17 | 1997-11-06 | Soltec Research Pty Ltd | Topical antifungal composition |
US5961957A (en) | 1997-10-20 | 1999-10-05 | Mcanalley; Bill H. | Foam compositions |
US5911981A (en) | 1997-10-24 | 1999-06-15 | R.I.T.A. Corporation | Surfactant blends for generating a stable wet foam |
US5865347A (en) | 1997-10-27 | 1999-02-02 | William T. Wilkinson | Multi-chamber dispenser for flowable materials |
JP3450680B2 (en) | 1997-10-28 | 2003-09-29 | 高砂香料工業株式会社 | Method for producing para-menthane-3,8-diol |
EP1027057A4 (en) | 1997-10-28 | 2003-01-02 | Vivus Inc | Treatment of female sexual dysfunction |
US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
PT1510213E (en) | 1997-11-10 | 2009-02-12 | Strakan Internat Ltd Uma Socie | Penetration enhancing and irritation reducing systems comprising testosterone |
DE29720316U1 (en) | 1997-11-17 | 1998-01-29 | Raimund Andris Gmbh & Co Kg, 78052 Villingen-Schwenningen | Two-chamber dispenser |
US5849042A (en) | 1997-11-19 | 1998-12-15 | Bristol-Myers Squibb | Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol |
US5871720A (en) | 1997-11-20 | 1999-02-16 | Colgate-Palmolive Company | Cosmetic compositions with DBS and functionalized silicones |
JP2001525371A (en) * | 1997-12-05 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | GLP-1 preparation |
TWI225793B (en) | 1997-12-25 | 2005-01-01 | Ajinomoto Kk | Cosmetic composition |
JP3050289U (en) | 1997-12-29 | 1998-06-30 | 丸隆株式会社 | Pet animal room excretion tools |
DE19802206A1 (en) | 1998-01-22 | 1999-07-29 | Beiersdorf Ag | Stable cosmetic or dermatological composition with low viscosity |
FR2774595A1 (en) | 1998-02-06 | 1999-08-13 | Rech D Innovation Et De Dev Ce | EMULSION FOR TRANSDERMAL STEROID ADMINISTRATION |
DE19805918A1 (en) | 1998-02-13 | 1999-08-19 | Beiersdorf Ag | Lipidreduced preparations |
US6110966A (en) | 1998-02-20 | 2000-08-29 | Medi-Cell Laboratories, Inc. | Triple action complex |
DE19807774A1 (en) | 1998-02-24 | 1999-08-26 | Beiersdorf Ag | Use of flavone, flavanone or flavonoid compound for protection of ascorbic acid or ascorbyl compound against oxidation, especially in cosmetic and dermatological preparations, |
JP3514105B2 (en) | 1998-02-27 | 2004-03-31 | ティアック株式会社 | Recording medium recording / reproducing device |
ATE302608T1 (en) | 1998-03-04 | 2005-09-15 | Teijin Ltd | LOTIONS CONTAINING ACTIVE VITAMIN D3 IN THE FORM OF EMULSIONS |
US6121210A (en) | 1998-03-12 | 2000-09-19 | Dap Products Inc. | Foamable silicone oil compositions and methods of use thereof |
US5990100A (en) | 1998-03-24 | 1999-11-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
US5919830A (en) * | 1998-04-30 | 1999-07-06 | Gopalkrishnan; Sridhar | Stable non-aqueous blends for personal care compositions |
US6649175B1 (en) | 1998-05-04 | 2003-11-18 | Schering-Plough Healthcare Products, Inc. | Skin barrier composition |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
FR2779637B1 (en) | 1998-06-15 | 2000-09-01 | Oreal | PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING A METAL OXIDE NANOPIGMENT AND AN ACRYLIC TERPOLYMER AND USE OF SUCH COMPOSITIONS FOR PROTECTING KERATINIC MATERIALS FROM ULTRAVIOLET RADIATION |
US6706290B1 (en) | 1998-07-06 | 2004-03-16 | Olvai E. Kajander | Methods for eradication of nanobacteria |
FR2780879B1 (en) | 1998-07-09 | 2002-09-20 | Oreal | PHOTOPROTECTOR COSMETIC COMPOSITION CONTAINING AN ANIONIC SURFACTANT, COMPOUND FILTERING ULTRAVIOLET RADIATION AND CATIONIC OR ZPHITTERIONIC AMPHIPHILIC COMPOUND AND USE THEREOF |
US6146664A (en) | 1998-07-10 | 2000-11-14 | Shaklee Corporation | Stable topical ascorbic acid compositions |
US6124362A (en) * | 1998-07-17 | 2000-09-26 | The Procter & Gamble Company | Method for regulating hair growth |
US6071541A (en) * | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
DE19835239A1 (en) | 1998-08-04 | 2000-02-24 | Johnson & Johnson Gmbh | Foaming oil preparation and its use |
JP4017758B2 (en) | 1998-08-04 | 2007-12-05 | 高砂香料工業株式会社 | Cooling agent composition |
GB9817817D0 (en) | 1998-08-14 | 1998-10-14 | Unilever Plc | Cosmetic composition |
PL346238A1 (en) | 1998-08-20 | 2002-01-28 | 3M Innovative Properties Co | Spray on bandage and drug delivery system |
JP3712868B2 (en) | 1998-09-02 | 2005-11-02 | 株式会社カネボウ化粧品 | Aerosol composition |
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
AUPP583198A0 (en) | 1998-09-11 | 1998-10-01 | Soltec Research Pty Ltd | Mousse composition |
US6087310A (en) * | 1998-09-23 | 2000-07-11 | Castrol Limited | Skin cleaning compositions and uses comprising a polymer latex emulsion |
AU760735B2 (en) | 1998-09-28 | 2003-05-22 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
US6914057B1 (en) | 1998-09-28 | 2005-07-05 | The Research Foundation Of State University Of New York | Inhibitor of cataract formation |
RU2134052C1 (en) | 1998-10-07 | 1999-08-10 | Нерушай Сергей Алексеевич | Method and apparatus for aerosol application of perfumery liquids |
US6287546B1 (en) | 1998-10-09 | 2001-09-11 | Colgate-Palmolive Company | Shampoos with stabilizers |
JP3876081B2 (en) | 1998-10-22 | 2007-01-31 | 東洋エアゾール工業株式会社 | Aerosol composition for foam formation |
US6110477A (en) | 1998-10-30 | 2000-08-29 | Topix Pharmaceuticals Inc. | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US5980904A (en) | 1998-11-18 | 1999-11-09 | Amway Corporation | Skin whitening composition containing bearberry extract and a reducing agent |
US6344218B1 (en) | 1998-11-23 | 2002-02-05 | The Procter & Gamble Company | Skin deodorizing and santizing compositions |
DE19855097A1 (en) | 1998-11-28 | 2000-05-31 | Wella Ag | Pigment-containing, foamable gel |
US20010006654A1 (en) | 1998-12-09 | 2001-07-05 | L'oreal | Compositions and methods for treating hair and skin using aqueous delivery systems |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6087317A (en) | 1998-12-10 | 2000-07-11 | Dow Corning Corporation | Particle size stable silicone emulsions |
US6262128B1 (en) | 1998-12-16 | 2001-07-17 | 3M Innovative Properties Company | Aqueous foaming compositions, foam compositions, and preparation of foam compositions |
FR2787325B1 (en) | 1998-12-17 | 2001-01-26 | Oreal | NANOEMULSION BASED ON OXYETHYLENE OR NON-OXYETHYLENE SORBITAN FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
FR2787728B1 (en) | 1998-12-23 | 2001-01-26 | Oreal | NANOEMULSION BASED ON FATTY ESTERS OF PHOSPHORIC ACID, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
JP2000191429A (en) | 1998-12-28 | 2000-07-11 | Kao Corp | Foamable cosmetic |
CN1195550C (en) | 1998-12-28 | 2005-04-06 | 大正制药株式会社 | External preparation |
FR2787703B1 (en) | 1998-12-29 | 2001-01-26 | Oreal | NANOEMULSION BASED ON ETHOXYL FATHER ETHERS OR ETHOXYL FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
FR2788007B1 (en) | 1999-01-05 | 2001-02-09 | Oreal | NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
US6270781B1 (en) * | 1999-01-08 | 2001-08-07 | Maxim Pharmaceuticals, Inc. | Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
FR2789371B1 (en) | 1999-02-05 | 2001-04-27 | Sofab | DISTRIBUTOR OF CHEMICALLY UNSTABLE PRODUCTS |
EP1025836A1 (en) | 1999-02-08 | 2000-08-09 | F. Hoffmann-La Roche Ag | Cosmetic light screening composition |
TWI262930B (en) | 1999-02-10 | 2006-10-01 | Mitsui Chemicals Inc | High-durability flexible polyurethane cold molded foam and process for producing the same |
US6423329B1 (en) | 1999-02-12 | 2002-07-23 | The Procter & Gamble Company | Skin sanitizing compositions |
US6224888B1 (en) | 1999-02-12 | 2001-05-01 | The Procter & Gamble Company | Cosmetic compositions |
JP3641152B2 (en) | 1999-02-17 | 2005-04-20 | 株式会社ヤクルト本社 | Topical skin preparation |
JP2002537107A (en) | 1999-02-26 | 2002-11-05 | ウエラ アクチェンゲゼルシャフト | Device for mixing, foaming and discharging liquids from separate compressed gas containers |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
IL129102A0 (en) | 1999-03-22 | 2000-02-17 | J P M E D Ltd | An emulsion |
EP1541039B1 (en) | 1999-03-31 | 2008-01-02 | Firmenich Sa | Flavour composition comprising cubebol and a further refreshing agent |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6264964B1 (en) | 1999-04-14 | 2001-07-24 | Conopco, Inc. | Foaming cosmetic products |
WO2000062776A1 (en) | 1999-04-16 | 2000-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal compositions |
US6284802B1 (en) | 1999-04-19 | 2001-09-04 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue |
EP2455083B1 (en) * | 1999-04-23 | 2013-09-18 | Leo Pharma A/S | Pharmaceutical composition for dermal use comprising calcipotriol and betamethasone for treating psoriasis |
US6433003B1 (en) | 1999-04-23 | 2002-08-13 | Arthur M. Bobrove | Method for treating hyperhidrosis in mammals |
GB9909711D0 (en) * | 1999-04-27 | 1999-06-23 | Unilever Plc | Mousse forming hair treatment composition |
FR2793479B1 (en) | 1999-05-10 | 2001-06-29 | Lir France Sa | DOUBLE DISPENSER FOR FLUID OR PASTY PRODUCTS |
US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
US6168576B1 (en) | 1999-05-24 | 2001-01-02 | Irene N. Reynolds | Device for dispensing vaginal medication |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6518228B1 (en) | 1999-05-27 | 2003-02-11 | Clairol Incorporated | Ultra-mild, clear, aqueous, foamable skin cleanser |
ES2244445T3 (en) | 1999-05-28 | 2005-12-16 | Unilever N.V. | FOAMABLE OLEOUS COMPOSITION FOR SHOWER. |
JP2000351726A (en) | 1999-06-08 | 2000-12-19 | Lion Corp | Aerosol preparation |
JP2000354623A (en) | 1999-06-14 | 2000-12-26 | Shiigeru Kk | Deodorant and deodorizing spray |
US6113888A (en) | 1999-06-15 | 2000-09-05 | Neutrogena Corporation | Self-tanning mousse |
GB9913951D0 (en) | 1999-06-15 | 1999-08-18 | Unilever Plc | Mousse-forming shampoo compositions |
US6190365B1 (en) | 1999-06-21 | 2001-02-20 | Chun Lim Abbott | Vaginal douche applicator and method of vaginal deodorization using the same |
NL1012419C2 (en) | 1999-06-23 | 2000-12-28 | Airspray Nv | Aerosol for dispensing a liquid. |
JP2001002526A (en) | 1999-06-23 | 2001-01-09 | Koike Kagaku Kk | Foam aerosol composition |
US6524594B1 (en) | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
US6551604B1 (en) | 1999-06-28 | 2003-04-22 | The Procter & Gamble Company | Skin care compositions |
WO2001001949A1 (en) | 1999-07-01 | 2001-01-11 | Johnson And Johnson Consumer Companies, Inc. | Cleansing compositions |
US6762158B2 (en) | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
FR2795643B1 (en) | 1999-07-02 | 2004-06-11 | Oreal | FIRMING COSMETIC COMPOSITION INCLUDING AT LEAST ONE HYDROXYSTILBENE IN ASSOCIATION WITH ASCORBIC ACID |
JP4058199B2 (en) | 1999-07-06 | 2008-03-05 | ポーラ化成工業株式会社 | Warm feeling pack |
WO2001005366A1 (en) | 1999-07-15 | 2001-01-25 | Playtex Products, Inc. | Sunscreen aerosol composition |
US6548074B1 (en) | 1999-07-22 | 2003-04-15 | Elizabeth Arden Co., Division Of Conopco, Inc. | Silicone elastomer emulsions stabilized with pentylene glycol |
FR2796925B1 (en) | 1999-07-29 | 2001-10-05 | Valois Sa | DISPENSER WITH ARTICULATED DISPENSING HEAD |
WO2001008681A1 (en) | 1999-08-02 | 2001-02-08 | First Horizon Pharmaceutical Corporation | Methods of administration of glycopyrrolate compositions |
US6303552B1 (en) | 1999-08-04 | 2001-10-16 | Napier International Technologies, Inc. | Aerosol paint stripper compositions |
DE19938757A1 (en) * | 1999-08-16 | 2001-02-22 | Beiersdorf Ag | Cosmetic or dermatological preparations of the oil-in-water type |
JP2003507437A (en) | 1999-08-26 | 2003-02-25 | ガネデン バイオテック, インコーポレイテッド | Use of emu oil, a carrier for antifungal, antibacterial, and antiviral drugs |
US6777591B1 (en) | 1999-08-27 | 2004-08-17 | Sembiosys Genetics Inc. | Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter |
US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
US6308863B1 (en) | 1999-09-02 | 2001-10-30 | Owens-Brockway Plastic Products Inc. | Dual chamber package for pressurized products |
JP4394775B2 (en) | 1999-09-03 | 2010-01-06 | 株式会社ダイゾー | Water-in-oil foam aerosol composition and method for producing the same |
JP4045475B2 (en) | 1999-09-06 | 2008-02-13 | 東洋紡績株式会社 | Nucleic acid / protein purification equipment |
US6986883B2 (en) | 1999-09-09 | 2006-01-17 | Discus Dental, Inc. | Increased peroxide content tooth bleaching gel |
US6283336B1 (en) | 1999-09-20 | 2001-09-04 | The Procter & Gamble Company | Article for the delivery of foam products |
US6437006B1 (en) | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
FR2798849B1 (en) | 1999-09-29 | 2001-11-23 | Oreal | COMPOSITION FOR WASHING KERATIN MATERIALS, BASED ON A DETERGENT SURFACE-ACTIVE AGENT, A DIALKYL DIALLYL AMMONIUM HOMOPOLYMER AND AN ACRYLIC TERPOLYMER |
US6667045B2 (en) | 1999-10-01 | 2003-12-23 | Joseph Scott Dahle | Topical applications for skin treatment |
US6790435B1 (en) | 1999-10-01 | 2004-09-14 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Antiperspirant compositions comprising microemulsions |
FR2799369B1 (en) | 1999-10-08 | 2001-12-21 | Oreal | COMBINATION OF ESCINE AND DEXTRAN SULFATE AND THE USE THEREOF |
US6186367B1 (en) | 1999-10-19 | 2001-02-13 | Valley Design Inc. | Metered liquid squeeze dispenser |
FR2799963B1 (en) | 1999-10-22 | 2002-07-19 | Oreal | EMULSIONS CONTAINING AT LEAST ONE INSOLUBLE ORGANIC UV FILTER AND A NON-FILTERING ORGANOMODIFIED SILICONE |
US6080394A (en) | 1999-11-08 | 2000-06-27 | Dow Corning Corporation | Polar solvent-in-oil emulsions and multiple emulsions |
US20030077301A1 (en) | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
UA66796C2 (en) | 1999-12-27 | 2004-06-15 | Univ Nat Pharmaceutical | Composition "profesol foamy" for treating radiation lesions of skin |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
IL133969A0 (en) | 2000-01-10 | 2001-04-30 | Thixo Ltd | Thixotropic compositions containing unsaturated oils and food products containing the same |
US6528033B1 (en) | 2000-01-18 | 2003-03-04 | Valence Technology, Inc. | Method of making lithium-containing materials |
US7001690B2 (en) | 2000-01-18 | 2006-02-21 | Valence Technology, Inc. | Lithium-based active materials and preparation thereof |
FR2804015B1 (en) | 2000-01-21 | 2005-12-23 | Oreal | NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND NONIONIC POLYMER AND USES THEREOF |
FR2804016B1 (en) | 2000-01-21 | 2006-07-28 | Oreal | NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND PEG ESTER AND USES THEREOF |
WO2001054679A2 (en) | 2000-01-27 | 2001-08-02 | Children's Hospital Research Foundation | Transdermal composition containing an anesthetic and a vasodilator agent |
US6780443B1 (en) | 2000-02-04 | 2004-08-24 | Takasago International Corporation | Sensate composition imparting initial sensation upon contact |
FR2804666B1 (en) | 2000-02-04 | 2002-06-14 | Oreal | DISPENSER FOR STORING AT LEAST TWO COMPONENTS AND SELECTIVE DISPENSING EITHER OF A SINGLE CONSTITUENT, EITHER OF THEIR MIXTURE, AND METHOD FOR THE IMPLEMENTATION THEREOF |
NL1014389C2 (en) | 2000-02-15 | 2001-08-16 | Dija Zeist Bv | Tanning preparation for the skin. |
US20040161447A1 (en) | 2000-02-17 | 2004-08-19 | Leonard Paul | Liquid foam producing compositions and dispensing system therefor |
DE60105362T2 (en) | 2000-02-22 | 2005-02-17 | Color Access, Inc. | AQUEOUS COSMETIC GEL |
EP3367268A1 (en) | 2000-02-22 | 2018-08-29 | Nokia Technologies Oy | Spatially coding and displaying information |
DE10008896A1 (en) * | 2000-02-25 | 2001-08-30 | Beiersdorf Ag | Improving the solubility and compatibility of benzotriazole UV filters in oils, e.g. in cosmetics or dermatological compositions, by addition of dialkylnaphthalates |
DE10008837A1 (en) | 2000-02-25 | 2001-08-30 | Henkel Kgaa | Dental cleaner containing propellant gas |
US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
IL135222A (en) | 2000-03-22 | 2005-06-19 | Univ Ben Gurion | Compositions containing molecular iodine |
DE20006099U1 (en) | 2000-04-01 | 2000-07-06 | Megaplast Gmbh & Co Kg | Dosing pump dispenser with at least two dosing pumps |
US6649571B1 (en) | 2000-04-04 | 2003-11-18 | Masi Technologies, L.L.C. | Method of generating gas bubbles in oleaginous liquids |
FR2807322B1 (en) | 2000-04-10 | 2004-02-20 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING ASCORBIC ACID IN ASSOCIATION WITH AN ASCORBIC ACID DERIVATIVE |
US7758888B2 (en) * | 2000-04-21 | 2010-07-20 | Sol-Gel Technologies Ltd. | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
JP2002012513A (en) | 2000-04-24 | 2002-01-15 | Kanebo Ltd | Urea-containing whipped cosmetic |
US6358541B1 (en) | 2000-05-03 | 2002-03-19 | David S. Goodman | Topical preparation for the treatment of hair loss |
US6410036B1 (en) | 2000-05-04 | 2002-06-25 | E-L Management Corp. | Eutectic mixtures in cosmetic compositions |
AU2001257534A1 (en) | 2000-05-05 | 2001-11-20 | R.P. Scherer Technologies, Inc. | Oil-in-water emulsion formulation containing hydroquinone and retinol |
EP1286652B1 (en) | 2000-05-08 | 2006-09-06 | Pfizer Products Inc. | Skin protectant spray compositions |
US6433024B1 (en) | 2000-05-08 | 2002-08-13 | Karl F. Popp | Topical anti-acne composition |
FR2808685B1 (en) | 2000-05-12 | 2004-10-08 | Sanofi Synthelabo | PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS |
JP2001326952A (en) | 2000-05-15 | 2001-11-22 | Nec Corp | Broadcast confirmation system, method and device for broadcast confirmation, and recording medium with broadcast confirmation program recorded thereon |
FR2809010B1 (en) | 2000-05-22 | 2002-07-12 | Oreal | NANOEMULSION BASED ON ANIONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
JP4653282B2 (en) | 2000-05-23 | 2011-03-16 | 昭和薬品化工株式会社 | Minocycline-containing composition |
DE10028638A1 (en) | 2000-06-09 | 2001-12-20 | Schuelke & Mayr Gmbh | Storage-stable composition useful in cosmetic and pharmaceutical compositions comprises combination of glycerol monoalkyl ether with antioxidant |
AU2001268451A1 (en) | 2000-06-13 | 2001-12-24 | Fd Management, Inc. | Cosmetic composition for stressed skin under extreme conditions |
AU2001272015A1 (en) | 2000-06-23 | 2002-01-08 | Combe International Ltd. | Stable foam for use in disposable wipe |
US20020164381A1 (en) | 2000-06-30 | 2002-11-07 | Medicis Pharmaceutical Corporation | Mitocidal compositions and methods |
US8512718B2 (en) * | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
CA2313659A1 (en) | 2000-07-06 | 2002-01-06 | Barry J. Barclay | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
DE10033414B4 (en) | 2000-07-08 | 2004-02-19 | Wella Aktiengesellschaft | Clear, two-phase, foam-forming aerosol hair care product |
FR2811564B1 (en) | 2000-07-13 | 2002-12-27 | Oreal | NANOEMULSION CONTAINING NON-IONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
DE10035930A1 (en) | 2000-07-21 | 2002-01-31 | Clariant Gmbh | fine emulsions |
US20020035070A1 (en) | 2000-07-26 | 2002-03-21 | The Procter & Gamble Company | Method of regulating hair growth using metal complexes of oxidized carbohydrates |
FR2812191B1 (en) | 2000-07-28 | 2003-10-17 | Oreal | USE OF PROSTAGLANDIN E2 RECEPTOR AGONISTS (EP-3) TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS |
JP4166931B2 (en) | 2000-08-02 | 2008-10-15 | ポーラ化成工業株式会社 | Fever foam cosmetic |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US6514487B1 (en) | 2000-08-08 | 2003-02-04 | Teresa Leigh Barr | Foam and gel oat protein complex and method of use |
WO2002015873A2 (en) | 2000-08-22 | 2002-02-28 | The Procter & Gamble Company | Personal care compositions containing adhesive elastomeric polymer and inorganic colloid |
AU2001286578A1 (en) | 2000-08-24 | 2002-03-04 | Tim Ioannides | Topical antioxidant having vitamin c and method of combination with topical agent by user |
US6299023B1 (en) | 2000-08-24 | 2001-10-09 | Miles Arnone | Device for dispensing two substances in a user selectable ratio with replaceable cartridges |
FR2813189B1 (en) | 2000-08-31 | 2003-02-28 | Oreal | COSMETIC FOAMING CREAM FOR THE TREATMENT OF OILY SKIN |
WO2002022086A2 (en) | 2000-09-14 | 2002-03-21 | Quantum Energy Technologies | Application of water nanoclusters to skin |
AU2001288039B2 (en) | 2000-09-21 | 2005-09-15 | Taisho Pharmaceutical Co., Ltd. | Suppositories sustained in the lower rectum |
AUPR048600A0 (en) | 2000-10-02 | 2000-10-26 | Soltec Research Pty Ltd | Pharmaceutical vehicle |
DE10049147A1 (en) | 2000-10-04 | 2002-04-25 | Wella Ag | Hair wax product with waxes, non-volatile oils and volatile, hydrophobic substances |
FR2814959A1 (en) | 2000-10-09 | 2002-04-12 | Menarini France | Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve |
US6547063B1 (en) | 2000-10-10 | 2003-04-15 | The Procter & Gamble Company | Article for the delivery of foam products |
GB2367809A (en) | 2000-10-12 | 2002-04-17 | Bespak Plc | Metering valve with collapsible chamber |
US6403069B1 (en) | 2000-10-20 | 2002-06-11 | Colgate-Palmolive Company | High oil clear emulsion with elastomer |
FR2815616B1 (en) | 2000-10-20 | 2003-01-24 | Oreal | DISTRIBUTION ASSEMBLY FOR THE EXTEMPORARY DISTRIBUTION OF TWO PRODUCTS |
US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
DE10058384B4 (en) | 2000-11-24 | 2004-12-16 | Wella Aktiengesellschaft | Cosmetic or dermatological agent in the form of a creamy permanent foam or a stably foamed cream, its use and method for producing the agent |
US6299032B1 (en) | 2000-11-27 | 2001-10-09 | George W. Hamilton | Disposable actuator with cap opener for aerosol cans |
US6969521B1 (en) | 2000-11-28 | 2005-11-29 | Avon Products, Inc. | Aerosol insect repellent composition having low VOC content and method of applying same to the skin |
AU2002217896A1 (en) | 2000-11-28 | 2002-06-11 | Avon Products Inc. | Foaming insect repellent compositions |
US20050013853A1 (en) | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
GB0030068D0 (en) | 2000-12-11 | 2001-01-24 | Lawrence Malcolm | Highway vehicular traffic flow control |
JP3497466B2 (en) | 2000-12-12 | 2004-02-16 | 高砂香料工業株式会社 | Warming composition |
US20060254597A1 (en) | 2000-12-14 | 2006-11-16 | 40J's Llc | Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound |
DE10063342A1 (en) | 2000-12-19 | 2002-06-20 | Beiersdorf Ag | Cosmetic or dermatological composition contains three-part emulsifier system and gas |
US6749860B2 (en) | 2000-12-22 | 2004-06-15 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with non-aqueous compositions containing botanicals |
US20040079361A1 (en) | 2001-01-17 | 2004-04-29 | Clayton Colin D. | Medicinal aerosols |
FR2819427B1 (en) | 2001-01-18 | 2003-04-11 | Oreal | TRANSLUCENT NANOEMULSION, MANUFACTURING METHOD THEREOF AND USES THEREOF IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
US20030013692A1 (en) | 2001-01-19 | 2003-01-16 | Gullans Steven R. | Methods of treating neurological disorders |
US20040063684A1 (en) | 2001-02-05 | 2004-04-01 | Kamm Michael A. | Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
DE10110336A1 (en) * | 2001-03-03 | 2002-09-12 | Clariant Gmbh | Surfactant-free cosmetic, dermatological and pharmaceutical agents |
KR20040052489A (en) | 2001-03-06 | 2004-06-23 | 셀러지 파마세우티칼스, 인크 | Compounds and methods for the treatment of urogenital disorders |
JP2004520437A (en) | 2001-03-07 | 2004-07-08 | ザ プロクター アンド ギャンブル カンパニー | Topical composition containing functional aromatic derivative cosmetic binder |
US6640805B2 (en) | 2001-03-26 | 2003-11-04 | 3M Innovative Properties Company | Metering valve for a metered dose inhaler having improved flow |
US7419958B2 (en) | 2001-03-26 | 2008-09-02 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
JP4959907B2 (en) | 2001-03-27 | 2012-06-27 | ワーナー チルコット(アイルランド)リミティド | Intravaginal drug delivery device for antimicrobial administration |
MXPA03008869A (en) | 2001-03-29 | 2004-05-24 | Dial Corp | Antibacterial compositions for skin care. |
JP2002302419A (en) | 2001-03-30 | 2002-10-18 | Aldeep Cosmetics Japan Inc | Cosmetic composition |
NZ529308A (en) | 2001-04-05 | 2005-03-24 | Collagenex Pharm Inc | Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity |
US6848597B2 (en) | 2001-04-18 | 2005-02-01 | James A. Vlodek | Methods and apparatus for extruding foam through orifices |
US6682726B2 (en) | 2001-04-30 | 2004-01-27 | The Gillette Company | Self-foaming shaving lotion |
US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
US20020187181A1 (en) | 2001-05-14 | 2002-12-12 | 3M Innovative Properties Company | System for delivering cosmetics and pharmaceuticals |
ITMI20011019A1 (en) | 2001-05-17 | 2002-11-17 | Carlo Ghisalberti | FURILIC SUBSTANCES FOR TOPICAL USE |
US20030017181A1 (en) | 2001-05-31 | 2003-01-23 | Rood Gloria A. | Dermatological compositions and methods |
WO2003000223A1 (en) | 2001-06-20 | 2003-01-03 | The Procter & Gamble Company | Personal care composition comprising polyol-in-silicone emulsion |
US7270828B2 (en) | 2001-06-20 | 2007-09-18 | The Procter & Gamble Company | Personal care composition comprising hydrophobic gel |
FR2826292B1 (en) | 2001-06-22 | 2004-01-23 | Rhodia Chimie Sa | OIL-IN-OIL EMULSIONS COMPRISING A SILICONE, DISPERSIONS OF SUCH EMULSIONS AND USE THEREOF |
US6428772B1 (en) | 2001-06-25 | 2002-08-06 | Blistex Inc. | Acne treatment composition with cooling effect |
US6544562B2 (en) | 2001-06-25 | 2003-04-08 | Blistex Inc. | Acne treatment including dual-package system |
WO2003002082A1 (en) | 2001-06-26 | 2003-01-09 | The Procter & Gamble Company | Pressurized anhydrous antiperspirant emulsions |
JP2003012511A (en) | 2001-06-27 | 2003-01-15 | Rohto Pharmaceut Co Ltd | Aerosol composition |
JP4051412B2 (en) | 2001-06-27 | 2008-02-27 | 株式会社カネボウ化粧品 | Mixed dispenser |
US20060194773A1 (en) | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
MXPA04000226A (en) | 2001-07-13 | 2004-05-21 | Procter & Gamble | Mousse forming compositions comprising quaternary ammonium agents. |
DE10134786A1 (en) | 2001-07-17 | 2003-02-06 | Beiersdorf Ag | Foamable preparations |
US7960416B2 (en) * | 2001-08-03 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Stable emulsion composition |
DE10138495B4 (en) | 2001-08-04 | 2004-11-11 | Beiersdorf Ag | Foaming preparations and their use |
ATE469639T1 (en) | 2001-08-08 | 2010-06-15 | Dominguez Maria Antonia Garcia-Olmedo | INJECTABLE FOAM AND NEW PHARMACEUTICAL APPLICATIONS THEREOF |
WO2003013439A2 (en) | 2001-08-09 | 2003-02-20 | Croda, Inc. | Anti-irritants |
JP4707279B2 (en) | 2001-08-09 | 2011-06-22 | ポーラ化成工業株式会社 | Cosmetics for massage with cool-down effect |
WO2003013984A1 (en) | 2001-08-11 | 2003-02-20 | Aventis Pharma Limited | Pressurised aerosol dispenser |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US20030049218A1 (en) | 2001-08-28 | 2003-03-13 | Amit Patel | Antiperspirant deodorant emulsion |
DK1455888T3 (en) | 2001-08-29 | 2009-08-24 | Pharmakodex Ltd | Topical administration device |
US6709663B2 (en) | 2001-08-31 | 2004-03-23 | Healthpoint, Ltd. | Multivesicular emulsion drug delivery systems |
US6479060B1 (en) | 2001-09-04 | 2002-11-12 | Healthpoint, Ltd. | Elegant hydrogenated castor oil ointments |
FR2829693B1 (en) | 2001-09-20 | 2004-02-27 | Oreal | FOAMING COSMETIC CREAM |
DE10147820A1 (en) | 2001-09-27 | 2003-04-10 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing waxes or lipids which are solid and / or semi-solid at room temperature |
US7931533B2 (en) | 2001-09-28 | 2011-04-26 | Igt | Game development architecture that decouples the game logic from the graphics logics |
US20030185839A1 (en) | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
JP4423047B2 (en) | 2001-10-10 | 2010-03-03 | エクソンモービル リサーチ アンド エンジニアリング カンパニー | Biodegradable non-toxic gear oil |
US20030082120A1 (en) | 2001-10-26 | 2003-05-01 | Milstein Harold J. | Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family |
DE60230893D1 (en) | 2001-10-26 | 2009-03-05 | Taiyo Kagaku Kk | OILY FOAMABLE AEROSOL COMPOSITION |
US7255869B2 (en) * | 2001-10-30 | 2007-08-14 | The Procter & Gamble Company | Anhydrous cosmetic compositions containing polyols |
DE10154324A1 (en) | 2001-11-06 | 2003-08-07 | Merz Pharma Gmbh & Co Kgaa | Topically applicable compositions with external active substance depot formation, their production and their use |
DE10155956A1 (en) | 2001-11-09 | 2003-05-22 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations |
WO2003041667A2 (en) | 2001-11-13 | 2003-05-22 | The Procter & Gamble Company | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care |
DE10155792A1 (en) * | 2001-11-14 | 2003-05-22 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing siloxane elastomers |
WO2004043469A1 (en) | 2001-11-16 | 2004-05-27 | Klysz Beatrice M | Anti-aging skin care composition and uses thereof |
DE10159002A1 (en) | 2001-11-30 | 2003-06-18 | Clariant Gmbh | Use of multi-phase foaming agents from foam dispensers |
FR2833246B1 (en) | 2001-12-06 | 2005-06-24 | Beatrice France Touteau | DEVICE FOR SIMULTANEOUSLY ACTING TWO AEROSOLS CONTAINING TWO PRODUCTS TO BE MIXED AT THE TIME OF USE |
US6531118B1 (en) | 2001-12-11 | 2003-03-11 | Avon Products, Inc. | Topical compositions with a reversible photochromic ingredient |
PL370889A1 (en) | 2001-12-20 | 2005-05-30 | Femmepharma, Inc. | Vaginal delivery of drugs |
US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
US20030118515A1 (en) | 2001-12-21 | 2003-06-26 | Robert Jew | Cosmetic composition containing carbon dioxide |
SE0104421D0 (en) | 2001-12-21 | 2001-12-21 | Ponsus Pharma Ab | New composition |
US20030129259A1 (en) | 2001-12-28 | 2003-07-10 | Avon Products, Inc. | Topical lightening compostitions and methods of use |
JP4549625B2 (en) | 2002-01-05 | 2010-09-22 | 株式會社アモーレパシフィック | Finely emulsified particles containing ginseng saponin metabolites as active ingredients, a method for producing the same, and a cosmetic composition for preventing skin aging containing the same |
US7192601B2 (en) | 2002-01-18 | 2007-03-20 | Walker Edward B | Antimicrobial and sporicidal composition |
US6992049B2 (en) | 2002-01-31 | 2006-01-31 | Exxonmobil Research And Engineering Company | Lubricating oil compositions |
NZ517094A (en) | 2002-02-08 | 2005-03-24 | Advanced Animal Technology Ltd | Improvements in and relating to substance delivery device |
EP1475381A1 (en) | 2002-02-14 | 2004-11-10 | Quimversion, S.L. | Aluminium and hexamethylenetetramine complex and the applications thereof |
US6589216B1 (en) | 2002-02-20 | 2003-07-08 | Abbott Research Group, Inc. | Vaginal douches, vaginal douche applicators and methods of vaginal douching |
US6682511B2 (en) | 2002-02-21 | 2004-01-27 | Robert Wallace Besoyan | Brief protector |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
US6691898B2 (en) | 2002-02-27 | 2004-02-17 | Fomo Products, Inc. | Push button foam dispensing device |
WO2003075851A2 (en) | 2002-03-06 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US20050281766A1 (en) | 2002-03-11 | 2005-12-22 | Avon Products, Inc. | Method of improving the aesthetic appearance of epithelia |
US6736860B2 (en) * | 2002-03-12 | 2004-05-18 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Gradual permanent coloring of hair using dye intermediates dissolved in alkaline water with fatty alcohol |
CA2422244A1 (en) | 2002-03-14 | 2003-09-14 | Homax Products, Inc. | Aerosol systems and methods for mixing and dispensing two-part materials |
CA2478810C (en) | 2002-03-19 | 2011-02-01 | Airspray International B.V. | Dispensing unit |
US20030180347A1 (en) | 2002-03-19 | 2003-09-25 | W.F. Young, Incorporated | Patch for the delivery of topical agents |
JP4322124B2 (en) | 2002-03-28 | 2009-08-26 | 伯東株式会社 | Method for stabilizing bubbles in foam-containing cosmetics |
AU2003230927A1 (en) | 2002-04-12 | 2003-10-27 | Dreamwell, Ltd. | Cassette bedding system |
US8192749B2 (en) | 2003-04-16 | 2012-06-05 | Galderma Laboratories Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
US8846039B2 (en) | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
US6875438B2 (en) | 2002-04-27 | 2005-04-05 | Aventis Pharma Deutschland Gmbh | Preparations for topical administration of substances having antiandrogenic activity |
CA2384922C (en) | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
WO2003092629A2 (en) | 2002-05-06 | 2003-11-13 | Collagenex Pharmaceuticals, Inc. | Methods of simultaneously treating mucositis and fungal infection |
AU2003240462A1 (en) * | 2002-05-10 | 2003-11-11 | Unilever Plc | Hair conditioning compositions |
US6783027B2 (en) | 2002-05-15 | 2004-08-31 | The Procter & Gamble Company | Metered-dose underarm product and package |
US20030215472A1 (en) | 2002-05-16 | 2003-11-20 | Bonda Craig A | Methods and compositions employing a dialkyl amide |
US20050164993A1 (en) | 2002-05-20 | 2005-07-28 | Ashley Robert A. | Methods of treating allergic reactions |
JP4050094B2 (en) | 2002-05-28 | 2008-02-20 | 株式会社三谷バルブ | Metering valve mechanism and aerosol products |
US6723309B1 (en) | 2002-06-10 | 2004-04-20 | Jeffrey Alan Deane | Hair cleansing conditioner |
US7763587B2 (en) | 2002-06-13 | 2010-07-27 | L'oreal S.A. | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process |
FR2840903B1 (en) | 2002-06-13 | 2005-01-28 | Oreal | GLUCOSE AND VITAMIN F DERIVATIVE, COMPOSITIONS COMPRISING THE SAME, AND USES FOR IMPROVING THE CONDITION OF HAIR AND HAIR |
US7163669B2 (en) | 2002-06-19 | 2007-01-16 | J.M. Huber Corporation | Cosmetic compositions comprising calcium silicates |
WO2003091128A1 (en) | 2002-06-26 | 2003-11-06 | Daizo Co.,Ltd. | Packaging container for discharge of plurality of contents, packaging product including the packaging container and process for producing the packaging product |
JP2004026605A (en) | 2002-06-27 | 2004-01-29 | Asahi Fiber Glass Co Ltd | Greige goods for glass fiber yarn and glass fiber yarn made using this |
US20040002550A1 (en) | 2002-06-28 | 2004-01-01 | Mercurio Anthony Fred | Post foaming compositions |
US6785629B2 (en) | 2002-07-02 | 2004-08-31 | Agilent Technologies, Inc. | Accuracy determination in bit line voltage measurements |
JP3833972B2 (en) | 2002-07-08 | 2006-10-18 | 古河電気工業株式会社 | Wire harness assembly system |
DE10233330B4 (en) | 2002-07-22 | 2007-04-26 | Sasol Germany Gmbh | Microemulsion containing UV photoprotective filter and / or anti-dandruff agent |
US7137536B2 (en) | 2002-07-22 | 2006-11-21 | Seaquist Perfect Dispensing Foreign, Inc. | Inverted aerosol dispenser |
US6897195B2 (en) * | 2002-07-24 | 2005-05-24 | Nanjing Zhongshi Chemical Co. | Composition of menthol and menthyl lactate, its preparation method and its applications as a cooling agent |
US20020182162A1 (en) | 2002-08-07 | 2002-12-05 | Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth |
FR2843373B1 (en) | 2002-08-12 | 2005-03-04 | Jean Augustin | DEVICE FOR PACKAGING AND APPLYING A PRODUCT IN FLUID FORM |
US7939170B2 (en) | 2002-08-15 | 2011-05-10 | The Rockefeller University | Water soluble metal and semiconductor nanoparticle complexes |
DE60323380D1 (en) | 2002-08-26 | 2008-10-16 | Sla Pharma Ag | TOPICAL FORMULATION WITH AT LEAST 10% METRONIDAZOLE IN DECORATED PETROLATE AND THEIR USE IN ANAL AND RECTIFIC AREAS |
US6770607B2 (en) | 2002-09-12 | 2004-08-03 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Viscoelastic cleansing gel with micellar surfactant solutions |
US7906473B2 (en) | 2002-09-13 | 2011-03-15 | Bissell Homecare, Inc. | Manual spray cleaner |
US6968982B1 (en) | 2002-09-18 | 2005-11-29 | Burns Caleb E S | Multiple-mist dispenser |
GB0221697D0 (en) | 2002-09-18 | 2002-10-30 | Unilever Plc | Novel compouds and their uses |
US7179481B2 (en) | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
US6949037B2 (en) | 2002-09-27 | 2005-09-27 | Richard A. Enos | Quick-release fastener for releasably attaching lacrosse stick head to shaft |
FR2845672B1 (en) | 2002-10-09 | 2006-02-10 | Airlessystems | FLUID PRODUCT DISPENSER |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
AU2003301516A1 (en) | 2002-10-24 | 2004-05-13 | Goldstein, Jay A | Antifungal formulations |
US7700076B2 (en) * | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
KR101108439B1 (en) | 2002-10-25 | 2012-01-31 | 포믹스 리미티드 | Cosmetic and pharmaceutical foam |
US20060193789A1 (en) | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
US20080317679A1 (en) | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US20120156144A1 (en) * | 2002-10-25 | 2012-06-21 | Foamix | Foamable Compositions, Kits and Methods for Hyperhidrosis |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8900554B2 (en) * | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US20050205086A1 (en) | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
US20080206161A1 (en) | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
US20050186142A1 (en) | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US20050271596A1 (en) | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
US20070292355A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20060233721A1 (en) | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US20070292359A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US20160158261A1 (en) | 2002-10-25 | 2016-06-09 | Foamix Pharmaceuticals Ltd. | Antibiotic Kit and Composition and Uses Thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8486376B2 (en) * | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9265725B2 (en) * | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US20060018937A1 (en) | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20080031907A1 (en) | 2002-10-25 | 2008-02-07 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
CN1300095C (en) | 2002-10-28 | 2007-02-14 | 吉万奥丹股份有限公司 | Coolant solutions and compositions comprising the sameitle |
JP2004250435A (en) | 2002-11-21 | 2004-09-09 | Dai Ichi Seiyaku Co Ltd | Composition for hair growth |
JP4282311B2 (en) | 2002-11-26 | 2009-06-17 | 三洋電機株式会社 | Ice making equipment |
CN1723009A (en) | 2002-12-12 | 2006-01-18 | 诺伊堡皮肤护理两合公司 | Stable foam cream |
GB0229071D0 (en) | 2002-12-13 | 2003-01-15 | Unilever Plc | Cosmetic method and composition for enhancing attractiveness |
US20040191196A1 (en) | 2002-12-16 | 2004-09-30 | Dov Tamarkin | Novel conjugate compounds and dermatological compositions thereof |
FR2848847B1 (en) | 2002-12-18 | 2005-10-14 | Coletica | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN AQUEOUS INSOLUBLE ENZYME AND USES THEREOF |
US7842791B2 (en) | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
FR2848998B1 (en) | 2002-12-20 | 2006-04-07 | Oreal | DISPENSING DEVICE HAVING MEANS FOR DISTRIBUTING TWO PRODUCTS IN VARIABLE PROPORTIONS |
EP1578421A4 (en) | 2003-01-02 | 2009-04-22 | Femmepharma Holding Co Inc | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
WO2004064769A2 (en) | 2003-01-21 | 2004-08-05 | Hector Herrera | Methods for making and using topical delivery agents |
AU2004206769B2 (en) | 2003-01-24 | 2009-11-26 | Stiefel Research Australia Pty Ltd | Clindamycin phosphate foam |
US20040151756A1 (en) | 2003-02-04 | 2004-08-05 | Richards Anthony P. | Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle |
US7517519B2 (en) | 2003-02-06 | 2009-04-14 | Cipla Limited | Topical immunotherapy and compositions for use therein |
CA2515731C (en) | 2003-02-12 | 2012-07-24 | Connetics Australia Pty Ltd | Sunscreen hydroethanolic foam |
US6841547B2 (en) | 2003-02-28 | 2005-01-11 | Albert Einstein College Of Medicine Of Yeshevia University | Method for decreasing low density lipoprotein |
US20040175347A1 (en) | 2003-03-04 | 2004-09-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using hexamidine compositions |
GB0305010D0 (en) | 2003-03-05 | 2003-04-09 | Unilever Plc | Changing colours |
US6843390B1 (en) | 2003-03-17 | 2005-01-18 | Joe G. Bristor | Multiple fluid closed system dispensing device |
US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
US7488757B2 (en) | 2003-03-24 | 2009-02-10 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
US20040192754A1 (en) | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
DE10315936A1 (en) | 2003-04-03 | 2004-10-28 | Ing. Erich Pfeiffer Gmbh | Discharge device for at least one medium |
GB0308585D0 (en) | 2003-04-14 | 2003-05-21 | Pz Cussons Int Ltd | Cleaning composition |
US20040229803A1 (en) | 2003-04-22 | 2004-11-18 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders |
US20040220187A1 (en) | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders |
US7575739B2 (en) * | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
DE10319771B4 (en) | 2003-05-02 | 2005-03-17 | Koenig & Bauer Ag | System for inspecting a printed image |
JP2004353084A (en) | 2003-05-08 | 2004-12-16 | Sanyo Electric Co Ltd | Evaporator fixation member |
FR2854821B1 (en) | 2003-05-16 | 2006-12-08 | Oreal | ASSEMBLY FOR PACKAGING AND DISPENSING A PRODUCT, IN PARTICULAR IN THE FORM OF A SAMPLE |
JP4232535B2 (en) | 2003-05-20 | 2009-03-04 | セイコーエプソン株式会社 | Printer maintenance system, print control server, client, method related thereto and program related thereto |
US7222802B2 (en) | 2003-05-23 | 2007-05-29 | Meadwestvaco Corporation | Dual sprayer with external mixing chamber |
WO2004103343A1 (en) | 2003-05-25 | 2004-12-02 | Yuwan Wang | Dimeticone-containing sustained formulation |
US7186416B2 (en) | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
EP1631248A1 (en) * | 2003-05-30 | 2006-03-08 | Gianfranco De Paoli Ambrosi | A formulation for chemical peeling |
US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
JP4018032B2 (en) | 2003-06-17 | 2007-12-05 | 高砂香料工業株式会社 | Hair and body cleaning composition |
ES2279391T3 (en) | 2003-06-18 | 2007-08-16 | Galderma S.A. | PHARMACEUTICAL COMPOSITION TOPICA OF DYE GREEN BASED METRONIDAZOL. |
KR100727327B1 (en) | 2003-06-19 | 2007-06-12 | 더 프록터 앤드 갬블 캄파니 | Polyol-in-silicone emulsions |
US20050042182A1 (en) | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
AU2004253410B2 (en) | 2003-07-03 | 2008-08-21 | Japan Science And Technology Agency | Remedy for sarcoidosis and method of treating the same |
US20070140999A1 (en) | 2003-07-18 | 2007-06-21 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
EP1653932A1 (en) | 2003-07-24 | 2006-05-10 | Ranbaxy Laboratories Limited | Modified release compositions for minocycline |
US7226230B2 (en) | 2003-07-28 | 2007-06-05 | Raymond Liberatore | Spreader |
US20080069779A1 (en) | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
MXPA06001381A (en) | 2003-08-04 | 2006-05-19 | Foamix Ltd | Foam carrier containing amphiphilic copolymeric gelling agent. |
JP2007503428A (en) | 2003-08-25 | 2007-02-22 | フォーミックス エルティーディー. | Osmotic pharmaceutical foaming agent |
US20060140990A1 (en) | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
KR20060088543A (en) | 2003-09-25 | 2006-08-04 | 디엠아이 바이오사이언스 인코포레이티드 | Methods and products which utilize n-acyl-l-aspartic acid |
FR2860143B1 (en) | 2003-09-26 | 2008-06-27 | Oreal | COSMETIC COMPOSITION COMPRISING A SEQUENCE POLYMER AND A NON-VOLATILE SILICONE OIL |
US20050084551A1 (en) | 2003-09-26 | 2005-04-21 | Jensen Claude J. | Morinda citrifolia-based oral care compositions and methods |
EP3428257B1 (en) | 2003-09-29 | 2023-06-14 | Deb IP Limited | High alcohol content gel-like and foaming compositions |
GB2406330B (en) | 2003-09-29 | 2005-12-07 | Bespak Plc | A dispensing apparatus |
CA2528818C (en) | 2003-10-03 | 2010-08-10 | Collegium Pharmaceutical, Inc. | Topical aerosol foams |
FR2860502B1 (en) | 2003-10-07 | 2007-09-14 | Valois Sas | DOSING VALVE AND DEVICE FOR DISPENSING FLUID PRODUCT COMPRISING SUCH A VALVE |
GB0323908D0 (en) | 2003-10-11 | 2003-11-12 | Nupharm Lab Ltd | Pharmaceutical foam formulation |
EP1689494B1 (en) | 2003-10-14 | 2008-12-03 | Showa Denko K.K. | Agent for skin external use containing salt of ascorbic acid derivative, method for stabilizing the agent for skin external use |
FR2860976B1 (en) | 2003-10-20 | 2006-02-10 | Ravi Shrivastava | NOVEL SYNERGISTIC COMPOSITIONS FOR IMPROVING THE BIODAVAILABILITY AND EFFICIENCY OF POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF BRAIN FUNCTIONING DISORDERS. |
US7419498B2 (en) | 2003-10-21 | 2008-09-02 | Nmt Medical, Inc. | Quick release knot attachment system |
MXPA06004826A (en) | 2003-10-31 | 2006-07-03 | Procter & Gamble | Skin care composition containing dehydroacetic acid and skin care actives. |
US8157788B2 (en) | 2003-11-06 | 2012-04-17 | Paolo L. Manfredi | Multi-site drug delivery platform |
AU2004286787B2 (en) * | 2003-11-06 | 2007-10-18 | Unilever Plc | Improved cosmetic composition comprising vitamin B3, vitamin B6 and an organic acid |
CA2544599A1 (en) | 2003-11-06 | 2005-05-26 | Maria Emanuel Ryan | Methods of treating eczema |
WO2005048966A1 (en) | 2003-11-17 | 2005-06-02 | The Procter & Gamble Company | Antiperspirant composition and applicator therefor |
DE10354051A1 (en) | 2003-11-17 | 2005-06-16 | Beiersdorf Ag | Dispensers containing cosmetic preparations containing aids for keeping the donor in motion |
CA2546195A1 (en) | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | The use of anti biotics as vaccine adjuvants |
US20050115988A1 (en) | 2003-12-01 | 2005-06-02 | Brian Law | Multiple liquid foamer |
US20050123496A1 (en) | 2003-12-08 | 2005-06-09 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Self foaming non-aqueous personal wash cleansers with little or no surfactant |
DE10361022A1 (en) | 2003-12-23 | 2005-07-28 | Merckle Gmbh Chem.-Pharm. Fabrik | Topical preparations containing dimethyl sulfoxide and dexpanthenol |
AU2004312546B2 (en) | 2003-12-30 | 2010-10-14 | Gilead Sciences, Inc. | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases |
IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
EP1727522A2 (en) | 2004-02-04 | 2006-12-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam with solid matter |
US7225518B2 (en) | 2004-02-23 | 2007-06-05 | Boston Scientific Scimed, Inc. | Apparatus for crimping a stent assembly |
JP4381169B2 (en) | 2004-02-27 | 2009-12-09 | 花王株式会社 | Hair cosmetics |
ES2691498T3 (en) | 2004-03-03 | 2018-11-27 | Revance Therapeutics, Inc. | Topical application and transdermal release of botulinum toxins |
US20050206214A1 (en) | 2004-03-18 | 2005-09-22 | Bodypoint Designs, Inc. | Pivoting side mount for a pelvic stabilization device |
DE102004016710B4 (en) | 2004-04-05 | 2020-11-19 | Greppmayr GmbH | Foot care formulation |
RU2375044C2 (en) | 2004-04-08 | 2009-12-10 | Новартис Аг | Pimecrolimus foamy composition including hexylene glycol, optionally oleyl alkohol and/or medium chain triglycerides |
CA2563678A1 (en) | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
NL1026031C2 (en) | 2004-04-23 | 2005-10-25 | Airspray Nv | Delivery assembly. |
AU2005204341A1 (en) | 2004-04-28 | 2005-11-17 | Foamix Ltd. | Body cavity foams |
US20050244354A1 (en) | 2004-04-30 | 2005-11-03 | Sam Speron | Oxygenated personal care products |
JP2005314323A (en) | 2004-04-30 | 2005-11-10 | Sato Pharmaceutical Co Ltd | Hair growth formulation |
WO2005115336A2 (en) | 2004-05-15 | 2005-12-08 | Collegium Pharmaceutical, Inc. | Sprayable formulations for the treatment of acute inflammatory skin conditions |
US7083125B2 (en) | 2004-05-17 | 2006-08-01 | S.C. Johnson & Son, Inc. | Detachable tube assembly |
US7143909B2 (en) | 2004-05-21 | 2006-12-05 | Sonoco Development, Inc. | Reconfigurable metered material dispenser |
WO2005117813A1 (en) | 2004-05-26 | 2005-12-15 | L'oreal | Cosmetic mousse formulations |
ITBO20040338A1 (en) | 2004-05-28 | 2004-08-28 | Progine Farmaceutici Srl | VAGINAL NEBULIZATION DISPENSER |
US20050268416A1 (en) | 2004-06-03 | 2005-12-08 | Sommers J E | Foldable lotion applicator |
JP4368250B2 (en) | 2004-06-09 | 2009-11-18 | ポーラ化成工業株式会社 | Post-form dosage form of warm cosmetic |
FR2871698B1 (en) * | 2004-06-17 | 2008-07-04 | Galderma Sa | SPRAY COMPOSITION COMPRISING AN ASSOCIATION OF PHARMACEUTICAL ASSETS AND AN OILY PHASE |
FR2871696B1 (en) | 2004-06-17 | 2006-11-10 | Galderma Sa | TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS |
US8211449B2 (en) | 2004-06-24 | 2012-07-03 | Dpt Laboratories, Ltd. | Pharmaceutically elegant, topical anhydrous aerosol foam |
JP4355264B2 (en) | 2004-06-25 | 2009-10-28 | ポーラ化成工業株式会社 | Warm feeling non-water foam cosmetic |
US7207655B2 (en) | 2004-06-28 | 2007-04-24 | Eastman Kodak Company | Latency stirring in fluid ejection mechanisms |
US6991789B2 (en) | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
US20060008432A1 (en) | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
UA93354C2 (en) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Topical antiviral formulations |
US20060121073A1 (en) | 2004-07-12 | 2006-06-08 | Sandhya Goyal | Topical gel formulation comprising insecticide and its preparation thereof |
EP1778216A1 (en) | 2004-07-19 | 2007-05-02 | Warner-Lambert Company LLC | Formulation for stimulating hair growth |
JP4557624B2 (en) | 2004-07-29 | 2010-10-06 | 株式会社吉野工業所 | Quantitative dispenser |
WO2006010589A2 (en) | 2004-07-29 | 2006-02-02 | Mipharm S.P.A. | Post foaming gel mousse |
US20060029565A1 (en) | 2004-08-09 | 2006-02-09 | The Gillette Company | Self-heating shave foam product |
EP1779558B1 (en) | 2004-08-12 | 2012-11-28 | Triaccess Technologies, Inc | Level detector for optical receivers |
RU2381023C2 (en) | 2004-08-31 | 2010-02-10 | Стифель Ресёрч Австралия Пти Лтд | Method for making microemulsions and submicron emulsions and based composition |
KR100623013B1 (en) | 2004-09-04 | 2006-09-19 | 김영대 | Nano-emulsion, the use thereof, and preparing method thereof |
WO2006032144A1 (en) | 2004-09-23 | 2006-03-30 | Arc Pharmaceuticals, Inc. | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources |
ES2747926T3 (en) | 2004-09-27 | 2020-03-12 | Special Water Patents B V | Methods and compositions for water treatment |
FR2875797B1 (en) | 2004-09-30 | 2006-11-24 | Oreal | DISTRIBUTION ASSEMBLY FOR THE EXTENDED DISTRIBUTION OF TWO PRODUCTS |
BRPI0404595A (en) | 2004-10-26 | 2006-06-13 | Natura Cosmeticos Sa | oil-in-water nanoemulsion, cosmetic composition and cosmetic product comprising same, process for preparing said nanoemulsion |
DE102004052986A1 (en) | 2004-11-02 | 2006-05-04 | Lindal Ventil Gmbh | Device for mixing two different components |
US7350673B2 (en) | 2004-11-19 | 2008-04-01 | Glynntech, Inc. | Metered dose squeeze dispenser |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
FR2880802B1 (en) | 2005-01-14 | 2008-12-19 | Sederma Soc Par Actions Simpli | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT |
US20060194769A1 (en) | 2005-01-25 | 2006-08-31 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
US20080193405A1 (en) | 2005-01-28 | 2008-08-14 | Basf Aktiengesellschaft | Use of a Water-In-Water Emulsion Polymers in the Form of a Thickener for Cosmetic Preparations |
US20060177392A1 (en) | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
US20060193813A1 (en) | 2005-02-11 | 2006-08-31 | L'oreal | Nanoemulsion containing a hydroxylated urea compound |
GB0506141D0 (en) | 2005-03-24 | 2005-05-04 | Transphase Ltd | A topical compostion and its uses |
EP1866033B1 (en) | 2005-03-24 | 2017-04-19 | Ensign Laboratories PTY LTD | Sunscreen aerosol spray |
US20060222675A1 (en) | 2005-03-29 | 2006-10-05 | Sabnis Ram W | Personal care compositions with color changing indicator |
US20060285912A1 (en) | 2005-04-19 | 2006-12-21 | Foamix Ltd. | Apparatus and method for releasing a measured amount of content from a container |
US9084734B2 (en) | 2005-05-05 | 2015-07-21 | Danisco Us Inc. | Peptide personal care compositions and methods for their use |
AU2006298442A1 (en) | 2005-05-09 | 2007-04-12 | Foamix Ltd. | Saccharide foamable compositions |
US9173835B2 (en) | 2005-05-10 | 2015-11-03 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
WO2006122158A2 (en) | 2005-05-10 | 2006-11-16 | Xanthone Plus International, Llc | Skin care compositions containing xanthones |
ES2407407T3 (en) | 2005-06-01 | 2013-06-12 | Glaxosmithkline Intellectual Property Development Limited | Vitamin formulation |
US20060272199A1 (en) | 2005-06-02 | 2006-12-07 | Bmc Manufacturing, Llc | Aqueous gel candle for use with a warming device |
US8211874B2 (en) | 2005-06-03 | 2012-07-03 | Galderma Laboratories Inc. | Inhibition of thrombin generation |
AU2006339311A1 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
WO2007085899A2 (en) | 2005-07-06 | 2007-08-02 | Foamix Ltd. | Foamable arthropocidal composition for tropical application |
US20070009607A1 (en) | 2005-07-11 | 2007-01-11 | George Jones | Antibacterial/anti-infalmmatory composition and method |
US20070015738A1 (en) | 2005-07-15 | 2007-01-18 | Walker Stephen G | Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells |
ES2765897T3 (en) | 2005-07-18 | 2020-06-11 | Procter & Gamble | Method for conditioning hair with a cream spray foam |
US20080152596A1 (en) | 2005-07-19 | 2008-06-26 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
WO2007085902A2 (en) | 2005-07-19 | 2007-08-02 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
CN100531515C (en) | 2005-07-22 | 2009-08-19 | 鸿富锦精密工业(深圳)有限公司 | Printing circuit board with modified power zone block |
DE602005010417D1 (en) | 2005-07-22 | 2008-11-27 | Wella Ag | Hair treatment method with a dry foam used as a mechanical vehicle |
WO2008051186A2 (en) | 2005-08-09 | 2008-05-02 | Nanobio Corporation | Nanoemulsion containing compositions having ant i -inflammatory activity |
CA2632183A1 (en) | 2005-08-25 | 2007-03-01 | Philip R. Houle | Treatment systems for delivery of sensitizer solutions |
WO2007119099A2 (en) | 2005-09-12 | 2007-10-25 | Foamix Ltd. | Apparatus and method for releasing a measure of content from a plurality of containers |
FR2890559B1 (en) | 2005-09-13 | 2011-06-24 | Galderma Sa | DERMATOLOGICAL FOAMS BASED ON METRONIDAZOLE AND EMULSIONS FOR PREPARATION |
DE202006004676U1 (en) | 2005-09-28 | 2007-02-08 | Neubourg Skin Care Gmbh & Co. Kg | Formulation, useful as foam skin cream and to treat e.g. dermatitis and psoriasis, comprises an aqueous emulsion, propellant gas, urea emulsion, hyaluronic acid, free fatty acid and at least two emulsions |
CA2626208A1 (en) | 2005-10-24 | 2007-05-03 | Collegium Pharmaceutical, Inc. | Topical pharmaceutical foam composition |
US20070134174A1 (en) | 2005-11-03 | 2007-06-14 | Christopher Irwin | Personal care composition |
JP2007131539A (en) | 2005-11-08 | 2007-05-31 | Koike Kagaku Kk | Chilling foam cosmetic |
US20070148194A1 (en) | 2005-11-29 | 2007-06-28 | Amiji Mansoor M | Novel nanoemulsion formulations |
JP4885529B2 (en) | 2005-12-08 | 2012-02-29 | 住友重機械工業株式会社 | Radiation detection unit and radiation inspection apparatus |
US20070160548A1 (en) | 2005-12-13 | 2007-07-12 | Playtex Products, Inc. | Moisturizing sunless tanning composition |
US20070142263A1 (en) | 2005-12-15 | 2007-06-21 | Stahl Katherine D | Color changing cleansing composition |
US20070148112A1 (en) | 2005-12-28 | 2007-06-28 | Avon Products, Inc. | Foaming, color-changing topical composition and method of imparting a cosmetic effect |
JP5184373B2 (en) | 2006-01-19 | 2013-04-17 | ディスファー・インターナショナル・ベー・フェー | Foam composition |
US20070166273A1 (en) | 2006-01-19 | 2007-07-19 | Krivulka Joseph J | Skin treatment educational kit |
WO2007103555A2 (en) * | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
US20070224143A1 (en) | 2006-03-21 | 2007-09-27 | Kamedis Ltd. | Cosmetic and pharmaceutical foam carrier |
WO2007111962A2 (en) | 2006-03-22 | 2007-10-04 | The Procter & Gamble Company | Aerosol product comprising a foaming concentrate composition comprising particulate materials |
US7252816B1 (en) * | 2006-03-29 | 2007-08-07 | Dow Pharmaceutical Sciences | Topical acne vulgairs medication with a sunscreen |
BRPI0709674A2 (en) * | 2006-03-31 | 2011-12-06 | Stiefel Res Australia Pty Ltd | sparkling suspension gel |
WO2008075207A2 (en) | 2006-04-04 | 2008-06-26 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20070264317A1 (en) | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
WO2007142967A2 (en) | 2006-05-31 | 2007-12-13 | The Dial Corporation | Alcohol-containing antimicrobial compositions having improved efficacy |
JP4892282B2 (en) | 2006-06-09 | 2012-03-07 | アルプス電気株式会社 | Lubricating composition for electrical contacts |
WO2008110872A2 (en) | 2006-06-23 | 2008-09-18 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US7826675B2 (en) | 2006-07-04 | 2010-11-02 | Hewlett-Packard Development Company, L.P. | Feature-aware image defect removal |
ES2530390T3 (en) | 2006-07-05 | 2015-03-02 | Foamix Pharmaceuticals Ltd | Foaming vehicle of carboxylic acid and pharmaceutical compositions thereof |
EP2046121B1 (en) | 2006-07-14 | 2012-08-22 | Stiefel Research Australia Pty Ltd | Fatty acid pharmaceutical foam |
US20100092401A1 (en) | 2006-07-18 | 2010-04-15 | Graceway Pharmaceuticals, Llc | Immune response modifier formulations |
US20080031908A1 (en) | 2006-07-25 | 2008-02-07 | L'oreal | Oily cosmetic composition in aerosol form |
JP2008040899A (en) | 2006-08-08 | 2008-02-21 | Fuji Xerox Co Ltd | Printing controller, program, and method |
KR20090064440A (en) | 2006-09-08 | 2009-06-18 | 포믹스 리미티드 | Colored or colorable foamable composition and foam |
ES2315123B1 (en) | 2006-09-25 | 2009-12-30 | Divasa-Farmavic, S.A. | STABLE PHARMACEUTICAL COMPOSITIONS OF TETRACICLINES IN SOLUTION, PROCEDURE FOR OBTAINING AND USES. |
HUP0600765A2 (en) | 2006-10-06 | 2008-10-28 | Istvan Piller | Container for stable carbondioxide foam, process for producing stable carbondioxide foam and method for using of foam |
WO2009007785A2 (en) | 2006-11-14 | 2009-01-15 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
EP2097065A2 (en) | 2006-11-29 | 2009-09-09 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
JP2010513289A (en) | 2006-12-15 | 2010-04-30 | ザ プロクター アンド ギャンブル カンパニー | Skin care composition |
US20080153789A1 (en) | 2006-12-26 | 2008-06-26 | Femmepharma Holding Company, Inc. | Topical administration of danazol |
US20080292560A1 (en) | 2007-01-12 | 2008-11-27 | Dov Tamarkin | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent |
US20100015064A1 (en) | 2007-01-16 | 2010-01-21 | Oystershell N.V. | Foamable composition for killing arthropods and uses thereof |
US20080188445A1 (en) | 2007-02-02 | 2008-08-07 | Warner Chilcott Company Inc. | Tetracycline compositions for topical administration |
US20080188446A1 (en) | 2007-02-02 | 2008-08-07 | Warner Chilcott Company Inc. | Tetracycline compositions for topical administration |
PT103661B (en) | 2007-02-23 | 2010-09-07 | Hovione Farmaciencia S A | MINOCYCINE PREPARATION PROCESS CRYSTALLINE |
GB0703909D0 (en) | 2007-02-28 | 2007-04-11 | Neuropharm Ltd | Treatment of anxiety disorders |
FR2915891B1 (en) | 2007-05-10 | 2012-05-11 | Oreal | FOAM COMPOSITION COMPRISING A SILICONE POLYMER |
US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009056991A2 (en) | 2007-09-04 | 2009-05-07 | Foamix Ltd. | Device for delivery of a foamable composition |
US20090130029A1 (en) | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
US8518376B2 (en) * | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009072007A2 (en) * | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
CA2711703A1 (en) | 2008-01-08 | 2009-07-16 | Foamix Ltd. | Sensation modifying topical composition foam |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8652443B2 (en) | 2008-02-14 | 2014-02-18 | Precision Dermatology, Inc. | Foamable microemulsion compositions for topical administration |
ES2330291B1 (en) | 2008-02-29 | 2010-10-18 | Lipotec Sa | USEFUL PEPTIDES IN THE TREATMENT OF SKIN, MUCOSAS AND / OR LEATHER HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS. |
BRPI0908565A2 (en) | 2008-03-06 | 2017-05-23 | Anacor Pharmaceuticals Inc | compound, pharmaceutical formulation, methods for reducing the release of a cytokine or chemokine, treating a condition in an animal and inhibiting a phosphodiesterase |
US20120141384A1 (en) | 2008-05-06 | 2012-06-07 | Dov Tamarkin | Antibacterial conjugated boronic acids and pharmaceutical compositions thereof |
US8253882B2 (en) | 2008-08-07 | 2012-08-28 | Sharp Kabushiki Kaisha | Display device |
PT2210588E (en) | 2008-12-23 | 2011-06-07 | Intendis Gmbh | Foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin |
JP5213734B2 (en) | 2009-01-22 | 2013-06-19 | サンウエーブ工業株式会社 | Cabinet with flap door |
MX354480B (en) | 2009-02-12 | 2018-03-07 | Prec Dermatology Inc Star | Foamable benzoyl peroxide compositions for topical administration. |
US10568859B2 (en) | 2009-02-25 | 2020-02-25 | Mayne Pharma Llc | Topical foam composition |
US20120164087A1 (en) | 2009-04-24 | 2012-06-28 | Carter Daniel C | Human Serum Albumin-Based Topical Ointment for Treatment of Acne, Psoriasis, Egfr-Induced Toxicity, Premature Skin Aging and Other Skin Conditions |
CA2760186C (en) * | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
PT104644B (en) * | 2009-06-26 | 2012-11-06 | Hovione Farmaciencia S A | Topical formulation containing a tetracycline and a method of treating skin infections using the same |
US8255186B2 (en) | 2009-07-09 | 2012-08-28 | Air Liquide Large Industries U.S. Lp | Presenting dynamic SCADA data |
CA2769677A1 (en) * | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) * | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011026094A2 (en) | 2009-08-31 | 2011-03-03 | Collegium Pharmaceutical, Inc. | Stable aerosol topical foams comprising a hypochlorite salt |
US20140121188A1 (en) | 2009-10-02 | 2014-05-01 | Foamix Ltd. | Compositions for the improved treatment of acne and related disorders |
EP2482788B1 (en) | 2009-10-02 | 2022-12-14 | Journey Medical Corporation | Topical tetracycline compositions |
US20140186269A1 (en) | 2013-01-03 | 2014-07-03 | Foamix Ltd. | Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders |
GB2474930B (en) | 2009-10-02 | 2012-07-04 | Foamix Ltd | Topical tetracycline compositions |
US9849142B2 (en) * | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8735377B1 (en) | 2010-02-04 | 2014-05-27 | Susan Anna Sipos | Methods of treating herpes zoster |
US20110212035A1 (en) | 2010-02-26 | 2011-09-01 | Collegium Pharmaceutical, Inc. | Emollient foams for treatment of dermatoses |
WO2011115700A2 (en) | 2010-03-18 | 2011-09-22 | Precision Dermatology, Inc. | Emollient foams for treatment of seborrheic dermatitis |
CA2794503C (en) | 2010-03-26 | 2017-11-07 | Precision Dermatology, Inc. | Aerosol foams comprising clindamycin phosphate |
WO2011133217A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacline, Llc | Topical drug delivery system with dual carriers |
US20130053353A1 (en) * | 2010-05-04 | 2013-02-28 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses |
WO2011156030A2 (en) | 2010-06-11 | 2011-12-15 | Precision Dermatology, Inc. | High oil-content emollient aerosol foam compositions |
US8978936B2 (en) * | 2010-07-12 | 2015-03-17 | Foamix Pharmaceuticals Ltd. | Apparatus and method for releasing a unit dose of content from a container |
CN109745313A (en) | 2010-08-11 | 2019-05-14 | 德雷克塞尔大学 | The D3 dopamine-receptor stimulant for treating dyskinesia in Parkinson's disease |
US20120064136A1 (en) * | 2010-09-10 | 2012-03-15 | Nanobio Corporation | Anti-aging and wrinkle treatment methods using nanoemulsion compositions |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
CN108619519A (en) | 2011-01-19 | 2018-10-09 | 护肤品实验室有限公司 | Local minocycline composition and its application method |
US20140221320A1 (en) | 2011-07-08 | 2014-08-07 | The Research Foundation For The State University Of New York | Topical minocycline ointment for suppression of allergic skin responses |
JP2014532717A (en) | 2011-11-03 | 2014-12-08 | プレシジョン ダーマトロジー インコーポレイテッドPrecision Dermatology, Inc. | Stable skin aerosol foam with reactive propellant |
US8801680B2 (en) | 2012-03-14 | 2014-08-12 | Becton, Dickinson And Company | Angled retracting sheath for safety needle |
CA2867419C (en) | 2012-03-15 | 2023-10-24 | Foamix Ltd. | Use of tetracycline compositions for wound treatment and skin restoration |
WO2013142251A1 (en) | 2012-03-22 | 2013-09-26 | Precision Dermatology, Inc. | Cyclodextrin-based microemulsions, and dermatological uses thereof |
CA2775393C (en) | 2012-05-02 | 2014-04-29 | Samy Saad | Topical non-aqueous pharmaceutical formulations |
EP2872146A4 (en) | 2012-07-13 | 2016-01-06 | Paratek Pharm Innc | Tetracycline compounds for treating neurodegenerative disorders |
PT106679B (en) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | TOPICAL FORMULATIONS OF TETRACYCLINES, THEIR PREPARATION AND USES |
CN105050584A (en) | 2013-02-28 | 2015-11-11 | 普雷西恩护肤公司 | Topical formulations of corticosteroids with enhanced bioavailability |
US20140243300A1 (en) | 2013-02-28 | 2014-08-28 | Precision Dermatology, Inc. | Controlling the Bioavailability of Active Ingredients in Topical Formulations |
WO2014151347A1 (en) | 2013-03-15 | 2014-09-25 | Revance Therapeutics, Inc. | Minocycline derivatives |
CA2915206A1 (en) | 2013-06-17 | 2014-12-24 | Contract Pharmaceuticals Limited | Non-aerosol foams for topical administration |
EP3065717A1 (en) | 2013-11-04 | 2016-09-14 | Biopharmx, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
US20160287614A1 (en) | 2013-11-20 | 2016-10-06 | Lupin Limited | Stable Pharmaceutical Formulation(s) of Tetracycline Antibiotic |
PT107433B (en) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | PARTICLE SIZE REDUCTION AND CONTROL PROCESS |
WO2015153864A2 (en) | 2014-04-02 | 2015-10-08 | Hopkins Patricia T | Methods for treating inflammatory conditions |
-
2007
- 2007-10-19 US US11/975,621 patent/US20080138296A1/en not_active Abandoned
-
2014
- 2014-02-04 US US14/172,466 patent/US9539208B2/en not_active Expired - Lifetime
-
2016
- 2016-12-02 US US15/368,236 patent/US20170231909A1/en not_active Abandoned
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Also Published As
Publication number | Publication date |
---|---|
US9539208B2 (en) | 2017-01-10 |
US20140193502A1 (en) | 2014-07-10 |
US20080138296A1 (en) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9539208B2 (en) | Foam prepared from nanoemulsions and uses | |
US20190307656A1 (en) | Foam containing unique oil globules | |
US11103454B2 (en) | Wax foamable vehicle and pharmaceutical compositions thereof | |
US9439857B2 (en) | Foam containing benzoyl peroxide | |
US8486376B2 (en) | Moisturizing foam containing lanolin | |
US9682021B2 (en) | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses | |
ES2635731T3 (en) | Foam formulations containing at least one triterpenoid | |
US9795564B2 (en) | Oil-based foamable carriers and formulations | |
US8119109B2 (en) | Foamable compositions, kits and methods for hyperhidrosis | |
US8518376B2 (en) | Oil-based foamable carriers and formulations | |
US20110097279A1 (en) | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses | |
US20120156144A1 (en) | Foamable Compositions, Kits and Methods for Hyperhidrosis | |
ZA200507018B (en) | Oleaginous pharmaceutical and cosmetic foam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |